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Summary
Biodegradable microparticles are already a well-established form of drug 
delivery. They can be used to deliver peptides, proteins or low molecular weight drugs 
by various routes for administration e.g. parenteral, pulmonary, oral and nasal. 
Currently their potential for use in the field of gene delivery is being explored.
This study focused on utilising Quadrant Healthcare’s proprietary spray drying 
technique to produce two different types of microparticles. Firstly, soluble mannitol 
microparticles with entrapped DNA/lipid complexes, which have potential for delivery 
of DNA to the lung. Secondly, cross-linked defatted human serum albumin 
microparticles which may have use as carriers for DNA vaccines for delivery to 
phagocytic macrophages or professional antigen presenting cells.
The mannitol microparticles were physically characterised through microscopy 
and particle size and found to be of appropriate size for lung deposition. In vitro gene 
expression experiments were used to assess the biological activity of the spray-dried 
DNA. DNA appeared to survive spray drying but was unstable on storage. The initial 
gene expression experiments were not suitably sensitive and suffered interference 
perhaps due to endogenous galactosidases. An alternative gene expression assay was 
established utilising the luciferase reporter gene. Luciferase expression was detectable 
after 4 hours and peaked 24-32 hours after transfection.
Cross-linked albumin microparticles were physically characterised via SEM and 
particle size. The microparticles were evaluated for their loading capacity for DNA 
with aid of cationic lipids, alky trimethyl bromides and polycations, polylysine and 
protamine. In vitro transfection experiments suggested that the particles were unable to 
transfect non-phagocytic cells. Phagocytic cells took up the particles in vitro. Animal 
experiments focused on assessing whether the presence of microparticles in vivo 
affected the number of macrophages present in RIF-1 tumour models. Macrophage 
presence was quantified in tumour tissue with the aid of enzyme histochemistry. An 
immune response was mediated in response to the presence of microparticles in vivo. 
Attempts were also made to study the fate of the particles after intratumoral injection 
using fluorescently labelled microparticles. Microparticles were located near the site of 
injection and in the periphery of the tumour tissue.
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CHAPTER 1
INTRODUCTION
Somatic gene therapy is a novel therapeutic approach defined as the introduction of 
genetic information into cells to achieve production of beneficial proteins to correct or 
modulate a disease. Somatic gene therapy can target many severe or debilitating 
diseases, including inherited genetic disorders such as cystic fibrosis and haemophilia, 
as well as acquired, multifactorial diseases such as arthritis, AIDS and cancers (Miller, 
1992; Anderson, 1992; Friedmann et al., 1989; Michael and Curiel, 1994; Ledley, 
1994a, 1994b). The intended purpose of gene therapy products is to overcome some of 
the limitations associated with the clinical use of protein drugs, including low 
bioavailability, poor stability and pharmacokinetics and high cost of manufacture. Gene 
therapy has great potential as it offers a new range of therapies based on selective, 
regulated expression of endogenous proteins or exogenous vaccines, at the appropriate 
target site. The initial approaches to gene therapy have exhibited promising 
pharmacological effects in several animal models of genetic and acquired diseases. 
Clinical trials have demonstrated that genes can be introduced into patients by several 
different methods and will express potentially therapeutic gene products (Crystal et al., 
1993; Caplen et al., 1995; Zabner et al., 1993; Grossman et al 1995). However, from 
the published clinical data it is apparent that there is a lack of clinical efficacy as a result 
of low gene expression following administration of a gene medicine. The expression 
system is an essential component of activity, but the design and optimisation of the 
delivery vehicle will also be a major part of the development of a successful gene 
medicine. The gene delivery process can be seen as a series of hurdles (both 
extracellular and intracellular) that successively deplete the mass of DNA that
l
progresses towards the target site. Improvement in the transfer efficiency across any 
individual step would be expected to improve overall efficiency. Therefore along with 
gaining an understanding into the various hurdles or barriers to gene delivery, basic 
research and development into formulating therapeutic DNA into a pharmaceutical 
product is also needed towards the formulation of successful, and site-specific gene 
therapy technologies. There is good reason to believe that different biological targets 
and pathologies will require different gene therapy technologies.
1.1. BARRIERS TO GENE DELIVERY
The enormity of the task of gene delivery can be better appreciated if the biological 
barriers hindering gene transfer within the body are considered. The exact barriers are 
dependent on the gene therapy strategy sought, and particularly the route of 
administration of the genetic material in the body. Transgenes may be introduced either 
ex vivo or in vivo. The current advantage of ex vivo strategies is that many of the 
biological barriers encountered within the body can be avoided. This is achieved by the 
removal of the target tissue and in vitro transfection of the target cells, often followed 
by selection processes designed to enhance the proportion of transfected cells. Finally, 
the surviving transfected cells are reintroduced into the body. There are, however many 
obstacles inherent to ex vivo gene delivery approaches, mainly involving limitations to 
the efficiency of transgene expression in vitro and the time and labour intensive 
processes involved with selection, which generally result in significant tissue loss, and 
the reintroduction of transformed cells in vivo (Kabanov, 1999).
The situation becomes more complicated in the case of in Wvo-based strategies. 
Practically every accepted in vivo route of administration has been considered for gene
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delivery, including systemic, intramuscular, oral, topical, ocular and alveolar. At 
present the most significant obstacle hindering in vivo gene therapy is delivery of the 
gene to the target site, and at levels that are biologically relevant. In the case of 
systemic administration for example, the availability of non-viral vectors to the target 
site is decreased by the uptake of vectors by non-target tissues (Mahato et al., 1997). 
DNA-containing complexes are generally too large to be easily taken up within the 
capillary tissues, and therefore become targets for elimination by cells of the 
reticuloendothelial system (RES), particularly in the liver. In addition to the physical 
barriers created by the formed body tissues, interactions with macromolecules present in 
the body fluids, such as serum proteins, can strongly affect the properties of the non- 
viral vector, perhaps modifying its tissue distribution (Kabanov, 1999).
In certain cases, following administration in the body the non-viral vector is 
separated from its target by a natural biological barrier. For instance, the blood-brain 
barrier impedes gene therapy targeting tumours in the central nervous system (review by 
Kabanov, 1999). Another example is the intestinal barrier, which has proven to be a 
major obstacle by decreasing the bioavailability of antisense oligonucleotides following 
oral administration (Agarwal et al., 1995). Sometimes the target site itself provides a 
formidable barrier for gene delivery, e.g. low permeability of tumour vasculature can 
significantly complicate gene transfer in solid tumours (Lemmon et al., 1997).
In addition to the physical barriers to gene therapy present within the body, 
degradation of vectors prior to reaching their targets must be avoided. Enzymatic 
digestion of the DNA by nucleases present in the body fluids can result in the 
elimination of the transgene before it reaches the target site. To avoid degradation non- 
viral vectors must remain stable until they reach their target. However, the non-viral
3
vectors cannot be too stable, because the DNA must be released during interaction with 
the target cell to enable the transgene expression.
The problems associated with transgene delivery do not end once the vector has 
arrived at the outer membrane of the target cells. The processes of transgene entry into, 
and movement through, the intracellular environment is currently the subject of 
increasing attention (Zabner et al., 1995; Tseng et al., 1997). Compared to a DNA 
molecule, a cell is an enormous place in which the DNA molecule can easily get lost. 
The transgene may be sequestered within the wrong compartments of the cell, leading to 
degradation instead of trafficking properly to its intracellular target. The transfection 
process can be divided into four major elements, the first process is the entry of DNA 
into the cell. The second involves the trafficking of the transgene through the 
cytoplasm, including both endosomal and lysosomal compartments. The third phase is 
the entry of DNA into the nucleus. The final element involves the ability to escape 
intranuclear mechanisms designed to purge foreign DNA, followed by the actual 
transcription of the transgene.
It is generally accepted that the first element, delivery of the non-viral vector 
into the cell, occurs through an endocytosis process, although the efficiency of this 
process is unknown (Zabner et al., 1995; Tseng et al., 1997; Wrobel and Collins, 1995). 
Subsequent intracellular vesicular trafficking involves targeting of vesicles to their 
correct destination, which is controlled by unique compartment-specific proteins 
(Slepnev and Camilli, 1998). The precise transport of naturally occurring molecules 
between intracellular organelles is crucial for normal cell functioning and viability. 
From this point of view, the non-viral vectors are ‘alien’ to the cell and they usually 
lack proper recognition characteristics necessary to direct their transport inside the cell. 
Furthermore, a common problem of non-viral gene delivery systems is how to
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overcome transgene degradation within the lysosomal compartments and increase 
transgene release from the transport vesicles. The subsequent mechanisms involved in 
transgene expression are not well defined, but many believe that these elements are 
dependent upon cellular mitosis, evidenced by the observation that primary cells, in 
contrast to rapidly dividing, transformed cell lines, are typically refractory to 
transfection (Kabanov, 1999).
Overall, multiple barriers exist that impede gene transfer both in vitro and in 
vivo, and formidable strategies will be required to overcome these problems. There are 
two primary branches of research striving to overcome these problems. One involves 
the design of the transgene itself to help to achieve expression levels as well as tissue 
and developmental specificity of transgene expression. The second branch, which is the 
primary focus of this chapter, is the selection of efficient transgene strategies.
1.2. STRATEGIES FOR SOMATIC GENE DELIVERY
A number of methods for transferring genes to cells have been explored (Miller, 
1992; Kay et al., 1993; Ledley, 1995; Knowles et al., 1995). Each of these methods 
offers distinct advantages as well as disadvantages. Methods can be distinguished based 
on the nature of the product to be administered to the patient. They include the use of: 
(1) cells, genetically modified ex vivo with viruses or other gene-transfer methods prior 
to re-introduction into the patients body, (2) viral vectors, based on genetically 
engineered, attentuated or defective viruses, (3) plasmid DNA alone, or formulated 
using synthetic delivery systems for direct in vivo administration.
5
1.2.1. Cell-Based Ex Vivo Gene Therapy
The first approved clinical trial involved an ex vivo approach (Blaese et al., 
1995). Retroviral vectors were used to introduce ex vivo the adenosine deaminase 
(ADA) gene permanently into the chromosomes of white blood cells from two patients 
suffering from severe combined immunodeficiency (SCID). These genetically 
engineered cells were then administered as an autologous transfusion. The biological 
benefits of this first ex vivo gene therapy trial have been relatively limited, partly 
because of the low number of cells containing the therapeutic gene and subsequent low 
levels of expression of ADA. An analogous approach has been used in a pilot study of 
gene therapy for familial hypercholesterolemia (LDL-receptor deficiency) (Grossman et 
al, 1995). Detectable expression levels of LDL-receptor were found in a small number 
of hepatic cells.
However, there are several factors that limit the clinical approach of ex vivo gene 
therapy the most important being the fact it is more invasive than a conventional 
pharmaceutical product. Also cultivation, genetic manipulation, quality control and 
transplantation of autologous cells is expensive relative to the cost of a conventional 
pharmaceutical or biological product as well as the fact it is more invasive than a 
conventional pharmaceutical product.
1.2.2. Viral-Based In vivo Gene Therapy
Viral-mediated gene therapy involves the genetic engineering of attenuated or 
defective viruses. These viral vectors are designed to transfer therapeutic genes into 
cells without causing viral disease, and function on the premise that they utilise highly
6
evolved pathways of infection to deliver and express genes in the body. Such pathways 
provide viral vectors with access to a number of target cells, uptake via receptor- 
mediated endocytosis and efficient intracellular trafficking from the endosomes to the 
nucleus. Due to their natural ability to infect cells, several viruses, such as retrovirus, 
adenovirus, adeno-associated vims have been investigated for in vivo gene delivery. 
These and more viral vectors have been extensively reviewed in the following articles, 
Miller, 1992; Takakura and Hashida, 1996; Roemer and Friedmann, 1992; Mulligan, 
1993; Anderson 1998; Ledley, 1996. Viral vectors will only be reviewed briefly as they 
are not the main focus of this thesis.
Retroviruses currently account for 60% of the vectors types used in clinical 
trials. The Retroviral vectors are essentially enveloped RNA viruses which can carry 
out efficient gene transfer into many cell types and can stably integrate into the host cell 
genome, thereby providing possibility of long term expression. However, they can only 
infect replicating cells and as they integrate genes into the host genome permanently it 
removes the ability to modify or terminate the therapy in response to any adverse side 
effects. Alternatively Adenoviruses, are human DNA vimses, which can efficiently 
infect both dividing and non-dividing cells and do not integrate genes into the host 
genome. Also they are large and therefore can carry larger foreign DNA inserts (upto 
35kb) where as the retrovirus can only carry less than 10 kb. Another human DNA 
vims is the Adeno-associated vims, it is essentially non-pathogenic and is the most 
widely found vims in the human population (about 80% of humans have antibodies 
against AAV). It is the only known mammalian vims that shows preferential 
integration into a specific region in the human genome (in the short arm of human 
chromosome 19). However, like the retrovirus it only has a small genome only 
allowing room for 4.8 kb of foreign DNA.
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There are many more virus based vectors under investigation but the underlying 
factor for all these viral vectors are problems with their safety when introduced into the 
human genome, apart from their inefficiency to produce high levels of gene transfer and 
difficulty to manufacture in large quantities. Until safety of these vectors can be 
improved and guaranteed non-viral vectors will be the preferred choice by many 
scientists.
1.2.3. Plasmid-Based, Non-viral Gene Delivery
The non-viral gene delivery methods overcome many of the inherent safety 
issues associated with the use of viral vectors. Plasmids of high quality can be purified 
from bacterial fermentation in high yield. Chemical stability of plasmids can be 
maintained at or near ambient temperatures (Manning, 1989) and plasmids may be 
stored for long periods as aqueous suspensions or lyophilised material. A plasmid- 
based delivery system generally consists of three components: a) a gene encoding a 
therapeutic protein or reporter protein, b) a plasmid-based gene expression system that 
controls the function of a gene within the target cell, c) a synthetic delivery system that 
controls the location of the gene within the body.
Non-viral gene delivery methods can be classified as either physical, non­
particulate and particulate systems. Physical methods include microinjection (Capecchi, 
1980), electroporation (Winterboume et al., 1988) and particle bombardment (Yang et 
a l, 1990). The afore mentioned are regular laboratory techniques but are less suitable 
for clinical purposes because of toxicity and lack of practicality although 
electroporation from a needle tip or particle bombardment using a ‘gene gun’ may find
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some use for local administration or vaccination strategies. Non-particulate and 
particulate systems will be the focus of the remainder of this review.
1.2.3.1. Non-particulate systems, Naked DNA
The simplest approach to non-viral delivery systems is the direct gene transfer 
with naked plasmid DNA. Plasmids are colloidal systems with characteristics 
unfavourable to cellular uptake (specific hydrodynamic size, very hydrophilic and have 
a net negative surface charge owing to the phosphate group on each nucleotide, and 
lability), despite this fact plasmid DNA is active in vivo under certain circumstances. 
Expression was first observed after injection of purified DNA into skeletal muscle 
(Wolff etal., 1990, 1991, 1992a). Although initial studies demonstrated that expression 
of reporter genes lasted for several months, expression was generally at low levels 
during this time. These early results stimulated further refinement in plasmid DNA 
construction (Hartikka et al., 1996) and delivery vehicles (Mumper et al., 1996), both of 
which significantly enhanced the level of transgene expression.
Plasmid expression has subsequently been found in other organs including 
cardiac muscle (Lin et al, 1991), endothelial cells (Riessen et al., 1993), thyroid gland 
(Sikes et al, 1994), liver (Hickman et al., 1995; Budker et al., 1996), lungs (Meyer et 
al., 1995), tumour cells (Yang and Huang, 1996), and the brain (Schwartz et al., 1995). 
The mechanism by which cells take up and express purified DNA remains puzzling. It 
has been proposed that, in muscle DNA is taken up through the T-tubules into the body 
of the cell (Wolff et al., 1992b). In thyroid it has been proposed that DNA is taken up 
passively during the normal course of endocytosis by thyroid follicular cells (Sikes et 
al., 1994).
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1.2.3.2. Non-Condensing Interactive Polymers
The level of gene expression following intramuscular injection of unformulated 
plasmids into non-occluded muscle tissue remains insufficient for a number of 
applications, resulting in highly variable levels of expression. Following on from this 
formulations of plasmid DNA for intramuscular administration with polymers such as 
polyvinyl pyrridone (PVP) and polyvinyl alcohol (PVA) (reviewed by Ledley, 1996) 
have been explored as a means for enhancing stability, retention, and dispersion of 
DNA within muscle (Mumper et al., 1995 Mumper et al., 1996). PVA and PVP interact 
with plasmids through hydrogen bonding (Mumper et al., 1998). This interaction 
affords the plasmid several properties, the plasmid gains some nuclease protection, 
through being provided with a hydrophobic coat by the polymers. This hydrophobicity 
also led to increase in uptake and movement within the muscle. A 10-fold enhancement 
in gene expression over naked DNA has been observed in rat muscle using the PVP and 
PVA polymer system (Mumper et al., 1995; Mumper et al., 1996). Also intramuscular 
injection of PVP-based plasmid formulations provide reproducible levels of gene 
expression along with a continued increase in expression as plasmid dose is increased to 
levels above 100 pg have been observed (Mumper et al., 1996). The ability of PVP- 
based formulations to extend the dose response kinetics suggests that the plasmid DNA 
enters cells by a different pathway than naked DNA (Levy et al., 1996), or that the PVP 
alters the capacity of one of the rate-limiting steps in this pathway.
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1.2.3.3. Particulate Systems
Non-viral delivery systems are primarily designed to interact with the phosphate 
groups of nucleotides, reducing the net negative surface charge of plasmids. 
Neutralisation of more than 90% of the plasmids negative charges results in 
condensation of the plasmid into a particle. In neutralising the plasmids negative 
charges the molecule can interact with biological membranes which also have a net 
negative charge. Uptake of cationic particles takes place non-specifically by adsorptive 
endocytosis. Today the principle ways of accomplishing condensation and packaging of 
plasmid DNA are either with hydrophobic cations or hydrophilic polycations. 
Hydrophobic cations form liposomes or micelles that can interact with DNA and 
reorganise into a cationic lipid/DNA complex called a ‘lipoplex’, the process of DNA 
delivery mediated by cationic lipids is termed ‘lipofection’. The hydrophilic 
‘polycations’, mainly polymers also form complexes with DNA, such a complex is 
described as a ‘polyplex’ (Feigner et al., 1997; Feigner, 1999) and cationic polymer 
mediated DNA delivery is termed ‘polyfection’.
The following discussion on non-viral particulate systems will look, not only at 
the first generation systems, but also at the more sophisticated systems, which are 
evolving to gain some of the elegant functions and complexities of viruses. The 
incorporation of both viral and non-viral functional groups into a transfer system should 
allow such a system to surmount the various extra- and intra-cellular barriers to gene 
delivery. The expanding array of non-viral vector platforms will be selected ultimately 
on their ability to effect gene transfer in vivo.
The levels of gene expression obtainable in animals with a number of non-viral 
formulations are in some instances comparable to levels seen with viral gene delivery
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systems. However, viruses are still much more efficient gene delivery systems. For 
example, adenoviruses are typically used in vitro at a multiplicity of infection of about 
100. Under these conditions, in which each cell is exposed to an average of only 100 
functional adenovirus particles, most of the cells exposed to the virus become 
transfected. To achieve comparable levels of transgene expression with non-viral 
systems, the cells must be exposed to about 1 million copies of plasmid per cell (5pg 
plasmid/million cells). Similar differences in efficiency are apparent from in vivo 
studies. In mouse lung, about 2 x 1013 copies of plasmid (130pg) were used, whereas, 
in a typical adenovirus vector study 109 virus particles are administered. There is 
therefore much scope for improving the efficiency of non-viral gene delivery and it is 
believed that much of the improvement will come from the development of new and 
improved non-viral gene delivery systems.
1.2.3.3.1. Cationic Lipid-Based Gene Delivery Systems
The most investigated approach in non-viral gene therapy are cationic lipid- 
based systems. In vivo they may enhance gene delivery in several ways including: (a) 
protecting DNA against degradation, (b) modifying the size, charge and surface 
characteristics of the DNA-containing particulate to control its biodistribution within 
the body and access to the target cell, (c) enhancing the interaction of DNA with the 
surface of the target cell, (d) inducing endocytosis, (e) enhancing release of DNA from 
the endosome and (f) enhancing the entry of DNA into the nucleus.
The prototype cationic lipid for gene transfer in vitro is Lipofectin a mixture of 
DOTMA and co-lipid DOPE (Feigner et al., 1987, 1994). Since its successful 
introduction a number of cationic lipids have been designed and synthesised, the more
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recent cationic lipids include the quaternary amine-based cationic lipids e.g. DMRIE 
and DOTAP (Feigner et al., 1994; Liu et al., 1995) and the cholesterol based cationic 
lipids e.g. DC-Chol (Goa and Huang, 1995). Neutral lipids such as DOPE and 
cholesterol are generally included in lipoplexes as colipids as they are thought to 
facilitate fusion between the lipids in the lipoplex and the endosomal membrane, 
destabilising the endosome and releasing the plasmids or lipoplexes into the body of the 
cell.
Differing structures have been reported on mixing cationic lipids with plasmid 
DNA. Gustafasson observed lipoplex systems that resembled multilamellar vesicles by 
cryoelectron microscopy suggesting that lipid bilayers were able to maintain structure 
and form stacks of bilayers with DNA intercalated between the bilayers (Gustafasson et 
al., 1995). Gao and Huang have reported to observe heterologous structures they 
describe as ‘spaghetti and meatball complexes’ (Gao and Huang, 1995). Another 
proposed model involves the reorganisation of the initial lipid structure for instance 
cationic liposomes by fusion of adjacent lipid structures induced by the polyanionic 
plasmid (Gershon et al., 1993; Sternberg et al., 1994).
Due to the intensive research in this area, novel cationic lipid molecules are 
regularly reported and it has also been discovered that the optimal composition of the 
lipid-based systems required to achieve maximal in vitro gene expression varies from 
cell line to cell line however, despite all this research no definite structure-activity 
relationship has emerged between the structure of the charge groups or fatty acid 
component and gene transfer (Feigner et al., 1994; Gao and Huang, 1995).
A small number of mechanistic studies have been initiated to try and 
characterise the pathway by which plasmid DNA enters the nucleus
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Cationic lipids have been used successfully to deliver genes to several target 
tissues in vivo. The lung appears to be particularly susceptible to cationic lipid- 
mediated delivery. Various lipid formulations have successfully transfected pulmonary 
epithelial cells after instillation and nebulisation to the airways (Caplen et a l, 1995; 
Logan et al., 1995; Middleton et al., 1994; Sorcher et a l, 1994). Successful expression 
of a  1-anti-trypsin (Canonico et al., 1994a,b) and cystic fibrosis transmembrane 
conductance regulator (CFTR) (Yoshimura et a l, 1992; Alton et al 1993; Hyde et al., 
1993), within the lung in animal studies has led to clinical trials of gene therapy for 
genetic deficiencies of these proteins.
Several studies have also employed lipoplexes for administration directly into 
tumour masses for anticancer therapy. Initial studies were aimed at expressing a foreign 
antigen within tumour cells to enhance the immunogenicity of the tumour or 
presentation of tumour-specific antigens. Studies in mice demonstrated the feasibility 
of gene delivery and expression in tumour cells after direct injection as well as 
stimulation of a cellular immune response against the tumour (Plautz et al., 1993; Corny 
et a l, 1994). A clinical trial has been reported in which the gene encoding HLA B7 
was introduced into melanomas as a xenoantigen, with the expectation that the immune 
response against this antigen, as well as potentially enhanced presentation of tumour- 
specific antigens, would lead to immunologically mediated destruction of the injected 
tumour and potentially a tumour vaccine against systemic disease (reviewed by Ledley, 
1995).
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1.2.3.3.2. Polypeptide Gene Delivery
Formulations of DNA with protein ligands have been developed to achieve 
receptor-mediated uptake of plasmids into certain target cells. Proteins are commonly 
complexed with DNA by covalently coupling the protein to polylvsine and binding this 
complex to DNA through ionic interaction between the positively charged polylysine 
and the negatively charged DNA (Wagner et al., 1990; Wagner et a l, 1991a). The 
interaction of polylysine with DNA also condenses the DNA and toroidal protein/DNA 
structures as small as 80 nm diameter have been reported (Wagner et a l, 1991a). The 
protein component of the resulting complex retains its ability to interact specifically 
with cognate receptors on the target cell, which leads to internalisation of the DNA into 
the cell by receptor-mediated endocytosis. Several different protein ligands have been 
used effectively in vitro. For example transferrin/polylysine/DNA complexes have 
shown effective gene delivery into various cell types in vitro including hematopoietic 
cells, T cells and pulmonary epithelium cells (Wagner et a l, 1990; Zenke et a l, 1990; 
Buschle et al., 1995; Harris et a l, 1993). Surfactant B/polylysine/DNA complexes and 
anti-thrombomodulin/polylysine/DNA complexes have both been used for effective 
gene delivery into epithelial airways (Trubetskoy et a l, 1992; Baatz et al., 1994).
These approaches, though successful in obtaining expression of therapeutic 
genes in animal models, present several limitations associated with the use of 
polypeptides such as pLL which is known to be toxic and to have variable quality. 
Additional problems include aggregation in biological fluids and low levels of DNA 
able to formulated, pLL-DNA complexes are only practical up to about 20jig/ml which 
makes animal work virtually impossible (Wagner et a l, 1998). Modifying the poly-L-
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lysine does reduce aggregation e.g. soluble DNA/transferrin-polylysine 
complexes can be generated at DNA concentrations upto 300pg/ml.
The limiting step in receptor-mediated gene transfer in vitro is the rapid 
degradation of DNA within the endosome after endocytosis (Curiel et al., 1991). 
Several methods have been described for enhancing the release of DNA from the 
endosome before fusion with the lysosome acidifies the endosomal compartment and 
introduces nuclease capable of rapidly digesting the DNA. One approach has been to 
add non-infectious adenoviral particles (Curiel et al., 1991; Curiel et al., 1992; Cotton et 
al., 1992; Wagner et al., 1992a) to the transfection mixture which has led to a 
significant increase in transfection efficiency in vitro. Adenoviral particles like many 
other viral particles, induce endosomal lysis during the process of adenoviral infection,. 
Endosomal lysis by adenoviral particles is mediated by the penton protein on the surface 
of the virus that undergoes a change in tertiary structure upon acidification of the 
endosome (Seth, 1994). This change in conformation creates a structure that is capable 
of penetrating and disrupting the endosomal membrane and causing release of the 
endosomal contents into the body of the cell. Endosomal release can also be mediated 
by fusogenic peptides such as the influenza virus hemagglutinin peptide. The active 
influenza hemagglutinin peptide has a globular structure at neutral pH and assumes an 
amphipathic helical structure at acid pH that is capable of penetrating and disrupting 
endosomal membranes (Wagner et a l, 1992b).
Despite considerable success with receptor-mediated gene transfer using protein 
and endosomal release agents in vitro, these methods have generally been ineffective in 
vivo. The major factors limiting the in vivo effectiveness of polypeptide/DNA 
complexes may be their poor bioavailability to many target cells and their colloidal 
instability in physiological fluids. Bioavailability may be limited by the size of the
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complex (particularly complexes incorporating adenoviral particles) as well as by 
aggregation and/or dissociation of these complexes in physiological fluids. Moreover, it 
has been difficult to achieve reproducible effects due to the intrinsic variability in the 
quality and size of polylysine, the covalent protein/polylysine complexes and methods 
used for producing formulations.
In vivo studies have revealed several different pathways for intracellular 
trafficking of DNA following receptor-mediated endocytosis. When plasmid DNA is 
delivered to hepatocytes in normal animals, DNA is cleared from the liver within 
several hours leading to gene expression only for several days (Wu and Wu, 1988; Wu 
et al., 1991; Wilson et al, 1992). In contrast, when the same material is injected into 
animals after a partial hepatectomy or treatment of animals with colchicine, DNA 
persists in the liver for several months leading to a prolonged period of gene expression. 
Studies by Chowdhury et al., demonstrate that partial hepatectomy leads to 
compartmentalisation of intact plasmid DNA within intracellular, membrane 
encapsulated vesicles. It was hypothesised that this persistence could be related to 
disruption of microtubules and the progression of the endosome along these 
microtubules to the lysosome. This hypothesis was confirmed with in vivo studies 
demonstrating that the administration with asialoorosomucoid/polylysine/DNA 
complexes leads to persistence of DNA in the liver and gene expression for 8-10 weeks 
(Chowdhury et al., 1996).
1.2.3.3.3. Condensing Cationic Polymers
Cationic polymers associate with negatively charged DNA similarly to cationic 
lipids by electrostatic interactions. Several different classes of cationic polymers have
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been described to enhance the uptake of DNA into cells and its release from the 
endosome they can be divide into two groups dendrimers and polyethylenimine.
1.2.3.3.3.1. Dendrimers
The first class are non-linear, such as polyamidoamine cascade dendrimers and 
Starburst™ have been synthesised. They are highly polycationic compounds that are 
able to condense DNA through electrostatic interactions of their terminal primary 
amines with the DNA phosphate groups. These complexes exhibit efficient gene 
delivery into a variety of cell types in vitro (Bielinka et al., 1996). These compounds 
can be intact or fractured. Perfect polyamidoamine dendrimers are rigid molecules that 
are able to condense DNA, have high charge density, and may be further protonated in 
the endosome. However it appears that the highest activity is observed when the 
cascade polymer is imperfect (partially degraded) allowing swelling, which may explain 
the enhanced activity of impure dendrimers (Tang et al., 1996).
1.2.3.3.3.2. Polyethylenimine
Polyethylenimine (PEI) (Boussif et al., 1995; Abdallah et al., 1996) is one of the 
most promising cationic polymers under investigation. PEIs can be linear or branched 
and are able to condense DNA at neutral pH. However, its branched structure, contains 
a proportion of tertiary amines that are protonated at lower pH. Thus, PEI becomes 
protonated in the endosome, which may disrupt the endosome either directly due to the 
membrane activity of the polycation, or possible by mechanical swelling or osmotic 
effects (Haensler and Szoka, 1993). PEI has been used for in vivo gene transfer via
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different routes of administration such as lung instillation, intracranial injection and 
intravenous administration. PEI has been shown to transfect a large variety of cell lines 
and primary cultures with efficiencies at least as high as those of cationic liposomes 
(Bousiff et al., 1996). Targeted gene delivery has also been reported by conjugating a 
ligand to PEI in vitro (Zanta et al., 1997). Encouraging in vivo results were obtained 
after intracranial injection in mice (Schwartz et al., 1996). The in vivo transfection 
efficiency was similar to their transfection efficiency in vitro for the same amount of 
DNA applied to neuronal cells. The highest transfection efficiencies in vivo was 
observed with PEI polyplexes bearing net charges around neutrality. Ferrari et al., 
1997, showed that instillation of linear PEI polyplexes into the lungs of rabbits 
transferred the luciferase gene more efficiently than trasfectam based gene complexes.
Gene transfer was also shown to be 10-1000 times more efficient after 
subcutaneous administration into tumours in mice with charge neutralised transferrin- 
PEI based polyplexes in comparison to naked DNA (reviewed by De Smedt et al, 
2000). Transferrin-PEI polyplexes were used to transfect cells in culture. The 
possibility of reaching high transfection efficiency by using complexes with a charge 
ratio close to neutral is a major advantage of PEI. Electrostatic interactions between 
charge-neutralised polyplexes and cell surfaces are absent, a way of establishing 
interactions is the use of ligands e.g. transferin, galactose. PEI covalently linked to 
galactose (via amine formation with lactose) groups resulted in an increase in in vitro 
transfection of hepatocytes (reviewed by De Smedt etal., 2000).
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1.3. MICROPARTICLES FOR GENE DELIVERY
While viral vectors and liposomes have been used in a majority of the gene 
therapy trials so far, results fail to show significant improvement compared to 
conventional methods of treating genetic disorders. Thus, novel vehicles for gene 
transfer are being developed and assessed in appropriate animal disease models. 
Microparticles are one class of vehicles currently being examined for gene delivery.
Microparticulate systems can be applied to a wide diversity of routes for 
administration e.g. pulmonary, intratumoral, oral and nasal to mention a few. Their 
main advantage is that they can be used to provide non-invasive controlled drug 
delivery for a period of time and do not need to be removed once the therapy is 
complete. However, several factors need to be considered when formulating 
microparticles for each of these routes of administration, these are listed in Table 1.1, as 
each of these routes of administration will require properties specific to the individual 
route.
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Table 1.1 Factors to be considered prior to introduction of microparticles for use in 
vivo (Pass and Burton, 1999).__________________________________________
• Structure and size of particles
• Surface properties of particles, such as charge and texture
• Degradability of the matrix during storage and persistence in vivo
• Toxicity of the particles when intact and when degraded
• Antigenicity/immunogenicity of the particles
• Physiochemical features of the drug to be loaded, such as hydrophilicity
• Stability of the drug during incorporation, storage and use
• A rational dose regimen determined from animal and clinical studies
• Mechanism of release of the drug from the carrier
• Administration via the carrier is at least as therapeutically efficient as free drug
Microparticles are generally fine spherical particles with diameters less than 125 pm to 
be of any therapeutic value, and can be divided into two categories: (a) microspheres, 
homogenous or monolithic in which the drug is dissolved or dispersed throughout the 
polymer matrix, solid dispersion and (b) reservoir type microcapsules in which the drug 
is surrounded by the polymer matrix in the mononuclear or polynuclear state, finally, (c) 
in some systems the drug is adsorbed or chemically conjugated on the surface of the 
polymer or entrapped inside the pores or channels in the matrix (Okada and Toguchi, 
1995).
Table 1.2. Factors affecting drug loading of microspheres (Dass and Burton, 1999).
• Chemical composition of sphere matrix
• Size of spheres
• Degree of porosity of matrix
• Micropshere formulation procedure
• Type of bonding between drug and microsphere surface
• Influence of other agents in die drug loading mixture
• Concentration of drug in die loading mixture
• Temperature at which drug is loaded
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Due to the versatility of the matrices available drugs of varying characteristics can be 
loaded. The incorporation of drugs and release of drugs from these microparticles are 
dependent on various factors, which are listed in table 1.2 and 1.3 respectively.
Table 1.3. Factors affecting drug release from microspheres (Dass and Burton, 1999).
• Chemical composition of sphere matrix
• Temperature at which spheres are formulated
• Treatment of postmanufactured preloaded spheres with heat
• Chemical treatment of postmanufactured preloaded spheres
• Percentage of drug loaded
• Type of bonding between drug and sphere surface
• Chemical treatment of loaded microspheres
• Temperature of eluting buffer
• Type of in vitro release system
These factors can be taken into account when formulating a gene delivery incorporating 
microparticles with plasmid DNA.
1.3.1. Matrix Composition of Microspheres
The choice of a matrix depends on several factors, including the chemical nature 
of the drug to be loaded, release characteristics from matrix, drug-loading capacity of 
spheres, and ease and cost of preparation. A variety of materials are used for fabrication 




The major advantages in using protein-based microspheres is their compatibility 
and degradability. Biodegradable microspheres release carried drug in three phases (a) 
initial burst effect due to release of weakly attached drug on surface of spheres, (b) 
second phase, where drug release is slow due to medium diffusing slowly into the 
polymer matrix, whereby degradation occurs and drug diffuses out into the medium, 
and (c) the final release phase, when matrix becomes water soluble, leading to an 
erosion of the residual matrix and eventual collapse of the spheres (Singh et al., 1996). 
Functional groups such as amine (-NH2) and carboxylic (-COOH) make proteins 
suitable for microspherical drug delivery. Albumin is prevalently used, although 
fibrinogen (Miyazaki et al., 1986), gelatin (Narayani and Rao, 1996a), haemoglobin 
(Chen et al., 1988), transferrin (Chen et al., 1988), fibrin (Ho et al., and casein (Chen et 
al., 1994) have also been used for microsphere formulation.
Albumin microspheres have been used for delivering epirubicin into mice 
(Novotny and Zinek, 1994), and adriamycin into rats (Goldberg et al., 1992) with 
greater tumour suppression compared to free drug. Albumin microspheres have also 
been investigated as a inhaled drug delivery system (Zeng et al., 1995).
1.3.1.2. Polysaccharides
Polysaccharides such as alginate, dextran and starch have been used for drug 
delivery. Degradable starch microspheres (DSMs) have also been used towards tumour 
therapy. If the blood supply to a tumour can be located and is accessible by catheter, 
regional perfusion with drugs can be affected. To enhance regional drug delivery DSMs
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of 15 to 80 fim in size are infused into the arterial blood supply of a tumour (Dass et al., 
1998).
1.3.1.3. Synthetic Polymers
Synthetic polymers are generally superior with respect to the reproducibility of 
the product compared to natural polymers. Synthetic polymers are highly lipophilic and 
dissolve in organic solvents in which lipophilic drugs can be dissolved, and hydrophilic 
drugs can be suspended or emulsified as an aqueous solution to prepare the 
microparticles. A major advantage of some of these polymers is that their degradation 
rate can be controlled through manipulating either the molecular weight of a 
homopolymer, or hydrophilicity and composition of a copolymer.
Microspheres with polystyrene-based matrices usually load and release drugs via 
ion-exchange resins depending on the availability of competing ions and diffusion rates 
of ions and drug molecules into and out of the resin matrix (reviewed by Dass and 
Burton, 1999). Factors influencing drug release include the size and concentration of 
the competing ions, selectively for the resin of the different ions involved, and the 
porosity or degree of cross-linkage of the resin matrix. One advantage of ion-exchange 
microspheres is that the drug is loaded postmanufacture and is not exposed to the 
usually harsh conditions of sphere formulation. This is especially important when 
fragile agents such as long strands of DNA are loaded. However, only drugs with an 
overall charge may be loaded on these microparticles.
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1.3.2. Generation of Microparticles
The most basic methods for formulating microparticles are the solvent 
evaporation and solvent extraction (coacervation) methods. The solvent evaporation 
method involves the following steps, firstly, the polymer e.g. PLGA or PLA is dissolved 
in an organic solvent e.g. methylene chloride or ethyl acetate. The aqueous or solid 
drug is then added, and the solution is mixed by sonication or homogenisation to form 
the primary emulsion (solid or water-in-oil). This emulsion is then transferred to water 
containing an emulsifying agent e.g. poly(vinyl alcohol). Mixing of the primary 
emulsion in the water phase produces the microspheres, resulting in a secondary 
emulsion (solid or water in-oil-in-water. The final emulsion is diluted with excess 
water to facilitate removal of the organic solvent in the oil phase, and the microspheres 
are then dried (Cleland, 1997).
Where as the solvent extraction method involves similar steps in the initial 
stages with dissolving the polymer in an organic solvent. The aqueous or solid is then 
added, and the solution is mixed by sonication or homogenisation to form the primary 
emulsion as before. This emulsion is then transferred to a nonsolvent, i.e. a solvent in 
which the polymer has a low or negligible solubility e.g. silicone oil. Mixing of the 
primary emulsion in the nonsolvent produces the microspheres, resulting in a secondary 
emulsion (solid or water in-oil-in-oil). Another nonsolvent e.g. heptane is added to the 
final emulsion to extract the organic solvent from the first oil phase. The excess 
solvents in the supernatant are then removed, and the final microspheres are dried 
(Cleland, 1997).
Recently, several new approaches have been developed to produce an improved 
process for encapsulation of proteins in microparticles. Many of these approaches have
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focused on methods that do not denature the protein e.g. operation of the 
microencapsulation process at low temperatures and in the absence of a water phase 
should result in increased stability of the protein during the process. One method 
employed the spray freeze drying of proteins to obtain solid protein particles of 2-5 pm 
in diameter. The solid protein was then suspended in the polymer phase, and the 
suspension was sprayed into a container with solid ethanol and liquid nitrogen. The 
microspheres formed during the spraying process settled onto the solid ethanol, and the 
solution was then warmed to -80°C. The microspheres were suspended in the cold, now 
liquid, ethanol to extract the organic solvent from the polymer phase. After repeated 
washing with cold ethanol, the microspheres were dried by lyphilization. This process 
was claimed to provide a high encapsulation efficiency and enhanced stability of the 
protein (reviewed by Cleland, 1997).
The conventional spray drying approach at high temperatures resulted in 
microspheres that tended to agglomerate and have variable morphology depending upon 
the polymer. The high-temperature spray drying process may cause significant protein 
denaturation (Pavanetto eta l, 1993).
Another method that utilised low-temperature processing without an aqueous 
phase involved supercritical fluid extraction techniques. The polymer, which was 
dissolved in an organic solvent, was sprayed into a continuous phase of supercritical 
carbon dioxide. The carbon dioxide acts as a nonsolvent for the polymer phase and 
extracts the organic solvent. The microsphere size should correlate to the density of the 
carbon dioxide phase (e.g. more dense, larger microspheres). This process should also 
provide high encapsulation efficiency and improved protein stability (Randolph et al, 
1994).
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Other new processes have involved modifications of the solvent evaporation 
method. To produce a more homogeneous emulsion and stabilise the protein, 
surfactants have been added to the protein phase. It has been suggested that the addition 
of hydrophobic ion pairs to the protein phase allows a more homogeneous mixture of 
the protein in the polymer phase and provides stabilisation of the protein (review by 
Cleland, 1997). Multiphase systems may also protect the protein from denature. One 
type of multiphase system involves the suspension of aqueous drug in a heavy oil phase 
(primary emulsion), which is then emulsified in a light oil phase containing the polymer 
(secondary emulsion), and the secondary emulsion is then added to an aqueous solution 
to extract the light oil e.g. methylene chloride and form a triple emulsion (Iwata and 
McGinity, 1993).
Surfactants have also been added to the polymer phase to alter the release 
properties of the microspheres. The addition of non-ionic surfactants such as pluronics 
(block copolymers of ethylene oxide and propylene oxide) provides a reduced initial 
burst of protein release from these microparticles is further reduced by the addition of 
Polyethylenimine, which coats the microspheres and interacts with the protein to inhibit 
release (Park et al, 1992b). However, these methods in their present form do not 
provide high encapsulation efficiencies, and hydrophobic proteins may remain 
entrapped in the surfactant-polymer microspheres.
1.3.3. Microparticles and DNA Delivery
There are various studies evaluating the potential of microparticles for DNA 
transport. For instance, single and double stranded DNA were encapsulated in gelatin 
microspheres (Cortesi et al., 1994). These researchers immobilised fragments of 144
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base-pairs length into microspheres and characterised the in vitro release. 
Encapsulation efficiency for both types of DNA was at least 85% under varying loading 
conditions. Release was byphasic for both types of DNA, with an initial rapid release 
followed by a slower release phase.
Ion-exchange microspheres have been used to bind and release plasmids without 
degradation of the nucleic acids (Dass et al., 1996, 1997b). Polyanhydride 
microparticles were used to deliver plasmid DNA encoding 13-galactosidase into rats via 
the oral cavity (Mathiowitz et al., 1997). Encapsulation of the plasmids within the 
microparticles allowed greater expression of the gene in both the small intestine and the 
liver. Increased expression may be attributed to delayed release of DNA due to slow 
dissolution of sphere matrix, increased DNA uptake into cells due to physical contact of 
microspheres with target cells, and resistance proffered by complexation of DNA with 
the microsphere matrix. However, transfection was not reproducible in the small 
number of animals studied, and more importantly, polyanhydride did not cause an 
immunological reaction with mammalian tissue, as documented elsewhere (Edwards et 
a l ., 1997).
In an attempt to decrease the dose of adenoviral vectors for gene transfer into 
glioblastomas, recombinant viral units were encapsulated in poly(lactic-glycolic) 
microspheres (Beer et al., 1997). Gene transfer was detected up to 15 days in HeLa 
cells, as was a dose-dependent increase in cytotoxicity of 9L gliosarcoma cells. A dose- 
dependent increase in gene expression in mice was noted at 7 days postinjection of 
microspheres.
Gold particles of diameters between 1-3 pm have been used for bombardment of 
genes into tumours in mice (Sun et al., 1995). DNA was coated onto particles with a 
capacity of 2.5 pm per milligram particles. Mice were placed with the tumour
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surgically exposed and directly in the path of electronically accelerated particles. 
Expression of foreign genes was observed in the tumour and not in other tissues 
analysed.
1.3.3.1. Microparticles fo r  Lung Delivery
There is a wealth of knowledge on delivery of macromolecules to the airways by 
inhalation (Patton, 1996). The requirements for deposition of particles in the airways 
have been known for many years, and have been used to design inhalation systems for 
low-molecular weight drugs. Generally particles of 2-5 pm are retained in the airways, 
so it will be necessary to disperse the gene delivery system within particles of these 
dimensions. Formulations of lipoplexes have been developed for aerosol formation by 
nebulisation (Schwarz et al., 1996; Eastman et al., 1997). It is necessary to select an 
appropriate nebulizer, which does not create too much force of shear, and also screen 
formulations for stability under conditions of shear. Higher concentrations of DNA in 
the formulation were made possible, in the studies of Eastman et al. (1997), by 
incorporation of some PEGylated lipids. The critical issue in delivery to the lung will 
be the interaction of the formulation with the biological barriers presented by the lung 
epithelium. Though it has been possible using gene therapy to treat cystic fibrosis in 
mouse models of the disease (Alton et al., 1993; Dorin et al, 1996), the results of the 
trials in patients have been less encouraging.
Gene expression systems have been introduced to the lungs of animals either by 
inhalation or by aerosolization (Brigham et al., 1989, 1993; Hazinski et al., 1991; 
Yoshimura et al., 1992; Logan et al., 1995) (Stribling et al., 1992; Alton et al., 1993; 
Canonico et al., 1994; MacLachlan et al., 1994), and more recently attempts have been
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made to optimise the formulation of lipoplexes for gene delivery to airways epithelia 
(Fasbender et a l, 1995; Lee et a l, 1996).
Another, recent method for aerosol gene delivery is a system designed by 
Schuster et a l, 1997. The AERx™ was designed as an alternative to nebulization, to 
avoid shear degradation via nebulization. Sorgi et a l, 1998, have formulated DNA into 
an artificial viral envelope (AVE™) vehicle in which plasmid DNA is condensed and 
protected with a bilayer of anionic liposomes. This AVE/DNA vehicle is then delivered 
via the AERx™ aerosol delivery system, which generates a respirable aerosol cloud by 
a single extrusion through an array of precise micron-sized holes.
However, considerable research and development has yet to be carried out 
regarding delivery of therapeutic genes to the lung via the use of microparticle 
formulations. Biodegradable microspheres of the appropriate size distribution have 
been shown to lodge within the capillary networks of the lung and release their bio­
active agent into neighbouring tissue by a process of diffusion and biodegradation 
(Willmott et a l, 1984). A similar approach was used by Schaefer and Singh, 1997, who 
produced poly-lactic acid microspheres loaded with etoposide a chemotherapeutic agent 
for intravenous administration by a simple process of mechanical entrapment in the 
capillary beds of the lung for passive targeting of lung tumours. Specific targeting of 
microspheres to the lung for tumour thereby will greatly increase the concentration of 
the etoposide locally and decrease the concentration systemically, thereby eliminating 
or lessening the potent side effects.
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1.3.3.2. Particulate DNA Vaccines
Direct DNA inoculation, without the use of any viral vectors, is among the most 
interesting new additions to vaccine development. This approach is conceptually 
simple and can be viewed as the most elegant form of sustained protein delivery. 
Plasmid DNA encoding the antigenic protein is directly introduced to the tissue either 
by intramuscular or intradermal injection or by bombardment of DNA-coated gold 
particles through a high-voltage gene gun. After taking up the plasmid by non-specific 
endocytosis or cell membrane disruption, the host cells produce, process, and present 
the encoded antigen to the antigen presenting cells (APCs) in a manner similar to that 
which would happen during the course of natural infection.
Direct DNA vaccination has generated both humoral (Mor et al., 1995) and 
cellular (Pertmer et al., 1995; Ulmer et al., 1994) protective immunity to a number of 
pathogens. Direct inoculation of a tumour-associated antigen gene has also been used 
to enhance the immunogenicity of tumour cells and stimulate long-term systemic 
immunity (Conry et al., 1995). For example delivery of the IL-6 gene by a gene gun 
into the tumour site reduced methylcholanthrene-induced fibrosarcoma growth, and 
similar inoculation of the TNF-a and IFN-ygenes have prolonged the survival of Renca 
tumour-bearing mice (reviewed by Zhao and Leong, 1996). Relatively high efficiency 
of vaccination is one of the attractive features of DNA vaccines, although an effective 
delivery of the DNA is crucial.
As DNA is not an effective delivery alone for reasons covered through this 
chapter, delivery systems that protect DNA and target it to antigen-presenting cells are 
essential for the successful design of plasmid DNA vaccines. Particulate carrier 
systems such as microspheres offer promise of effective delivery of plasmid DNA for
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vaccination. The potential advantages of microparticles for vaccine development are 
shown in table 1.4. As well as offering the possibility of offering a controlled rate of 
release of the entrapped antigens they enhance the immunogenicity of the DNA vaccine.
Table 1.4. The potential advantages of microparticles for vaccine development.
• Safety: biodegradable and biocompatible polymers
• Acceptable for administration to man
• Controlled-release might enable the development of single-dose vaccines
• Adjuvants might be entrapped simultaneously in the microparticles
• Many antigens can be administered by mucosal routes, including oral delivery
• Antigens are protected from degradation in the intestine
• Antigens are targeted to lymphoid tissue
• Microparticles induce serum and secretary antibodies
• Microparticles induce cell-mediated immunity
• Freeze-dried formulations, with enhanced stability for entrapped antigens
• Large scale manufacture of microparticles has already been achieved
The adjuvant effect achieved through the association of antigens with polymeric 
microparticles has been repeatedly demonstrated (O’Hagan, 1997). Encapsulation of 
antigens into microparticles, including submicron particles, promotes their entry into 
lymph nodes and provides a high local concentration of antigen over an extended time- 
period. Microparticles also promote the interaction of encapsulated antigens with APCs 
e.g. macrophages. The poly(lactide-co-glycolides), biodegradable and biocompatible 
polyesters, are primary candidates for the development of microparticles as vaccines, 
because they have been used in man for many years as controlled delivery systems for 
peptide drugs. However, the adjuvant effect achieved by the encapsulation of antigens 
into poly(lactide-co-glycolide) microparticles has been demonstrated only relatively 
recently (O’Hagan et al 1991a). Particle size was shown to be an important factor 
affecting immunogenicity, because smaller microparticles (<10 pm) were significantly
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more immunogenic than larger particles (O’Hagan, 1993). The adjuvant effect of 
microparticles can also be enhanced by co-administration with additional adjuvants 
(O’Hagan, 1991b). Recent studies have shown that microparticles exert an adjuvant 
effect for cell-mediated immunity, including the induction of cytotoxic T-cell responses, 
(which are desirable for the immunotherapy of cancer) after both systemic and mucosal 
administration (Maloy et al., 1994; Moore et al., 1995). The induction of cytotoxic T- 
cell responses are important for the eradication of virally infected cells and for immune 
responses against alternative intracellular pathogens.
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1.4. AIMS AND OBJECTIVES
Microparticulate systems can be applied to a wide diversity of routes for 
administration e.g. pulmonary, intratumoral, oral and nasal to mention a few. Their 
main advantage is that they can be used to provide non-invasive controlled drug 
delivery for a period of time and do not need to be removed once the therapy is 
complete.
The objective of this research was to investigate the potential of spray dried 
microparticles produced by an established spray drying procedure at Quadrant 
Healthcare (previously, Andaris Ltd) to act as carriers for therapeutic DNA for 
pulmonary and intratumoral delivery. In Chapter 2 the possibility of producing 
reproducible soluble mannitol microparticles as carriers for DNA/lipid complexes for 
lung delivery through utilising Quadrant’s proprietary spray drying method was 
investigated.
Transfection in vitro with reporter genes is a good assay to assess biological 
activity of plasmid DNA and efficiency of gene delivery vectors whether they are lipids, 
polymers or microparticles. However, when trying to detect very low levels of 
transfection, a very sensitive assay is needed. 6-gal is a very popular reporter gene, 
however as mammalian cells have apparent galactosidase activity, the levels of basal 
activity are quite high. This results in interference when trying to detect low levels of 
transfection activity. Hence an alternative assay was investigated in Chapter 3, based 
on the luciferase reporter plasmid. In Chapter 4 the potential of spray-dried cross- 
linked albumin microparticles (produced by Quadrant’s proprietary spray drying 
method) to be used as carriers for DNA vaccines was investigated.
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In the final results chapter, Chapter 5 the location and stability of the cross- 
linked albumin microparticles in tumour tissue was investigated in vivo after 
intratumoral injection, as was the relationship between the presence of the albumin 




EVALUATION OF MANNITOL MICROPARTICLES AS GENE THERAPY
VECTORS FOR THE LUNG
2.1. INTRODUCTION
The pulmonary route of administration, is attractive for the delivery of 
pharmaceuticals due to the large surface area, high degree of vascularisation and ease of 
accessibility, which the lung provides. The same holds true for the delivery of proteins, 
peptides and genes. Several DNA-based delivery systems, i.e. the adenovirus 
(Rosenfeld et al, 1994), adeno-associated virus (Flotte et al, 1993) and liposomes 
(Schreier and Sawyer, 1996) have been used, to varying degrees of success, to deliver 
genetic material to the lung. However, most have been administered by direct 
instillation (Brigham et al, 1989; Logan et al, 1995) or aerosolisation (Stribling et al, 
1992; Alton et al, 1993; McLachlan et al, 1995). Direct instillation of the vector into 
the lung is impractical and undesirable as a manner of delivery for maintenance dosing. 
Most aerosolised vectors are in liquid form and are aerosolised by nebulisation, which is 
inefficient and irreproducible and may induce shear degradation of the plasmid DNA 
(Schwarz et al, 1996; Eastman et al, 1997).
Another alternative, is to formulate a DNA-based delivery system as a dry 
powder formulation which could be administered using an existing dry powder delivery 
device, many of which are known to be fairly efficient and reproducible in their mode of 
delivery. One way of formulating the plasmid DNA into a dry powder formulation, 
may be to encapsulate the DNA-based vector in a protective matrix formed by spray- 
drying with a sugar for example, thereby enhancing DNA stability and protecting the
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biological activity of the plasmid. The method of spray drying will be a reproducible 
method which can produce microparticles of an appropriate size, which enables them to 
be inhaled and deposited in the lungs.
This chapter investigates the possibility of using Quadrant’s proprietary spray 
drying method to produce soluble mannitol microparticles carrying a DNA-lipid 
complex as a dry powder formulation. Firstly, it was necessary to investigate the 
feasibility of producing uniform reproducible microparticles via spray drying. 
Secondly, survival of the plasmid after undergoing the spray drying process was 
investigated. Finally, attention was given to the stability of the plasmid and its 





Escherica coli strain XL 1-Blue (Stratagene), which has resistance to tetracyline 
was used for propagation of plasmids.
2.2.1.2. Deoxyribonucleic A d d  (DNA)
Two types of plasmids, pRSVlacZ and pCMV/acZ were used. Both plasmids 
contain the E.coli lacZ gene, which encodes the 13 galactosidase enzyme.
2.2.1.3. pRSVlacZ
pRSVlacZ was obtained from Dr Ogilvie (Zeneca Pharmaceuticals). It is a 7.8 
kb plasmid where the E.coli lacZ gene is under the transcriptional control of the Rous 
sarcoma vims (RSV) long terminal repeat promoter/enhancer sequence. The RSV 
promoter is a moderate to high strength promoter causing moderate levels of transgene 
expression in mammalian cells. The plasmid map for pRSNlacZ may be found in 
appendix A.
2.2.1.4. pCMVlacZ
pCMNlacZ, a 7.2 kb plasmid was obtained from Clontech, UK. In this vector 
the E.coli lacZ gene is under the transcriptional control of the human cytomegalovirus 
(CMV) immediate early promoter/enhancer element. The CMV promoter is a strong
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viral promoter causing high levels of transgene expression in mammalian cells. The 
plasmid map for pCMV/acZ may be found in appendix A.
2.2.1.5 Plasmid Propagation, Isolation and Purification
A single colony of E.coli XLl-Blue isolated from an LB agar plate 
supplemented with ampicillin and tetracycline (50pg/ml and 12.5pg/ml respectively) 
was incubated into 10ml of LB broth (1° culture) containing the same antibiotics. The 
1° culture was grown for 8 hours at 37°C in a shaking incubator at 300rpm (New 
Brunswick Scientific), then a 5ml aliquot from the 1° culture was expanded in 500mls 
of LB broth overnight. The plasmid was isolated according to the alkaline lysis method 
and the cell lysate purified by anion exchange chromatography using the Plasmid Mega 
Kit (Qiagen Inc, UK) following the manufacturer’s protocol. The isolated DNA was 
dissolved in sterilised Milli-Q water and stored at -20°C.
2.2.1.6 Sample Purity and Quantification
For quantification of plasmid DNA, a 10pi aliquot of sample was diluted to 1ml 
with sterilised Milli-Q water and the absorbance of the solution measured at 260nm 
(A260) and 280nm (A280). The concentration of DNA in the original solution was 
calculated as follows:
Concentration of DNA (pg/ml) = Dilution factor x 501 x A260
1 based on the assumption that a 50 pg/ml solution of double standard DNA has an 
absorbance of 1 at 260nm (Sambrook et al, 1989; reviewed by Feigner, 1997).
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The purity of DNA was calculated as follows:
Ratio — A260 /  A280
Ratios between 1.8 and 2.0 (which indicates high purity) were obtained consistently.
2.2.1.7. Sample Identification
A sample of purified DNA was linearised with a restriction endonuclease (New 
England Biolabs, UK). Xba I for pRSWlacZ or EcoK I, Pst I, Not I for pCMNlacZ 
enzymes for one hour at 37 °C and then loaded onto a 1% agarose gel (Ultrapure grade, 
Gibco, UK) in lx  TBE buffer. The gel was subjected to electrophoresis in the same 
buffer at 80 volts for one hour and 45 minutes against marker DNA (EcoK V Hind DI 
cut DNA, see Appendix) of variable length to confirm the size of isolated DNA. 
Control of indigested DNA were also run to exclude the presence of contamination 
genomic DNA or RNA in samples (appendix B7).
2.2.2. Gene Delivery Vectors
2.2.2.I. DOTAP
N-[-l-(2,3-Dioleolyoxy)propyl]-N,N,N-trimethylammonium-methylsulphate 
(Avanti Polar Lipids, USA). DOTAP a cationic lipid presented in this case as a powder, 
was used to prepare liposomes as described in section 2.2.2.3.
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2.2,2.2. DOPE
Dioleoylphosphatidylethanolamine (Avanti Polar Lipids, USA). DOPE a neutral 
lipid presented in this case as a powder, was used to prepare liposomes as described in 
section 22.23 .
2.2.23. Preparation o f Liposomes 
2.2.2.3(a) DOTAP Liposomes
Liposomes were prepared by the reverse phase evaporation method (Szoka & 
Papahadjopoulos, 1978, Hug & Sleight, 1991). DOTAP powder was dissolved in 
chloroform to produce a 5 mg/ml stock solution. An appropriate volume of solution 
was transferred to a clean 4 ml HPLC glass vial. The chloroform was evaporated, by 
bubbling nitrogen gas, leaving a thin lipid film on the glass wall. Residual amounts of 
chloroform were removed by placing vials under high vacuum overnight. The lipid film 
was subsequently re-dispersed in sterile 95% w/v mannitol solution to give a 5mg/ml 
solution of large multilamellar vesicles by vortexing following preparation. Liposomes 
were stored at 4 °C and used within 7 days.
2.2.2.3(b) DOTAP.DOPE Liposome
Liposomes containing a 50:50 weight mixture of the cationic amphiphile 
DOTAP to the neutral lipid DOPE, were prepared by the reverse phase evaporation 
methods described in section 2.2.2.3(a). The lipid film was re-dispersed in sterile 95% 
w/v mannitol solution to give a 5mg/ml solution of large multilamellar vesicles by
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vortexing. Following preparation, liposomes were stored at 4 0 C and used within 7 
days.
2.2.3. Spray Drying
Spray drying is a one-step process that converts a liquid feed to a dried 
particulate form. In a typical application, the fluid is first atomised to a spray form, 
which is in thermal contact with a hot gaseous medium. The large surface area of 
contact results in rapid evaporation of the droplets to form dried solid particles/granules, 
which are then separated from the gas by means of a cyclone, electrostatic precipitator, 
or bag filter (Sacchetti and Van Oort, 1996).
The spray drying process can be broken down into four fundamental stages: 
circulation of drying gas, atomisation, drying and separation. The first consideration is 
whether it is an open or closed cycle operation. An open cycle system is a system 
where the drying gas, usually air is vented out into the atmosphere; where as in a closed 
cycle system the (hying gas (usually nitrogen with an oxygen content maintained less 
than 5%, below level required for ignition) is recirculated.
Atomisation is a process whereby a liquid is broken up into a collection of 
droplets. Since the surface area and surface free energy are increased upon spray 
formation, atomising a fluid requires work. The amount of work and the manner in 
which it is done (i.e. nozzle design) on the liquid can affect the droplet sizes, and can 
thus provide flexibility and control in generating a desired particle size distribution. 
There are many methods of atomising a liquid, the chief ones of which can be classified 
according to the way energy is transferred to the liquid: centrifugal (rotary), pneumatic 
(air-assist), high pressure, effervescent, ultrasonic and electrostatic. For more details of 
how the afore mentioned atomisation methods work see Sacchetti and Van Oort (1996).
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Once the liquid is atomised it is in intimate contact with the heated gas, and 
evaporation of the drops occurs, accomplishing drying. During their residence in the 
main chamber these droplets dry to form solid particles/granules. This (hying step is 
critical for several reasons. Although initial droplet size is determined by atomisation 
variables, it is during the drying process that solid particles form. The final size, shape, 
density, crystallinity and moisture content of the particles is affected by the conditions 
in the drying chamber (Sacchetti and Van Oort, 1996).
Finally, after the spray-dried powder is formed, it must be separated from the 
circulating gas medium. The three methods for separation are cyclone separators, bag 
filters and electrostatic precipitators. In a conventional cyclone the tangential entry 
produces a downward spiralling vortex with a central core of upward flowing gas. The 
circulation of the velocity field produces a centrifugal force on the entrained spray-dried 
particles. Thus, the particles migrate radially outward, will impact on the cyclone wall 
and will be removed from the gas flow with a certain collection efficiency. The 
downward velocity component of the spiralling motion results in powder collection in 
the vessel attached to the bottom of the cyclone. Bag filters, as the name implies is a 
woven fabric used to remove spray-dried particles by filtration from the gas flow. The 
fabric is attached to the output of the drying chamber as a stand-alone unit or is used 
after a cyclone in a two-stage recovery to collect the ultrafine particles. Electrostatic 
precipitators used in spray drying are normally of parallel plate design with a discharge 
electrode to ionise the gas stream. The spray-dried particles acquire charge and migrate 
to the grounded plates for removal from the gas flow (Sacchetti and Van Oort, 1996).
This variety of atomisation, drying and separation techniques enables spray 
drying to be adapted to many applications.
43
2.2.3.1. Spray Drying Method
The spray drying process used at Quadrant Healthcare pic (formerly Andaris 
Ltd) Nottingham, UK, was a low temperature ‘open cycle’ spray drying process, with 
pneumatic atomisation (twin-fluid), in this case achieved with an external mixing 
nozzle. Fig 2.1 shows a schematic layout of the “open cycle” spray drying process and 
the components special to this particular set up. The lipoplex formulations were spray 
dried aseptically, using the afore mentioned process in conjunction with a Research 
Scale Spray Diyer, proprietary instrument of Andaris. This instrument is designed as 
part of a scalable system, which offers better simulation of a process-scale than 
laboratory bench spray dryers. The conditions of the process were monitored and 
documented (see results).
Figure 2.1 Schematic layout of the Research Scale Spray Dryer and the ‘Open Cycle’ 












Briefly, the air was exhausted directly into the ductwork of the sterile chamber. 
The drying gas was heated to the desired temperature, which was monitored and 
maintained by a thermocouple and feedback system. The drying gas passed through the 
distributor plate and passed into the main chamber, where it was mixed with the spray 
generated by the atomiser. The enormous surface area of the spray and its intimate 
contact with the heated gas result in rapid drying and solidification of the feed 
substance. The majority of the mass passed through the cyclone, where it was separated 
from the gas flow and collected in the vessel. The filter bag removed the ultra fine 
particles before exhausting the moist gas to the atmosphere. Exact conditions are 
detailed later in this chapter.
The product was recovered from the spray drier by carefully brushing through 
all the chambers and collating all the powder in the collection vessel. It was then 
transferred to a sterile vial under sterile conditions.
2.2.3.2. Preparation o f Formulae fo r Spray Drying
The minimum volume that could be spray dried in the mini-spray dryer was 
approximately 2 ml of a solution with a minimum solid content of 500mg, to ensure 
recovery of at least 10% of the product. These practical constraints were particularly 
important for DNA formulation. DNA was difficult to produce, time consuming, very 
expensive and only small amounts (2.5 mg per lot) could be produced at bench scale. 
Therefore the formulations used in this study were adapted with the minimum volume 
in mind. Since a maximum of 2.5mg of plasmid DNA could be produced per batch it 
was appropriate to use DNA at 0.5 mg/ml for spray drying. Control batches were spray 
dried for each formulation consisting of cationic lipid in mannitol solution. Spray 
drying experiments were carried out in duplicate.
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Tables 2.1a-b show the formulations used for spray drying. Two batches were 
prepared in each case.
(a)











2.2.4. Physical Characterisation Methods
2.2.4.I. Light Microscopy
A small number of particles were taken and placed on a microscope slide to 
which a few drops of acetone were added before a cover slip was placed on the slide. 
The slide was then visualised under a light microscope at a magnification of x400. 
Images were taken of the microparticles, this was carried out for each batch produced.
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2.2.4.2. Particle Size Analysis
Particle sizing was achieved using the Small Volume Module Laser Sizer LS23 
(Coulter). 18 mg of each sample was placed in 6 ml of acetone, then sonicated for 30 
seconds to deaggregate the particles before sizing. A saturated representation of each 
sample was introduced into the cell containing isobutyl alcohol as the dispersant, 
dropwise using a pastuer pipette. The Laser Sizer uses the principle of Fraunhofer 
Diffraction Theory. Basically, the laser beam (i.e. a monochromatic light source) hits 
the sample of suspended particles. The light is diffracted at right angles and the 
diffracted light beams are focused onto a series of concentric rings, each one associated 
with a particular range of particle sizes. From here the signals are amplified by means 
of a photomultiplier tube and digitised by computer. Particles between 0.04-2000 pm 
can be measured. Hence particle size measurements are calculated by volume and 
represented as volume median diameter (VMD). The values at 10, 50, and 90% levels 
represent the percentage cumulative undersize for the samples tested.
2.2.4.3. Electrophoresis
Identification and integrity of the plasmid after spray drying was assessed, by 
electrophoresis. A sample of Formulation 1 prepared for transfection was loaded onto a 
0.8% agarose gel along with a sample of DNA from the original stock of the same 
batch. The gel was run in lx TBE buffer at 80 volts for 1 hour and 45 minutes against 
marker DNA (EcoK I/Hind ID cut xDNA).
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2.2.5. Cell Culture
All biochemicals were of analytical grade and purchased from Sigma Chemicals, 
UK except where indicated.
2.2.5.1. Solutions
2.2.5.1.1. Water
Fresh Milli-Q water was used for the preparation of all culture media and
solutions and was obtained from the Milli-Q Plus PF (Millipore UK Ltd).
2.2.5.1.2. Phosphate buffered saline (PBS)
PBS tablets without magnesium or calcium ions were obtained from Oxoid Ltd, 
UK. One tablet was dissolved in 100ml Milli-Q water with a final pH of 7.3 and 
sterilised by autoclaving at 121°C for 15 minutes.
2.2.5.1.3. Ethylene diamine tetraacetic acid (EDTA)
A 0.02% w/v solution of EDTA was prepared in PBS and sterilised by
autoclave.
2.2.5.1.4. Sodium bicarbonate and Sodium Hydroxide
Solutions of 7.5% w/v sodium bicarbonate and 1M sodium hydroxide were 
prepared individually with Milli-Q water and sterilised by autoclaving.
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2.2.5.1.5. Trypan Blue
Trypan Blue used for assessing cell viability, was obtained from BDH 
Laboratory Reagents Ltd and was prepared as a 0.1% w/v solution in PBS..
2.2.5.2. Culture Media and Additives
Culture media were prepared aseptically according to the formulae shown 
below, and stored at 4 °C and used within 3 weeks of preparation.
1M NaOH adjust to pH 7.4
All solution used above were obtained from Gibco BRL, Paisley. Eagle’s 
Minimum Essential Medium - Eagle’s (MEM) with Earle’s salts was obtained as lOx 
concentrate and contained phenol red as an indicator. MEM non-essential amino acids 
solution, the antibiotics L-glutamine (200mM) and penicillin (10000 IU/ml) / 
Streptomycin (10000 pg/ml) were obtained as lOOx concentrates.
Foetal calf serum (FCS) from various suppliers was batch tested to determine 
which provided optimum growth of cells. Batch 06Q7554F was found to support 









MEM non essential amino acids
L-glutamine
Penicillin/Streptomycin
7.5% w/v NaHC03 




All aseptic techniques were carried out in laminar flow cabinets (MDH Ltd) 
designed for vertical re-circulation of air. The cells were cultured in a LEEC PF2 
anhydric incubator (Laboratory and Engineering Company) with a pre-set temperature 
of 37 °C.
Growing cell cultures were viewed daily under an inverted light microscope 
(WILD MS, Wild Heerbrugg Ltd). For determination of cell concentration in 
suspension, appropriately diluted samples were counted on a standard double grid 
haemocytometer (Neubauer 0.1 mm Dept, Weber, UK).
2.2.5.3.2. Disposable Items
Sterile 75 cm2 and 175 cm2 filter top tissue culture flasks were obtained from 
Falcon Becton and Dickson and Co, UK. Six-well plates were obtained from Nunc, 
(Denmark). Cryopreservation ampoules used for storing stocks of frozen cells in liquid 
nitrogen were obtained from Coming, UK.
2.2.5.4. Cell Culture Methods
2.2.5.4.I. Cell line
B16 cells, a murine melanoma cell line was donated by L.R. Kelland, Institute of 
Cancer Research, Sutton. This line was used for transfection studies because it was
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known to express high levels of reporter genes under the control of the CMV or RSV 
promoter.
2.2.5A2. Cell line maintenance
B16 cells were maintained at 37 °C in a LEEC anhydric incubator in a 
humidified atmosphere consisting of 95% air/ 5% CO2 (v/v). Cells were visually 
assessed on a daily basis for evidence for microbial contamination.
B16 cells were grown as a monolayer cultured in MEM and subcultured at 80- 
100% confluence. Cells were subcultured lin 10 i.e. 175cm2 flasks were rinsed 3x with 
10ml aliquots of PBS and then incubated at 37 °C with 2ml of a 0.02% EDTA solution 
for approximately 5 minutes to detach the cells from the flask. The detached cells were 
diluted to 10ml with MEM, counted on the haemocytometer to calculate concentration, 
and an appropriate aliquot of suspension transferred to a sterile 175 cm2 flask containing 
50 ml of fresh culture medium. For routine culture, cells were subcultured 1 in 10 twice 
weekly and the medium changed every 48 hours.
2.2.5.4.3. Determination of cell concentration
After detachment of cells, the suspension was briefly vortexed to ensure 
uniformity. 100 pi of the suspension was taken and to it was added 200 pi of 0.1% w/v 
trypan blue solution. A few drops of the samples were loaded onto a grid 
haemocytometer overlaid with a cover slip. The viable cell number in the four squares 
surrounding the central square was counted and this was repeated for the other side of 
the haemocytometer grid using an inverted light microscope. Viable cells were detected
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by a bright ‘halo’of light around their cell membrane, where as dead cells took up the 
dye.
The following equation was used to calculate cell concentration:
cells/ml = Total cell count in 8 chambers x 104 x 5
8
2.2.5.4.4. Cell Storage and Recovery
Cell suspensions were prepared from a confluent monolayer during subculture 
and centrifuged at 1000 rpm for 8 minutes. The supernatant was then discarded and the 
cells resuspended in a filter sterilised (0.2 pm Acrodisc) solution of culture medium 
supplemented with 10% DMSO as a cryoprotectant. Cell suspensions were then 
dispersed in 2.0ml aliquots in Coming tubes, transferred to a Union Carbide BF6 
biological freezer unit plug which fitted into a Union Carbide LR-40 liquid nitrogen 
freezer. Left to cool down to -70 ° C at a rate of 1 ° C/ min. The cells were then 
transferred to a Union Carbide LR-40 liquid nitrogen unit for long term storage.
For cell recovery, the contents of an ampoule were rapidly thawed by brief 
incubation at 37 0 C in a water bath. Then diluted with 10ml of fresh MEM, added over 
approximately 2 minutes. Cells were centrifuged for 8 minutes at 1000 rpm and the 
supernatant was discarded. The cells were then transferred to a 175 cm 2 flask with 50 
ml of MEM and incubated under standard conditions. Before any experiments were 
carried out the cells were cultured for at least two passages.
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2.2.6. Transfection of Mammalian Cells
2.2.6.1. Preparation o f Transfection Complexes
For freshly prepared controls, 2 pg plasmid DNA (pRSVP-gal) was diluted to 
250 pi with HBS in a sterile polystyrene tube (Costar, UK). Quantities of the GDV that 
would give charge ratios of 2.4 were separately diluted to 250 pi with HBS. Complexes 
were prepared by adding the 250 pi of GDV to the 250 pi of DNA. Gentle mixing of 
the two solutions was executed by pipetting the solution up and down 5 times using a 1 
ml Gilson pipette. The spray dried plasmid DNA/liposome complexes were re-hydrated 
with sterile milli-Q water and an appropriate volume was taken to give 2 pg DNA per 
well and diluted up to 500 pi with HBS. All complexes were incubated for 15 minutes 
at 37 °C.
2.2.6.2. Transfection o f Cells
B16 cells were seeded at a density of 105 cells per well on a 6 well plate and 
incubated for 16-20 hours under standard condition. One hour prior to transfection, the 
monolayers of rapidly dividing cells were washed with warm Opti-MEM™, which is a 
serum-free medium specifically designed for transfection experiments and then 1.5 ml 
of this medium was added to each well. Five hundred microlitres of freshly prepared 
complexes containing 2 pg of DNA and the rehydrated spray-dried plasmid DNA/ 
liposome complexes were then added to the culture medium overlaying the cells. Cells 
were transfected for 4 hours at 37 °C after which time the transfection medium was 
replaced with fresh culture medium and cells were cultured for a further 44 hours before
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harvesting for analysis. For all transfection studies, each data point represents the mean 
± standard error of the mean (SEM) of triplicate samples and each experiment was 
repeated 3 times.
2.2.7. Methods for Quantifying Expression
2.2.7.1. Preparation o f Cell Extracts fo r Analysis 
Solutions
Phosphate buffered saline (PBS)
Lysis buffer (0.1% [w/v] Triton X - 100 in 250mM Tris buffer pH 8)
2.2.7.2. Detergent Lysis M ethod
After the appropriate period of incubation post transfection the cell monolayer 
was washed twice with 2 ml of PBS. Cells were then treated with 250 pi of lysis buffer 
per well and the plates were then frozen at -70 ° C. After thawing at room temperature 
for 30 minutes, the cell extracts were collected and transferred into sterile micro­
centrifuge tubes and centrifuged for 10 minutes at 1000 rpm and the supernatant used 
for analysis.
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2.2.7.3. o-nitro-phenyl-fi-D-galactosidase (ONPG) (MacGregor et al, 1991)
Solutions
2x ONPG assay buffer 1.35 mg/ml ONPG
2 mM Mg CI2
40 mM 2-mercaptoethanol
100 mM sodium phosphate (pH 7.3)
1M di-sodium carbonate
0.1 M sodium phophate buffer (pH 7.3)
An appropriate volume of cell extract (maximum of 100 pi) was diluted to 300 
pi with 0.1M sodium phosphate buffer. This was incubated for 10 minutes at 37 °C and 
300 pi of 2x assay buffer previously incubated at the same temperature was added. The 
mixture was briefly vortexed and incubated for a further 30 minutes. After the 30 
minutes the reaction was terminated by the addition of 1 ml of 1M di-sodium carbonate 
solution. The production of a-nitro-phenol, a yellow chromogenic substance liberated 
by hydrolysis of ONPG, was measured at 420nm on a Milton Roy 750 
spectrophotometer. A typical standard curve is shown in appendix Cl.
2.2.7.4. Protein Assay
(3-galactosidase activity was converted to relative values by dividing the assay 
per well by the amount of protein (mg) in the well at the end of the transfection. The 
protein content in cell extracts was measured using the Bio-Rad Dc protein assay kit. 
Samples were prepared according to the manufacturer’s protocol and calibration curves 
were constructed using bovine serum albumin as a standard. Spectrophotometric 




Number of moles of positive charges = Mass of GDV x Number of positive charged groups
Molecular weight of GDV
Number of moles of negative charges = Mass of DNA
330
± Charge ratio = Number of moles of positive charges 
Number of moles of negative charges
where 330 is the average molecular weight of a nucleotide (reviewed by Feigner et al, 
1997).
22.1.52. Transfection Activity
p-galactosidase activity per well = 250 x f3-gal activity per sample
sample volume (pi)
Protein content per well = 250x protein content per sample
sample volume (pi)
Transfection efficiency = Total (3-gal activity per plate (mU or RLU)
Total protein per plate (pg)
where RLU is relative light units and mU is the activity of p-galactosidase in milli units.
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2.3. RESULTS
2.3.1. Spray Drying of the Lipoplexes
Spray drying was achieved using the Research Scale Spray Dryer and adopting 
the ‘open cycle’ process. The conditions were documented in the tables below. As 
shown in Table 2.2a masses of 400 pg per batch were spray-dried. The tables below 
also show that the conditions during spray drying of all batches were controlled quite 
rigorously. One of the most important parameters regarding spray drying is the outlet 
temperature, which can greatly influence the morphology of the final product. This 
remained fairly constant throughout the spray drying cycle, between a range of 72.8- 
84.6 °C over the four batches. However, the percentage recovery was low, which 
indicated there was a lot of room for improvement in the spray drying process itself. 
The percentage of mass recovered over the four batches spray-dried was 35.25-43.75%.


















10 10 10 10
Volume (ml) 4 4 4 4
Mass Spray 
Dried (g)
0.4 0.4 0.4 0.4
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(b) Feed Details: -
Conditions Control 
Formulation 1
Formulation 1 Control 
Formulation 2
Formulation 2
Pump Settings 95 rpm 95 rpm 95 rpm 95 rpm
Tube Detail 0.5D/1.6D 0.5D/1.6D 0.5D/1.6D 0.5D/1.6D
Feed Rate 
(g/min)
Batch 1/Batch 2 
0.70/0.72
Batch 1/Batch 2 
0.72/0.72
Batch 1/Batch 2 
0.74/0.72
Batch l/Batch 2 
0.70/0.76
(c) Drying Conditions: -
Conditions Control 
Formulation 1




























Start 82.0 75.8 76.9 72.8 73.8 76.8 77.9 76.9





















































Mass of Vessel 
(8)




22.883 23.552 23.106 22.900 22.491 23.189 23.584 23.406
Mass Recovered
<s>
0.164 0.164 0.175 0.151 0.141 0.161 0.158 0.158
Recovery (%) 41.0 41.0 43.75 37.75 35.25 40.25 39.5 39.5
2.3.2. Microscopic Imaging of the Spray Dried Microparticles
The morphology of the spray dried formulations of lipoplexes were examined 
using light microscopy at a magnification of x400. Typical images of the spray dried 
lipoplex microparticles are shown in Figure 2.2. The microparticles from both batches 
appear to have smooth surfaces with some particles containing internal voidages i.e. 
they appear toroidal in shape. Although microscopic studies suggested that particles 
were aggregated it was thought that this was due to the difficulty of dispersing particles 
in acetone on microscope slide, as the acetone evaporated off quickly. For sizing 
studies the particles were sonicated in acetone, before sizing in isobutyl alcohol, which 







Figure 2.2a Light microscopy images showing morphology of the spray dried 
microparticles. (A) Image of microparticles produced from spray drying Control 
Formulation 1 (x 400). (B) Image of microparticles produced from spray drying





Figure 2.2b Light microscopy images showing morphology of the spray dried 
microparticles. (C) and (D) are images of microparticles produced from spray drying 
Formulation 1 (x 400).
oO
Figure 2.2c Light microscopy images showing morphology of the spray dried 
microparticles. (E) and (F) are images of microparticles produced from spray drying 
Formulation 2 (x 400).
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2.3.3. Particle Size Analysis
Particle size analysis of the spray dried batches of the microparticles was 
achieved using the Small Volume Module Laser Sizer LS23. The microparticles were 
dispersed in isobutyl alcohol and background readings were taken before actual 
measurements of the microparticles were taken. The data below shows the volume 
median diameter values for the samples analysed. The values at 10, 50, and 90% levels 
represent the percentage cumulative undersize for the samples tested. Therefore, the 
value quoted at 10 % indicates that 10 % of the particles are smaller than that value and 
90 % are greater than that value in the volume analysed.
Table 2.3 Mean particle size of the spray dried batches of various formulations.
Mean Particle Size (pm)
Sample ID Batch D(0.1) 0(0.5) D(0.9)
Control Formulation 1 1 1.419 (±1.9) 3.906 (±2.6) 9.525 (±7.6)
2 1.338 (±5.3) 3.984 (±9.9) 9.588 (±16.7)
Formulation 1 1 1.433 (±1.0) 5.510 (±2.7) 13.10 (±4.9)
2 1.445 (±2.9) 3.210 (±1.8) 11.48 (±3.8)
Control Formulation 2 1 4.482 (±12.0) 3.598 (±3.0) 8.470 (±4.9)
2 5.102 (±9.0) 3.939 (±4.7) 9.250 (±14.5)
Formulation 2 *1 1.445 (±5.5) 6.02 (±7.6) 12.265 (±4.6)
t2 1.297 4.679 10.06
* for batch 1 values represented the range of two samples, t for batch 2 values represent 
one sample analysed.
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2.3.4 Transfection Activity of the Spray Dried Lipoplexes
The survival of the plasmid lipid complexes after the spray drying process was 
assessed using a bioassay. B16 cells were transfected as described in section 2.2.6. with 
reconstituted spray dried lipoplexes, each dose containing 2 pg DNA /10 pg lipid, 


























A Naked DNA 
B DOTAP/DNA 
C DOTAP/DOPE/DNA 
D Spray dried DOTAP/DNA 
E Spray dried DOTAP/DOPE/DNA 
F Spray dried DOTAP/DOPE/DNA
A Naked DNA 
B DOTAP/DNA 
C DOTAP/DOPE/DNA 
D Spray dried DOTAP/DNA 
E Spray dried DOTAP/DOPE/DNA 
F Spray dried DOTAP/DOPE/DNA
I
Figure 2.3 a & b Biological activity remaining after spray drying lipoplexes. B16 cells were 
transfected with the spray dried lipoplexes for 4hours and cells harvested after a further 44 
hours for analysis of p-galactosidase activity. Data represent the mean of triplicate sample + 
SEM.
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In the first experiment, shown in Figure 2.3 it appeared that some of the plasmid 
had survived the spray drying process, as there appeared to be some p-galactosidase 
activity. However P-galactosidase expression was low compared to the freshly prepared 
positive controls.
No attempts were made to optimise the storage conditions in these preliminary 
experiments so it was not clear whether loss of activity occurred during spray-drying or 
during subsequent storage. All batches were spray-dried and collected under aseptic 
conditions. The samples were stored in sealed clear vials at 4 °C, and were used for 
transfection approximately four weeks after preparation. The distance between the 
manufacturing site and testing site created problems which needed to be more carefully 
managed in future experiments.
2.3.5. Optimisation of Formulation 1 for In Vitro Transfection
To determine the optimum charge ratio of the pCMV/acZ/DOTAP complex for 
use in future transfection efficiency experiments in B16 cells, 2 |ig of pCMVlacZ was 
complexed with variable quantities of DOTAP and these freshly prepared complexes 





Figure 2.4 a, b & c Transfection of B16 cells with DOTAP over a range of charge ratios. 
B16 cells were transfected with 2 pg of pCMVlacZ complexed with variable quantities of 
DOTAP for 4hours and cells harvested after a further 44 hours for analysis of p-galactosidase 
activity. Data represent the mean of triplicate sample +_SEM.
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As shown in Figure 2.4 it appeared that to achieve a high level of expression the 
charge ratio for pCMV/acZ/DOTAP complexes needed to be in excess of 1.5 (+/-). 
Since activity has been reported to be reduced at higher charge ratios (+/-), it was 
considered that 2.5 (+/-) would be appropriate for future work (Uduehi, 1997).
2.3.6. Homogeneity of Spray Dried Formulation 1
To determine whether formulation 1 was homogeneous after spray drying a 
single batch was spray dried and aliquoted out into hplc vials. Samples were taken 
reconstituted within 24 hours and used to transfect B16 cells for 4 hours using 
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control control
Figure 2.5 Biological activity remaining in samples after spray drying lipoplexes. B16 cells 
were transfected for 4hours with the spray dried lipoplexes within 24hours of preparation for 
4hours and cells harvested after a further 44 hours for analysis of p-galactosidase activity. Data 
represent the mean of triplicate sample +_SEM.
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As shown in Figure 2.5 it appears that there seems to be no apparent difference 
between samples. A relatively small amount of activity (an average of 13.1%) was lost 
during the spray drying process.
The integrity of the plasmid was also examined by running spray-dried samples 
an on a 0.8% agarose gel. Traces of the plasmid could be observed. Only one band was 
evident, which corresponded to the single band obtained from the DNA from the 
original stock. Supercoiled DNA was generally represented at a proportion of about 70 
-80 % of the total in common with the starting material. The expectation is that the 
supercoiled DNA is the active material since strand nicks were likely to be random.
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Figure 2.6. Agarose Gel showing the presence of plasmid DNA in the Spray Dried Complex 
(see section 2.2.4.3.) Lane 5 contains £coR I/Hind III cut xDNA marker. Lane 3 contains 
pCMyiacZ  from original stock. Lane 2 contains spray dried pCMV/acZ. Analysis of plasmids 
run on a 0.8% agarose gel for 1 hour and 45 minutes at 80V.
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2.3.6. Stability of Spray Dried Lipoplexes
The stability of the spray-dried lipoplexes was evaluated after storage at room 
temperature. Stability was assessed by percentage of P-galactosidase remaining after 
incubation at room temperature in amber coloured vials. Samples were taken from vials 
packaged aseptically and used to transfect B16 cells at intervals of 0, 1, 2, 4 weeks.
Figure 2.7 Percentage of p-galactosidase remaining after incubation at room temperature. B16 
cells were transfected with the spray dried lipoplexes over a period of 4 weeks. Transfection 
was for 4hours and cells harvested after a further 44 hours for analysis of p-galactosidase 
activity. Data represent the mean of triplicate sample j^SEM.
Figure 2.7 shows that the spray dried lipoplexes were not very stable at room 
temperature as P-galactosidase activity seems to have decreased by practically half after 
the 1st week and very rapidly after that. This confirmed earlier results indicating a loss 
of activity after four weeks (Figure 2.3).
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2.4. DISCUSSION
Experiments described in chapter 2 were designed to assess the use of soluble 
microparticles, produced by adopting Quadrant’s proprietary spray drying process, 
which produces microparticles from 0.1 to 50 microns, in gene therapy.
All transfection results presented in this thesis represent data from a single 
experiment although all the experiments were reproduced in triplicate. The decision to 
show a representative experiment instead of the average of the triplicate experiments 
was made for two reasons, firstly taking the mean of triplicate experiments would not 
allow intra-experimental variability to be easily assessed and secondly, the specific p- 
galactosidase activity was found to vary between experiments. Although the rank order 
of the various factors within each study was generally consistent. Inter-experiment 
variability is a well recognised problem in transfection studies and is commonly 
observed in biological systems (Boussif et al, 1996). This variability was due to various 
factors such as environmental conditions, cell passage number and the growth rate of 
cells, that most of which are not readily controllable.
Before any spray drying could be done a formulation had to be proposed. 
Mannitol, a sugar was used as the carrier material for its protectant properties 
(Broadhead, 1994). It had all ready been established at Quadrant that it was possible to 
spray dry mannitol at low temperature and form consistently size controlled particles as 
hollow spheres.
pRSV/orcZ was chosen as a reporter gene because of the versatility in methods 
currently available for detecting the gene product, P-galactosidase. This is a bacterial 
enzyme derived from Ecoli, which cleaves P-galactosides into their constituent sugars. 
The relatively high levels of enzyme activity in B16 cell extracts following transfection
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with pRSVZorcZ meant that quantification by UV absorbance measurements using g -  
nitro-phenyl-p-D-galactoside (ONPG) was possible. In order to make reasonable 
comparisons between and within experiments, a suitable method for calculating 
transfection efficiency had to be adopted. One option was to examine the total enzyme 
activity (mU p-galactosidase) in cell extracts or standardise the results by taking into 
account the protein content in corresponding samples i.e. specific P-galactosidase 
activity (p-galactosidase/mg protein). The protein content in all extracts is directly 
proportional to the viable cell number. Hence the latter approach was used because it 
accounted for cell viability, an important factor when considering the toxicity of the 
different gene delivery vectors.
The cationic lipid DOTAP was used as it is already a well-established gene 
delivery vector, and is known to give high levels of transfection efficiency in B16 cells 
(Uduehi, 1997). The neutral lipid DOPE was used, as it has been reported to be 
successful in transfection experiments in conjunction with some cationic lipids, 
promoting formation of stable liposomes, and is believed to enhance the cytoplasmic 
delivery of DNA (Feigner et al, 1994).
The conditions of the spray drying process were well controlled. The outlet 
spray drying temperatures were in the range of 70°-85° C. The slight variation in 
temperature is a batch to batch difference due to differing days. The percentage 
recovery of the product was 35.25-43.75% which appears to be low, although this is a 
major problem often encountered with laboratory-scale spray dryers (Broadhead, 1994). 
For this particular method and taking into account however that only 10 % w/v was 
spray dried this was quite a good level of product recovery. Also the feed rate and the 
inlet temperature and the interaction between the two determines the yield obtained
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(Broadhead, 1994) e.g. the lowest yield was observed when the feed rate was at its 
highest (however, in this case the inlet temperature is fixed).
As can be seen from the photographs all the formulations formed spherical 
hollow microparticles under the spray drying conditions used. This phenomenon is 
governed partly by the conditions used during the spray drying process, in particular the 
relationship between inlet temperature and the boiling point of the solvent, and partly 
down to the chemical nature of the solute. Drying of the droplets can be divided into 2 
phases the 1st phase being generally similar in most cases as it is independent of the 
chemical nature of the solute. As the droplet forms rapid evaporation transpires at the 
surface, thereby introducing concentration gradients between the liquid surface and 
interior, the former becoming more concentrated in solute, this eventually leads to 
“crust” formation. From this point the shape of the final particle is dependent on the 
porosity and rheology of the crust i.e. the chemical nature of the solute, plus the 2nd 
drying phase i.e. it is here that the relation between inlet temperature (drying 
temperature) and the boiling point of the solvent are most significant. If the inlet 
temperature is below the solution boiling point, then three cases can be delineated, 
depending on material properties. For porous crusts, further evaporation occurs, 
although at a less rapid rate than in the first period, by diffusion of solvent through the 
pores to the interface accompanied by no change in the particle size for rigid materials. 
For less porous solid skins, stresses develop that fracture the crust followed by 
evaporation as in the first period. Materials exhibiting viscoelasticity undergo 
shrivelling as the particle volume decreases during evaporation, producing a “raisin” 
like morphology.
Alternatively, if the inlet temperature is higher than the boiling point then as 
before no change in particle size occurs for porous solid skins. For more impervious,
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rigid crusts, the decreased evaporation rate after crust formation results in a rise of the 
encased solution temperature to boiling point, and subsequent bubbling results in minor 
or major fractures presumably depending on the drying temperature and extent of void 
space available for solvent diffusion through the solid surface structure. In contrast, for 
low porosity viscoelastic crusts, the positive pressure can cause inflation to sizes larger 
than the droplet diameter, which can be followed by collapse if the skin permeability 
increases to sufficiently large value upon expansion. If the solid skin permeability does 
not increase significantly ruptures can develop, leading to shrivelling and in some cases 
a “spongy” structure if multiple inflation/collapse events occur.
Therefore once the crust has been formed the chemical nature of mannitol 
probably gave it rigid and porous properties, and the inlet temperature being at 130°C 
and the boiling point of water being only 100° C lead to the spherical hollow 
microparticles being formed (Sacchetti & Van Oort, 1996).
The most important step in successfully spray drying a drug for respiratory 
therapy is to control the particle size distribution. As these particles were for pulmonary 
delivery in the long term, hence the use of the pneumatic atomiser as they can be readily 
adapted to inhalation drugs or excipients both in bench-scale and production scale work, 
as has been demonstrated by scientific literature and patents. (Sacchetti & Van Oort, 
1996).
The fundamental aspects of the spray drying process control the particle size: 
droplet formation, solvent type, solution concentration and droplet evaporation 
dynamics. All of the latter were discussed earlier except for droplet formation, which is 
affected by the type of atomiser used. There are many variations of the pneumatic 
nozzle, but we will be concentrating on the use of the external mixing nozzle, as it is the 
one applied to this thesis. The liquid feed is usually pumped at relatively low flow rates
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through a tube and at the discharge orifice is impinged by a gas under pressure. The 
velocity of the gas is much larger than that of the liquid at the orifice, and it is this 
relative velocity that provides the force and work needed to create the surface area of a 
spray. In practise these two variables are controlled by the flow rate of the liquid and 
the gas pressure for a given nozzle.
On the fine end, sprays with a mean droplet size of 5-20 pm can be produced at 
high relative velocity and the reverse for coarser particles.
As can be seen in Table 2.3 generally the particle size distribution at 50% 
cumulative under size for all four batches fell in the range required for deposition of 
particle in the airways, 3.210-6.02 pm. An interesting point was that with incorporation 
of the plasmid the volume median diameters of the spray-dried microparticles increased.
The integrity of the plasmid was assessed post spray drying, as plasmid DNA is 
a sensitive material and may be prone to thermal degradation at high temperatures. 
Figure 2.3 shows that there was P-galactosidase activity present although it appeared to 
be quite low. The latter may be accounted for by the fact that these transfection 
experiments were not carried out immediately after the batch was spray dried but it was 
at least 4 weeks, due to the time taken to set up the initial tissue culture experiments. 
Further experiments were required to assess the stability of the product.
Other factors which might have also contributed to the low enzyme activity are 
that the B16 cells were confluent at the time of transfection, which has been reported to 
result in a lower level of transgene expression (Vitiello et al, 1996). Distribution of the 
plasmid throughout the spray-dried batch, and the net charge of the complex formed 
with DNA (Fasbender et al, 1995), which has been reported to affect transfection 
efficiency levels.
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Before another batch was prepared to investigate the formulation in terms of 
transfection efficiency it was necessary look at the optimum charge ratio of plasmid 
DNA (pCMVlacZ). Figure 2.4 shows that an increase in the quantity of DOTAP led to 
an increase in transfection activity. The optimum charge ratio in the range tested of 0.5 
-  2.5, was found to be 2.5. Charge ratios higher than 2.5 in this case were not assessed 
as they have been reported to be toxic in vivo (Lasic & Templeton, 1996), which would 
not be productive if this formulation was tested in vivo.
The homogeneity of the spray-dried batch was assessed via transfection of B16 
cells. The spray-dried batch was aliquoted out into amber coloured small HPLC vials, 
and stored at room temperature. Random samples were taken and the batch was 
transfected within 24 hours of spray drying. Figure 2.5 shows that only a small amount 
of activity was lost during the process. Also the formulation appeared to be 
homogeneous, as there were no significant differences between the samples taken at 
random.
Stability of spray dried batches was assessed by the percentage of (3- 
galactosidase remaining after incubation at room temperature. Figure 2.6 shows that the 
spray dried lipoplexes were not stable at room temperature as activity appeared to have 
decreased by half after 1 week and then continued to decrease over 4 weeks. It is not 
possible to explain the nature of this instability at present, but clearly this aspect of the 
system would need to be carefully examined if spray-dried particles are to be developed.
It has been established that cationic lipid-DNA complexes can be entrapped in 
spray-dried mannitol particles which are a suitable size for lung deposition. Biological 
activity, as assessed by transfection of mammalian cells in culture, can be recovered 
when the particles are dispersed in aqueous solution. However it is now known that 
cationic lipid-DNA complexes are relatively inefficient gene delivery systems in vivo,
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due to their inability to deliver DNA to the nuclei of non-dividing cells. Thus we 
consider that the mannitol systems is a promising carrier technology for inhalation 
which is waiting for a more efficient intracellular DNA delivery system, specifically a 
system which is able to transfect differentiated, non-dividing epithelia. Given the lack 
of efficiency a decision was made not to examine the mechanism of instability of spray- 
dried lipid.DNA complexes at this stage.
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CHAPTER 3
OPTIMISATION OF A LUCIFERASE REPORTER ASSAY
3.1. INTRODUCTION
Before commencing a pre-clinical study or even gene transfer to cells in culture it 
is essential to test the variables and pinpoint the conditions leading to the best use of the 
reporter gene. All the transfections described in Chapter 2 were carried out using the 
pRSVB or pCMVB plasmid. The 13-galactosidase protein is useful as a reporter because 
its half-life in vivo is 20 hours compared to 3 hours for the commonly used luciferase 
protein (Tsuneoka and Mekada, 1992). However, the sensitivity of the assay is 
decreased due to the relatively high levels of endogenous 13-galactosidase activity in 
some mammalian cells. In contrast, the luciferase protein is foreign to mammalian cells 
and as such gives very low background levels resulting in higher sensitivity and a lower 
detection limit (1 fg). Luciferase reporter genes have been used successfully for 
assessment of gene transfer using non-viral gene delivery vectors in vivo (Schwartz et 
a l, 1995; Thierry et a l, 1995). This chapter concentrates on the optimisation of a 






Escherichia coli strain DH5a was used for the propagation of the plasmids.
3.2.1.2. pCMVluc
The pCMV luciferase plasmid was kindly donated by J P Behr (CNRS, 
Strasbourg). The plasmid map can be seen in appendix A.
3.2.1.3. pTDE-SV40
The pTDE-SV40 plasmid was kindly donated by R G Vile (ICRF, London). 
pTDE-SV40 is a synthetic firefly luciferase reporter gene construct, under the control of 
the SV40 promoter and extra enhancer elements, which are responsive to cAMP. The 
plasmid map can be seen in appendix A.
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3.2.2. In Vitro Transfection of B16 to Investigate the Time-course of Luciferase 
Expression using pCMVluc and pTDE-SV40 Luciferase Reporter-Gene Systems
To follow the onset and duration of luciferase expression in B16 mouse 
melanoma cells when driven by the CMV promoter, transfection complexes of 
DOTAP/pCMV luciferase were freshly prepared at charge ratio of 2.5 and B16 cells 
were cultured as described in Chapter 2. After incubation of transfection complexes 
with B16 cells for 4 hours, the cells were washed with complete medium and incubated 
for a further 12, 24, 32, 40, 44, 48 and 72 hour period. The cells were then harvested 
for analysis, as described in Chapter 2.
The above was repeated for transfection of B16 cells with pTDE-SV40 to 
compare the onset and duration of expression of the luciferase reporter gene, when 
driven by two different promoters in the same cell line. B16 cells were analysed using 
the luciferase assay.
3.2.2. Stimulation of the Luciferase Reporter-Gene Systems pCMV and pTDE-
SV40
To see if expression of the reporter gene in B16 cells could be enhanced further 
the reporter gene-system was stimulated with a cAMP-elevating agent, aMSH, or the 
cAMP analogue 8-bromo-cAMP. The 8-bromo-cAMP was added to the B16 cells 5 
hours prior to harvesting the B16 cells for analysis. For a negative control cAMP alone 
was used. The B16 cells were harvested 24 hours post transfection.
Further experiments were carried out with the pTDE-SV40 reporter gene- 
system. Comparisons were made between 8-bromo-cAMP and a  melanocyte -
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stimulating hormone (aMSH), which interacts with the MSH G-protein-coupled 
receptor to stimulate the production of cAMP via the activation of adenylate cyclase. 
B16 cells were stimulated with 8-bromo-cAMP and aMSH 5 hours prior to harvesting 
the cells for analysis. The cells were harvested 24 hours post transfection and analysed 
using the luciferase assay.
3.2.4. Method for Quantifying Expression
3.2.4.1. Preparation o f Cell Extract fo r  Analysis
After the appropriate period of incubation post transfection, the cell monolayer 
was prepared for analysis as described in Chapter 2. The lysis protocol in chapter 2 was 
followed substituting the Promega lysis buffer (lx: 25 mM Tris-phosphate, pH 7.8; 2 
mM DTT; 2 mM l,2-diaminocyclohexane-N,N,N’.,N’-tetraacetic acid (CDTA); 10% 
glycerol; 1% Triton X-100 and BSA 1 mg/ml) for the phosphate buffer. 
Supplementation with 1 mg/ml BSA was used to ensure that luciferase was not lost 
from solution by adsorption onto container walls.
3.2.4.2. Luciferase Assay
Luciferase levels within cells were quantified using the Promega luciferase assay 
system (Promega, UK) according to the manufacturer’s protocol. As little as 10-20 
moles (0.00lpg) of firefly luciferase can be measured using this kit. A standard curve 
of light units vs. relative enzyme concentration was produced using purified firefly 
luciferase from Promega. After centrifugation of the cell lysate, 20 pi of cell extract
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(supernatant) collected at ambient temperature were mixed with 100 pi of luciferase 
assay reagent (luciferase assay substrate + 10 ml of assay buffer) again at ambient 
temperature. The disposable test tube containing the reaction was then immediately 
placed into the luminometer (TD-20/20). The instrument settings were optimised as 
follows: sensitivity 25.1, delay 2 seconds and the integration 10 seconds. A typical 
standard curve is shown in appendix C2.
Luciferase activity was converted to relative values by dividing activity per well 
by the amount of protein (mg) in the well as described in Chapter 2.
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3.3. RESULTS
3.3.1. Onset and Duration of Expression of Luciferase
The onset and duration of expression of the luciferase reporter gene was 
assessed in detail. B16 cells were transfected as described in section 3.2.3 with 
lipoplexes of pCMNluc or pTDE-SV40, each formed with DOTAP, at a charge ratio of 
2.5. After initial incubation of the B16 cells with lipoplexes for 4 hours, the cells were 
washed with complete medium and incubated further at time intervals of 4, 8, 12, 16, 
24, 32, 40, 44, 48, and 72 hours post transfection. The cells were harvested for analysis 
for luciferase activity and protein content. The luminescent assay proved to be very 
sensitive. Expression of luciferase could be detected immediately after the 4 hour 
treatment of B16 cells with pCMV/wc/DOTAP (see Figure 3.1). Extent of expression 
per well increased sharply over 24 hours and was maintained at a high level until 48 
hours, after which the total expression declined, (see Figure 3.2). Total protein content 
per well was used as a measure of cell growth during the experiments. Growth 
proceeded throughout the 72 hour period of the experiment (see Figure 3.3) at which 
point the cultures were approaching confluence. When the luminescence data was 
compared to controls it was possible to calculate the mass of luciferase expression per 
unit mass of total cell protein, which represents the relative gene expression per cell (see 
Figure 3.3). Peak expression per cell occurred at 24-32 hours, after which expression 
per cell declined steadily over the 72 hour period.
As a comparison of the behaviour of two different reporter-gene systems for the 
expression of the same gene in the same cell line, B16 cells were transfected with 
lipoplexes of pTDE-SV40/DOTAP. Onset of expression of the luciferase reporter gene
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could be observed at 12 hours. Extent of expression per well increased sharply over a 
32 hour period and was maintained at a high level until 48 hours, after which the total 
expression declined (see Figure 3.4). Peak expression per cell appears to have occurred 
at 32 hours.
After the time-course for the expression of the luciferase reporter gene was 
established, when B16 cells were transfected with the pTDE-SV40 reporter gene 
system, experiments were carried out to see if an expression enhancing element could 
affect the time-course obtained from transfection with pTDE-SV40. B16 cells were 
transfected as described earlier. 8-bromo-cAMP an analog of cyclic AMP was used to 
stimulate cells 5 hours prior to harvesting. Once harvested cells were analysed for 
luciferase activity and protein content.
Figure 3.5. shows that the time-course for expression of luciferase profile 
appeared to follow the same pattern as before stimulation was in this experiment. 
Expression levels of the luciferase reporter gene appeared to be higher upon stimulation 
with 8-bromo-cAMP.
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Figure 3.1. a & b. Luciferase expression after transfection of B16 murine melanoma cells with 
pCMV/ttC. B16 cells were incubated with the lipoplexes for 4 hours. The cells were then 
harvested post transfection at time intervals from 4 and 8 hours for luciferase activity. Data 





Figure 3.2 a-c. Time-course of luciferase expression after transfection of B16 murine 
melanoma cells with pCMV-/wc. B16 cells were incubated with the lipoplexes for 4 
hours. The cells were then harvested post transfection at time intervals from 4, 8, 12, 
16, 24, 32, 40, 44, 48 and 72 hours for analysis of luciferase activity. Data represents 
































































































































































Figure 3.3. Effect of incubation period post transfection on the expression of luciferase 
in B16 cells transfected with pCMVluciferase/DOTAP and the total mean protein 
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Figure 3.4 a & b. Time-course of luciferase expression after transfection of B16 
murine melanoma cells with pTDE-SV40. B16 cells were incubated with the lipoplexes 
for 4 hours. The cells were then harvested post transfection at time intervals from 12, 
24, 32, 40, 44, 48 and 72 hours for analysis of luciferase activity. Data represents the 
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Figure 3.5. Time-course of luciferase expression after transfection with pTDE-SV40. 
Cells were stimulated with 8-bromo-cAMP 5 hours prior to harvesting. The lipoplexes 
were incubated with the B16 cells for 4 hours. The cells were then harvested post 
transfection at intervals of 12, 24, 32, 40, 44, 48 and 72 hours for analysis of luciferase 
activity. Data represents the mean of triplicate samples ±SEM.
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3.3.2. Stimulation of the Luciferase Reporter-Gene Systems pCMV and pTDE- 
SV40
Expression of the luciferase reporter gene in B16 cells was stimulated with a 
cAMP-elevating agent, 8-bromo-cAMP, an analogue of cAMP. B16 cells were 
transfected with lipoplexes of pCMV/wc/DOTAP and pTDE-SV40/DOTAP at charge a 
ratio of 2.5 as described earlier in this chapter. 8-bromo-cAMP was added to the B16 
cells 5 hours prior to harvesting the cells for analysis. The B16 cells were analysed for 
luciferase activity and protein content. It is clear from Figure 3.6 that treatment of B16 
cells with 8-bromo-cAMP after transfection with pCMV/wc/DOTAP did not increase 
the expression of the luciferase reporter gene. Treatment of the B16 cells transfected 
with pTDE-SV40 with the 8-bromo-cAMP appeared to have induced a relatively small 
increase in expression of the luciferase reporter gene.
Further experiments to enhance the expression of the luciferase reporter gene 
were carried out using aMSH. Transfection of B16 cells with pTDE-SV40/DOTAP 
lipoplexes was carried out as before to compare the effects of 8-bromo-cAMP and 
aMSH (Figure 3.7). Stimulation of pTDE-SV40 at 24 or 48 hours did not appear to 
further enhance the expression of the luciferase reporter gene, although it was 
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Figure 3.6. Stimulation of pCMV versus pTDE-SV40 with 8-bromo-cAMP. The 
lipoplexes were incubated with B16 cells for 4 hours. The cells were stimulated with 8- 
bromo-cAMP 5 hours prior to harvesting. The cells were then harvested 24 hours post 
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Figure 3.7. Stimulation of pTDE-SV40 with a-MSH, cAMP, and 8-bromo-cAMP, at 
24 hours and 48 hours. The lipoplexes were incubated with the B 16 cells for 4 hours. 
The cells were then stimulated with the transfection enhancers 5 hours prior to 
harvesting. The cells were then harvested at 24 hours and 48 hours post transfection for 
analysis of luciferase activity. Data represents the mean o f triplicate samples ±SEM.
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3.4. DISCUSSION
Expression of luciferase in B16 cells was monitored via in vitro transfection. 
Optimal expression of luciferase on transfection of B16 cells with pCMVluc/DOTAP 
lipoplexes was between 24-32 hours, after which expression per cell declined steadily 
over the 72 hour period. The decline in enzyme activity over the 72 hour period is 
probably due to the dilution of plasmid within the growing population of cells. Since 
the luciferase reporter lacks a mammalian origin of replication and remains episomal, 
following cell division, it will not be equally distributed to daughter cells. However, 
since expression in vivo is frequently found to be transient, there are other factors which 
may contribute to loss of activity. Hence, with each cycle of cell division, there were 
less luciferase expressing cells whilst the total protein per well increased. This suggests 
that the plasmid is cleared or modified.
The time for maximum gene expression was dependent on the promoter driving 
expression; the promoter pCMV gave maximum expression between 24-32 hours where 
as expression driven by the promoter/enhancer elements pTDE-SV40 was found to be at 
its optimal at 32 hours. However, the profile of the time-course for expression of the 
luciferase for both promoters was very similar onset occurred early on between 4-12 
hours and decline of expression for both promoters started at 48 hour. Stimulation of 
both reporter gene systems with the cAMP-elevating agent a  MSH or the cAMP 
analogue 8 -bromo-cAMP was not evident (Figures 3.6 and 3.7). The B16 cells may 
already have had high levels of cAMP having differentiated over some time and 
becoming more melanotic, hence any further stimulation of the reporter genes with a  
MSH or 8 -bromo-cAMP would not take effect. Another, possibility could be that the 5 




CROSS-LINKED MICROPARTICLES FOR DELIVERY TO ANTIGEN
PRESENTING CELLS
4.1. INTRODUCTION
Gene therapy has considerable promise in the treatment of cancer. The majority 
of gene therapy trials currently underway are related to cancer and most of the protocols 
are based on immunotherapy strategies. There are various approaches to cancer 
immunotherapy, one popular approach is to express genetically modified tumour 
vaccines. Alternatively, the environment of the tumour can be modified by expression 
of genes which encourage Thl responses and induce specific cell-mediated antitumour 
activity (Machiewicz, 1998). A third approach is to modify the function of professional 
antigen-presenting cells (APCs) particularly macrophages, which have the ability to 
take up particles by phagocytosis. The remainder of this thesis is concerned with gene 
delivery to professional APCs particularly macrophages. One of the most important 
questions when designing gene therapy to be taken up by professional APCs is which 
gene delivery system best reaches the intended target cells? Particulate carrier systems 
such as microparticles offer promise of effective delivery of DNA or polypeptides to 
APCs and macrophages, since they are phagocytosed by these cells. Particulate systems 
have been reported to enhance the immunogenicity of DNA vaccines (O’Hagan et al, 
1991a). The ‘adjuvant effect’ achieved through the association of polypeptide antigens 
with polymeric microparticles has also been demonstrated repeatedly (O’Hagan, 1997). 
Recent studies have shown that microparticles exert adjuvant effects for cell-mediated 
immunity, including the induction of cytotoxic-T-cell responses, which are desirable for 
the immunotherapy of cancer, after both systemic and mucosal administration (Maloy et
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al, 1994; Moore el al 1995). At present it is not clear whether particulate systems will 
have advantages over other formulations for DNA vaccines but the prospect of 
delivering to phagocytic cells is exciting.
This chapter explores the possibility of using albumin microparticles produced 
by Quadrant’s proprietary spray drying process, as carriers for DNA vaccines. Albumin 
is the most abundant protein circulating in blood, being an important carrier for drugs 
and endogenous substances like fatty acids, bilirubin and some hormones. There has 
been great interest shown in the ability of albumin microspheres to achieve specificity 
in drug delivery (Blake, 1974; Lohner, 1994). Albumin microparticles are a potentially 
useful means of delivering drugs to phagocytic cells because they will remain intact 
until they are taken up, but should ultimately be degradable, and are amenable to 
preparation in large batches (Blake, 1974; Lohner, 1994). As yet they have not been 
used to deliver DNA.
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4.2. METHODS
Microparticles used in this work were prepared during a period of secondment at 
Quadrant (formerly Andaris), using established methods.
4.2.1. Preparation of cross-linked microparticles
The cross-linked microparticles were prepared in 3 steps, the first involved the 
removal of fatty acids from human serum albumin using activated charcoal, to create 
potential binding sites for cationic lipids which would in turn allow loading of DNA. 
Secondly concentration of the defatted human serum albumin (DHSA) was concentrated 
via diafiltration to reduce the volume of solution that was required to be spray dried. 
Finally the DHSA was spray dried to create microparticles which were subsequently 
subjected to heat fixation to create the cross-links within the microparticles. The process 
produced particles, which were solvated by water but remained intact in physiological 
buffer solutions.
4.2.1.1. Defatting o f Human Serum Albumin by activated Charcoal (Chen, 1967)
8000ml of 5 %w/w human serum albumin (Red Cross), was concentrated via 
diafiltration (Amicon) to 4000 ml (2000 ml of HSA was passed through the diafiltration 
unit at a time). This solution was split into 2 x2000ml and each batch was washed with 
10 L of purified water first, then re-concentrated and pooled resulting in a final volume 
of 2000 ml at approximately 20 % w/w HSA. The HSA was then defatted. For 
defatting the 2 0 0 0  ml was divided into 2  and 125 g of activated charcoal (Sigma) was 
added to each batch. The pH was reduced to 3.0 using concentrated HC1. The mixture
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was placed in an ice bath, stirring continuously for 1 hour, and then centrifuged for 2 0  
minutes at lOOOOrpm. The supernatant was then filtered through a Whatman no. 54 
filter paper on a Buchner funnel under slight vacuum. This was repeated until the 
solution was clear. The final protein concentration was established via the Biuret test. 
Finally the solution was filter sterilised into sterile containers ready for spray drying.
4.2.1.2. Biuret Assay
A protein standard of 5 mg albumin/ml was freshly prepared. The Biuret 
reagent consisted of 3 g copper sulphate and 9 g sodium potassium tartrate in 500ml of 
0.2 mol/litre sodium hydroxide to which was added 5 g potassium iodide and made upto 
1 litre with 0.2 mol/litre sodium hydroxide. The reagent was placed in a water bath at 37 
° C for 20 minutes. For assay 3 ml of the biuret reagent was mixed with 2 ml of the 
protein solution and incubated at 37 ° C for 10 minutes. The solution was then cooled 
and the absorbance was determined and compared with the standard solution at 540 nm. 
A standard curve can be found in appendix C4.
4.2.1.3. Spray Drying o f Defatted Human Serum Albumin
Spray drying was achieved by adapting a low temperature spray drying process 
developed by Quadrant Healthcare pic (formerly Andaris Ltd) at Quadrant Healthcare 
pic, Nottingham, UK which was similar to that described in Chapter 2. To produce 
albumin microparticles the Niro Mobile Minor spray dryer was used as larger volumes 
were being spray dried. The spray dried microparticles in the collection vessel were 
then transferred to an oven and held at 175°C for 55 minutes for heat fixation. The
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microparticles were then blended with Mannitol (Sigma) at ratio of 4 part mannitol to 1 
part microparticles to increase bulk density.
4.2.2. Physical Characterisation
4.2.2.1. Scanning Electron Microscopy (SEM)
The DHSA microparticles were examined for particle shape and surface 
characteristics. A representative sample of powder was mounted on aluminium 
specimen stubs using carbon-coated adhesive fixers. A thin, conductive layer of gold 
was evaporated onto the sample surface using a sputter coater (Model: S150B, Edwards 
High Vacuum, Crawley, UK) for 5 minutes. The prepared specimens were examined 
using the JEOL 6310 SEM (Japanese Electron Optics Ltd, Tokyo). Typical 
instrumentation settings, operating voltage 5-10 kV, spot size 12.
4.2.2.2. Particle Size Analysis
Particle sizing was performed using the MSX1 small volume unit Malvern 
Mastersizer X (Malvern Instruments Ltd., Malvern, UK, which had a maximum 
capacity of 20 ml. The particles were dispersed in acetone and sonicated for one minute. 
Then a representative sample was introduced into the sizing cell containing cyclohexane 
as the dispersant, drop wise using a pastuer pipette. The Mastersizer works on the 
principle of Franhofer Diffraction Theory as explained in Chapter 2. The laser passed 
through a lens with focal length of 100 mm (measurement range 0.2-180 pm). Particle 
size was calculated by volume.
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4.2.3. DNA Loading onto DHSA Microparticles
In order to load DNA onto the microparticles, it was necessary to introduce a 
cationic functional group onto the surface of the microparticles to change the charge on 
the surface so that DNA could be adsorbed. The initial approach was to bind cationic 




(Avanti Polar Lipids, USA). DOTAP powder was used to prepare liposomes as 
described in Chapter 2.
4.2.3.1.2. Alkyl trimethylammonium bromides
Dodecyltrimethylammonium bromide C15H34NBr (C12TAB), 
tetradecyltrimethylammonium bromide C17H38NBr (C14TAB), 
hexadecyltrimethylammonium bromide also known as cetrimide USP C19H42NBr 




Plasmid DNA pCMV/wc was propagated, purified and isolated as described in 
Chapter 2.
4.2.3.3. Collection o f Microparticles from  Blend
50 mg of powder blend was re-suspended in 1ml of purified water, allowing the 
sample to resuspend on a roller mixer for 5 minutes. The samples were centrifuged for 3 
minutes at 3000rpm, and the supernatant was then removed and the pellet was re­
suspended again in purified water and washed until three washings had been performed.
4.2.3.4. Loading o f Lipid
The required quantity of lipid was dissolved in 1 ml of purified water. (If the 
lipid was insoluble in water, it was dissolved in chloroform, dried and reconstituted in 
water). The defatted HSA microparticles were washed and re-suspended with the lipid 
suspension and placed on a roller mixer for 30 minutes. Subsequently the samples were 
centrifuged for ten minutes at 3000rpm. The supernatant was removed and the pellet re­
suspended in a further 1 ml of purified water. The suspension was centrifuge for 10 
minutes at 3000 rpm and again the supernatant, was discarded. The pellet was air dried 
before further treatment.
100
4.2.3.5. Monitoring DNA loading via Nucleic Acid Staining
As DNA and albumin both absorb at 280 nm it was difficult to monitor the 
loading of DNA onto albumin by a direct method. The assay of DNA at low 
concentrations in the presence of the particles, was compromised by the leaching of 
small amounts of protein from the particles. The binding of DNA could be estimated, if 
the wavelength at which the DNA ‘absorbed’ could be shifted further up the UV 
spectrum. This was achieved by labelling plasmid DNA with a nucleic acid stain, 
YOYO-1, (Molecular Probes) which has a strong binding affinity for DNA and can 
provide ultra-high detection sensitivity for nucleic acids (Molecular Probes, UK). In 
addition to its high-affinity binding it is essentially non-fluorescent in the absence of 
nucleic acids and exhibits a large increase in fluorescence upon DNA binding.
The fatty acid content, of different commercial preparations of HSA are known 
to vary (Birkett et al, 1978). Also it is difficult to establish the number of fatty acids 
binding sites on a single albumin molecule as fatty acids are not permanently bound to 
albumin molecules but in equilibrium. It was estimated that HSA contained one fatty 
acid binding site per molecule of HSA, on this assumption cationic lipid DOTAP with 
on positive charge would bind to the fatty acid binding site, and cause a charge reversal 
from negative to positive. The latter in turn would create a charge environment to 
adsorb the negatively charged DNA (one negative charge) to the positive charges 
provided by the cationic lipid. Since these particles were to be assessed in vitro 
eventually a charge ratio of 2.5 for DNA/DOTAP was adopted (see Chapter 2). The 
microparticles were prepared as mentioned above loading DOTAP calculated to a 
charge ratio of 2.5 on the assumption that 10 pg of DNA would be loaded onto 10 mg of 
DOTAP loaded microparticles. The ratio of plasmid to YOYO-1 was chosen to be 50
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base pairs: 1 dye ratio as this was the most concentrated ratio that could be detected via 
spectrophotometry without leaving the linear range. Microparticles were incubated for 
2 hours in a solution of plasmid/dye at concentration of 50 : 1 base pair/dye ratio 
respectively. The microparticles were then collected by centrifugation and absorbance 
readings of the supernatants were taken at excitation 491nm and emission 509nm. The 
control sample consisted of the original concentration of DNA/YOYO-1 without the 
presence of microparticles. Standard curve can be found in appendix D. Quantity of 
plasmid bound to the microparticles was calculated using the following equations: -
Equation 1:
Control sample absorbance -  Test sample absorbance = Absorbance due to bound DNA 
Equation 2:
Absorbance due to bound DNA x Concentration of DNA in sample = Concentration of 
Absorbance of Control Sample DNA bound
4.2.3.6. Poly cations which were grafted onto DHSA Microparticles
4.2.3.6.1. Poly-L-lysine hydrobromide
The synthetic cationic polypeptide (average molecular weight of 30000 -  70000 
Da) purchased from Sigma, UK.
4.2.3.6.2. Protamine
The natural cationic polypeptide protamine (calculated molecular weight 4100) 
was purchased from Sigma, UK, as an extract from salmon.
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4.2.3.7. Grafting of Poly cations onto the DHSA Microparticles
50 mg of the DHSA microparticles were incubated with either 0.1, 1, or 10 mg 
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) (Sigma, 
UK) and 5 mg of a cationic polymer dissolved in 5 ml of Milli-Q water for 30 minutes 
on a shaking incubator. EDAC is a water-soluble carbodiimide crosslinking reagent, 
which couples carboxylic acid groups to amines, forming an amide linkage.
4.2.3.8. Measuring the Zeta Potential
The zeta potentials of poly-L-lysine-DHSA microparticle complexes and 
protamine-DHSA microparticles produced using different cross linking reactions were 
determined using an electrophoretic method using the Malvern Zetasizer 3 with Multi 8 
computing correlator (Malvern Instruments, Malvern UK). Measurements were 
possible in water at a concentration of 250 pg of particles per ml. All glass and 
plasticware was washed three times with pre-filtered water to reduce particulate 
contamination. For each batch of polymer grafted microparticles, mean particle 
electrophoretic mobility was measured in a thermostatically controlled micro­
electrophoresis cell (AZ4) equilibrated to 25 °C. Three measurements were made for 
each batch. The instrument uses the Smoluchowski equation to calculate the zeta 
potential.
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4.2.3.9. DNA Loading onto Poly cation Coated DHSA Microparticles
Poly-L-lysine or protamine coated microparticles were incubated with 
pCMV/wc. 1.5 mg of each batch of microparticles were incubated in a solution of 12, 
24, 48, and 96 pg labelled DNA in 1.5 ml of PBS (at a DNA/YOYO-1 ratio of 50:1 as 
described earlier). Microparticles were incubated with the DNA solution for 2 hours on 
a shaking incubator, and subsequently collected by centrifugation at 3000 rpm. The 
supernatant was analysed for the DNA remaining in the solution, thus enabling the 
calculation of the quantity of DNA loaded onto the microparticles.
4.2.3.10. In Vitro Transfection o f RIF-1 Cells
RIF-1 cells were cultured to carry out in vitro transfection as described in 
Chapter 2. 1.5 mg of microparticles grafted with poly-L-lysine at polymer
microparticle ratio of 50:1, were incubated with pCMYluc at 7 pg/1.5 ml and 21 pg/1.5 
ml in PBS for 2 hours on a shaking incubator. After 2 hours the microparticles were 
collected via centrifugation at 3000 rpm. The DNA loaded microparticles were 
redistributed in 500 pi of HBS. For transfection experiments, the negative controls 
were naked pCMVine at 7 pg and 21 pg in 500 pi of HBS, and the positive controls 
were, pCMV/wc/DOTAP complexes at charge ratio of 2.5 for both 7 pg and 21 pg of 
plasmid in the same volume (500pl). The transfection complexes were incubated with 
the RIF-1 cells under OptiMEM for 4 hours. The transfection medium was then 
removed and replaced with complete medium for a further 24 hours. After 24 hours the 
RIF-1 cells were harvested for analysis of luciferase activity and protein content.
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4.3. RESULTS
4.3.1. Spray Drying of Defatted Albumin
Spray drying of DHSA or 2% protamine/DHSA particles was performed using 
the Niro Mobile Minor and adopting the ‘open cycle’ process. The conditions are 
documented in the tables below (Tables 4.1a-d). Batches of 59.0 g of DHSA and 10.1 g 
2 % (w/w) Protamine/DHS A were spray-dried respectively. Tables 4.1a-d also show 
that the conditions during spray drying of both compounds were controlled rigorously. 
The outlet temperature, which would be expected to greatly influence the morphology 
of the final product, remained fairly constant throughout the spray drying cycle; at 97.5- 
98.0 °C for DHSA and 94.0 -93.7 °C for 2 % (w/w) Protamine/DHS A. The percentage 
recovery was quite low, which indicated that improvement in the efficiency of the spray 
drying process could have been made. The percentage of mass recovered for DHSA 
was 15 % and for 2%(w/w) Protamine/DHS A was 26.24%.
Tables 4.1. a-d Spray Drying Conditions
(a) Feed Material:
Conditions Defatted -HSA 2% Protamine/Defatted -HSA 
(w/w)
Material Type














Conditions Defatted -HSA 2% Protamine/Defatted -HSA 
(w/w)
Pump settings 30 rpm 30 rpm
Tube Detail (mm) 0.8D/1.6D 0.8D/1.6D
Feed Rate (g/min) 5.1 7.43
(c) Drying Conditions
Defatted -HSA 2% Protamine/Defatted -HSA 
(w/w)





Atomisation Type Twin-fluid Twin-fluid
Atomisation Pressure (barg) 7.5 7.5
(d) Recovery
Defatted -HSA 2% Protamine/Defatted -HSA 
(w/w)
Mass of Vessel (g) 594.1 594.1
Mass of Vessel + Product (g) 602.9 596.7
Mass Recovered (g) 8.9 2.7
Recovery (%) 15.0 26.2
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4.3.2. Scanning Electron Microscopy
The surface morphology of the two batches of spray dried defatted albumin 
microparticles were examined using scanning electron microscopy. Typical images of 
DHSA microparticles and 2%(w/w) Protamine/DHSA microparticles are shown in 
Figure 4.1. The microparticles from both batches appear to have smooth surfaces with 
some particles containing internal voidages i.e. they are donut in shape. There appeared 
to be some aggregation within both batches, the DHSA alone being more aggregated 
than the 2% (w/w) Protamine/DHSA. The size ranges of the microparticles of both 
batches appeared to be between 1-10 pm. The crystalline fragments that can be 
observed in both batches is the mannitol they were blended with to increase bulk 
density.
107
Figure 4.1. A and B are typical scanning electron microscopy images of spray dried 
defatted human serum albumin microparticles.
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Figure 4.2. A and B are typical scanning electron microscopy images of spray dried 
defatted human serum albumin microparticles with 2%(w/w) Protamine.
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4.3.3. Particle Size Analysis
Particle size analysis of the DHSA microparticles and the 2%(w/w) 
Protamine/DHSA microparticles was determined using the MSX1 small volume unit 
Malvern Mastersizer X. This system measures particle size according to the principle of 
the Fraunhofer Diffraction Theory, which was explained in Chapter 2. The particles 
were dispersed in cyclohexane and background readings were taken of the cyclohexane 
as a control, before actual measurements of the microparticles were taken. The data 
below shows the volume median diameter values for the samples analysed. The values 
at 10, 50, and 90% levels represent the percentage cumulative undersize for the samples 
tested. Therefore, the value quoted at 10 % indicates that 10 % of the particles are 
smaller than that value and 90 % are greater than that value in the volume analysed. 
Table 4.2 shows that before sonication of the samples the particles were aggregated and 
gave a very skewed distribution. However, after sonication the aggregated particles 
were dispersed to give a truer estimate of the particle size distribution.
Table 4.2. Particle Size of Spray Dried DHSA and 2%(w/w) Protamine/DHSA
Mean Particle Size (pm)
Sample ID Sonication Time D(0.1) D(0.5) D(0.9)
Defatted HSA 0 min 2.58 (±5.3) 6.19 (±11.1) 99.43 (±57.3)
1 min 1.72 (±2.5) 3.53 (±1.0) 5.93 (±3.2)
2%Protamine/ 0 min 2.91 (±9.1) 8.07 (±27.7) 126.21(±26.9)
DHSA (w/w) 1 min 1.71 (±3.7) 3.66 (±1.9) 5.98 (±2.8)
(NB: all samples had 3 replicates, va ues in brackets are relative standard deviation)
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4.3.4. Nucleic acid Staining
To monitor the loading of DNA onto the lipid loaded DHSA microparticles, it 
was necessary to label the DNA with a probe, which allowed the unbound DNA to be 
detected by spectrofluorimetry. One method, which has been developed over the past 5 
years is to stain nucleic acids with a cyanine dye (Molecular Probes, UK). Cyanine 
dyes have unique properties, which make them an ideal choice for monitoring DNA 
loading. They are weakly fluorescent in the absence of nucleic acids but exhibit 
significant fluorescent enhancement upon DNA binding across the cyanine dye family 
(a possible increase from 100 to 1000 fold). This compares favourably with the 
fluorescence enhancement of thiazole orange upon DNA binding (-3000 fold). In this 
study the cyanine dye YOYO-1 was chosen which exhibits absorption/emission maxima 
of 491/509 when bound to double stranded DNA. YOYO-1 has ultra-high detection 
sensitivity (can detect YOYO bound DNA at concentrations as low as 100 pg/pl) (Rye 
et al, 1992) and produces stable complexes once bound. It has been found to exhibit at 
least two distinct binding mechanisms. At low dye: base pair ratios, the binding mode 
appears to consist primarily of intercalation. At high dye:base pair ratios, a second 
mode involving external binding begins to contribute (Haugland, 1996). To establish 
the time taken for the YOYO-1 to bind to plasmid DNA and to ensure the stability of 
complex once formed, samples of YOYO-1 and plasmid DNA were prepared at molar 
ratios of 50 base pair:l molecule of YOYO-1 (Manufacturer’s Protocol, Molecular 
Probes, UK) in sterile Milli-Q water. Absorbance readings were taken from time 0 -  
220 minutes. In order to ensure minimal loss of dye through adsorption onto the 
surfaces of containers, samples were prepared in plastic containers with a minimum of 
transfer steps, as recommended by the manufacturer’s protocol.
i l l
Figure 4.3 shows that the staining of the nucleic acid appears to have occurred 










Figure 4.3. Time taken for staining of pCMV/wc by YOYO-1 to reach equilibrium. A 
concentration of 50 base pairs : 1 dye ratio was monitored using a spectrofluorimeter at Em/Ex 
491/509 over a period of 3 hours and 40 minutes. Data represents a mean of triplicate samples 
+ SEM.
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4.3.5. DNA Loading onto DHSA Microparticles
The loading of plasmid DNA was monitored using DNA/YOYO-1 complexes as 
described in section 4.3.4. 15 mg of DOTAP loaded DHSA microparticles were
incubated for 2 hours with 1.5 ml DNA/YOYO-1 solutions at concentrations from 1-10 
pg/ml. Absorbance readings were taken at excitation/emission maxima 491/509 and 
exact quantity of plasmid loaded onto the microparticles was calculated with the aid of 
the method described in section 4.2.3.5. Figure 4.4 shows a control experiment to show 
that DNA was removed by the lipid loaded microparticles. Figure 4.5 shows that the 
loading of DNA onto DOTAP loaded microparticles was generally less than 1.5 pg/15 
mg. An adsorption isotherm was obtained with considerable scatter due to the weak 
interaction. The highest quantity loaded was in the region of 1.5 pg per 15 mg of 
microparticles too low to be practical. Doses of DNA in animal experiments are 



















Figure 4.4. Control experiment to show that the cationic lipid DOTAP adsorbs DNA onto the 
surface of the microparticles. Absorbance readings were taken of samples incubated for 2 hours 
of DNA/YOYO-1, DNA/YOYO-l/microparticles, and DNA/YOYO-l/DOTAP/microparticles. 
Data represents the mean of triplicate samples ±SEM.
8 10 
Cone DNA In Suspension (ug/ml)
Figure 4.5. Plasmid loaded onto defatted albumin microparticles. 15 mg deffated albumin 
microparticles were incubated with a plasmid and YOYO-1 complex solution for 2 hours, at 
varying concentration of plasmid from 0 -1 0  |ig/ml.
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4.3.6. DHSA Microparticles Complexed with Different Mono Alkyl
Cationic Surfactants
As an alternative to DOTAP the DHSA microparticles were loaded with mono 
alkyl cationic surfactants to see if there could be an improvement in the amount of 
plasmid that could be loaded onto these microparticles. These mono alkyl surfactants 
were micellar and could be complexed from solution. The DOTAP loaded DHSA 
microparticles were used as a control. 15 mg samples of microparticles were loaded 
with 79.875 pg of DOTAP, C12TAB, C14TAB, or C16TAB. Subsequently the lipid- 
loaded DHSA microparticles were incubated for 2 hours in a 1.5 ml DNA/YOYO-1 
solution at a concentration of 10 pg/ml DNA. The quantity loaded onto DHSA 
microparticle was determined as described in the previous section. Figure 4.6 shows 
that the mono alkyl surfactants were more successful at loading plasmid DNA onto the 
surface of the microparticles than the dialkyl cationic lipid (DOTAP). The longer chain 
length of these CTAB lipids appeared to increase the binding of plasmid DNA, which 
reached 14.8 pg/15 mg with C16TAB.
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Figure 4.6. Mass of plasmid loaded onto defatted albumin microparticles complexed with 
different lipids. Defatted albumin microparticles were complexed with DOTAP, Ci2TAB, 
C14TAB, C16TAB, and incubated for 2 hours in a plasmid/YOYO-1 solution at 10 pg/ml of 
plasmid.
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4.3.7. Effect of DNA Loading by Varying Concentration of C16TAB to DHSA
Microparticles
In order to determine the optimum concentration of C16TAB for particle 
complexation 15 mg samples of DHSA microparticles were loaded with varying 
concentrations of C16TAB at 0.2, 0.5, 1.0, 2.0, 5.0, and 25.0 mg/15 mg DHSA 
microparticles in 1.5 ml. The C16TAB loaded DHSA microparticles were then 
harvested and incubated for 2 hours, in 1.5 ml of a solution of plasmid DNA/YOYO-1 
at a concentration of 10 pg/ml of DNA. The quantity of DNA loaded onto the C16TAB- 
DHSA microparticles was determined as described previously.
Figure 4.7 shows that the concentration of C16TAB used to load C16TAB onto 
the surface of the DHSA microparticles had a marked influence on the quantity of DNA 
that can be loaded onto the surface of the DHSA microparticles. It appeared that 
C16TAB loading was most efficient at 2 mg/15 mg microparticles which gave the 
highest mass taken up of 14.85 pg of plasmid DNA. Below 2 mg/15 mg microparticles 
C16TAB was suboptimal. At C16TAB concentration > 2 mg/15 mg microparticles the 










Concentration of C16TAB (mg/15 mg microparticles)
Figure 4.7. Plasmid loaded onto defatted albumin microparticles complexed with varying 
concentrations of C^TAB. Defatted albumin microparticles were complexed with Ci6TAB at 
0.2, 0.5, 1.0, 2.0, 5.0, 25.0 mg/15 mg microparticles in 1.5 ml PBS and incubated for 2 hours in 
a solution of plasmid/Y OYO-1 at 10 pg/ml concentration of plasmid.
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4.3.8. Zeta Potential of Polycation Grafted Microparticles
Zeta potential is the potential at the surface of shear between the charged surface 
and electrolyte solution. Surfaces of particles dispersed in a solvent become charged as 
a result of the adsorption of ions or ionisation of surface groups. The effects generate 
an electrical double layer around the particle in which the potential is highest at the 
particle surface, reaching zero in bulk solution. The inner layer known as the Stem 
plane consists mainly of counter ions attracted to the surface by electrostatic or Van der 
Waals forces and solvent ions. The outer layer, the diffuse layer extends a distance 
from the particle, which is determined by the surface charge on the particle, and the 
nature and concentration of the ions in the surrounding electrolyte (Shaw, 1994).
Some ions are more or less rigidly attached to the particle and when exposed to 
an electric field each particle will move toward the appropriate pole carrying with it 
those ions sufficiently attracted to the surface. The boundary between the moving 
particles with its bound counter-ions and the surrounding solution constitutes the shear 
plane. It is virtually impossible to measure the potential at the particle surface or at its 
stem layer. However, one can measure relatively easily the potential at the shear plane. 
The potential measured at this plane is termed the zeta potential.
The surface charge of the microparticles is expected to influence its interactions 
with various biological and chemical components, as well as its distribution, access and 
entry into target cells. The zeta potential of the defatted human serum albumin 
microparticles without and with grafted polymers poly-L-lysine and protamine were 
investigated (see Table 4.3).
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Table 4.3. Mean zeta potentials of DHSA microparticles and those coated with
polycations. 3 replicate measurements were taken.
Sample Mean Zeta Potential 
(mV)
Standard Deviation
DHSA Microparticles (uncoated) -53.0 1.0













The DHSA microparticles exhibited a relatively high negative charge, and as 
expected, DHSA microparticles containing 2%(w/w) protamine, a cationic polymer, 
reduced the negative charge, though not enough to render the charge positive. 
Complexation of poly-L-lysine to the surface of the DHSA microparticles led to a clear 
change in charge on the surface to highly positive. The positive surface charge for 
poly-L-lysine complexed DHSA microparticles was similar regardless of the three 
conditions used for grafting.
The DHSA microparticles with protamine complexed to their surface also had a 
positive surface charge, and again regardless of the reaction conditions, the surface 
charge remained similar. However, the surface charge of DHSA microparticles 
complexed with protamine exhibited a lower positive surface charge than the DHSA 
microparticles complexed with poly-L-lysine.
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4.3.9. DNA Loading onto Polycation Coated Microparticles
1.5 mg of either poly-L-lysine or protamine-coated DHSA microparticles 
produced using each of the 3 protocols were incubated with 12, 24, 48, and 96 pg of 
pCMVluc in 1.5 ml PBS for 2 hours (using DNA:YOYO-1 molar ratios of 50:1). The 
microparticles were collected via centrifugation and the supernatant was analysed for 
plasmid remaining, which allowed estimation of the quantity of plasmid loaded onto the 
microparticles (see section 4.2.3.5). The loading of plasmid DNA was generally similar 
for the 3 different batches of poly-L-lysine coated DHSA microparticles (see Figure 
4.8). This was also true for the 3 batches of protamine coated microparticles. The poly- 
L-lysine coated DHSA microparticles generally loaded more plasmid DNA onto their 
surface than their protamine-coated counterparts. For protamine coated microparticles 
prepared at MPE ratios of 50:5:0.1 (mg) and 50:5:1.0 (mg), it was difficult to obtain an 
accurate measurement when microparticles were incubated with 96 pg plasmid 
DNA1.5 ml. This was due to the relative amount of DNA remaining in the supernatant, 










Figure 4.8.a &b Plasmid loaded onto defatted albumin microparticles complexed with poly-L- 
lysine (MpLLE) (w/w) (a) and protamine (MPE) (w/w) (b). (A) is incubation with 12 pg of 
pCMV7ttc/1.5 ml. (B) is incubation with 24 pg of pCMV/wc/1.5 ml. (C) is incubation with 48 
pg pCMV/wc/1.5 ml. (D) is incubation with 96 pg pCMVluc.
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4.3.10. In Vitro Transfection of RIF-1 cells with DNA Loaded Microparticles
The ability of the DNA loaded microparticles to transfect tumour cells was 
assessed by in vitro transfection of RIF-1 cells. 1.5 mg DHSA microparticles grafted 
with poly-L-lysine (MpLLE mass ratio 50:5:1) were loaded with 7 or 21 pg of 
pCMV/wc in 1.5 ml of PBS as described earlier. The transfection complexes were 
incubated with the RIF-1 cells for 4 hours, the cells were then harvested 24 hours post 
transfection for analysis of luciferase activity and protein content.
a b c d e f
naked  DNA naked DNA DNA/DOTAP DNA/DOTAP DNA-loaded DNA-loaded 
(7ug) (21 ug) (7ug) (21 ug) m icroparticles m icroparticles
(7ug) (21 ug)
Figure 4.9. A logarithmic plot of luciferase expression after transfection with pCMV/wc loaded 
microparticles. RIF-1 cells were incubated with the transfection complexes for 4 hours. The 
cells were then harvested 24 hours post transfection for analysis of luciferase activity. Data 
represents the mean of triplicate samples ±SEM.
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Figure 4.10. Luciferase expression after transfection of RIF-1 cells with pCM\lu c  loaded 
microparticles and the total mean protein produced per sample. The data represents the mean of 
triplicate samples ±SEM.




Apart from using microparticles as carriers of therapeutic gene to the lung, 
microparticles can also be used as carriers for particulate DNA vaccines, acting as 
immunogenic agents themselves or acting as carriers for DNA delivery to antigen 
presenting cells (APCs) and macrophages. There appears to be great potential in 
vaccine development, but the mechanisms of action need to be studied in more detail. 
One clear advantage of microparticles is that they can be produced from biodegradable 
and biocompatible polymers. Controlled-release might enable the development of 
single-dose vaccine, and adjuvants might be entrapped simultaneously in the 
microparticles. Mucosal administration of microparticles can induce serum and 
secretary antibodies as well as inducing cell-mediated immunity.
This chapter has investigated the use of defatted human serum albumin 
microparticles as possible carriers for DNA vaccines. After defatting the HSA it was 
spray dried to produce microparticles which were then heat fixed by incubating the 
microparticles at 175°C. Heat fixation is known to cause cross-linking of the polymer 
matrices rendering the microparticles in soluble in aqueous medium (Arshady, 1990). 
The initial idea to removing the fatty acid from the human serum albumin was to create 
acyl chain binding sites, which would enable the loading of cationic lipids on the 
surface. Removal of the fatty acids was performed by the activated charcoal method 
described in section 4.2.1.1. The activated charcoal, possess a large surface area which 
enables the adsorption of the fatty acids from the albumin over time. This method was 
labour intensive and time consuming as well as being potentially quite harmful due to 
exposure low pH. An alternative would be the Lipidex 1000 chromatography method 
where fatty acids are removed by chromatography at 37°C on a column of Lipidex
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1000. The latter method is milder and more rapid, since the harmful low pH and 
centrifugation step are not necessary; it has been reported to be more efficient (Glatz 
and Veerkamp, 1983).
Two batches of the defatted human serum albumin were spray dried, one batch 
contained 2%(w/w) protamine, a cationic polypeptide which is used in food products. 
Protamine was included to investigate whether the surface properties of the 
microparticles could be changed towards promoting an increase in DNA loading. The 
spray drying process used in both cases was Quadrants proprietary spray drying process, 
an ‘open cycle’ process using the Niro mobile minor, spray dryer and pneumatic 
atomisation (twin-fluid). The conditions of the spray drying process were well- 
controlled. The spray drying temperatures, the inlet temperature was fixed at 250°C, 
and the outlet temperature ranged from 93.7-98°C. The percentage recovery of the 
product was quite low for both batches, 15% for DHSA batch and 26.24% for the 
2%(w/w) protamine/DHS A batch. The latter higher yield achieved in this case could be 
due to the fact the polymer in the second batch was more concentrated due to the 
smaller volume. The low product recovery could be due to several possibilities, as loss 
generally occurs after the spray-dried powder is formed, due to process of separation of 
the powder from the circulating gas, in this case it was the cyclone method. The main 
drying chamber had a very large diameter and hence large surface area, and it has been 
reported that a significant build up of powder can occur on the internal walls of a spray 
drying unit. This problem can be particularly prevalent with the fine particles of drugs, 
which exhibit adhesion forces to the wall that are much greater than the shear stresses 
imposed by the velocity field of the gas. Although tapping the main chamber and joint 
areas of the pipe-work, which is known to help, there will always be a thin layer that
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cannot be dislodged by this method (Saatchi and Van Oorte, 1996). The latter problem 
could also be overcome by increasing gas inlet velocity and increasing mass loading.
The microparticles were visualised using SEM to investigate morphology and 
surface characteristics (see Figures 4.1 and 4.2). From the SEM images it can be 
observed that both batches of the DHSA without and with protamine produced spherical 
hollow ‘doughnut’ like microparticles under the spray drying conditions used. As 
mentioned in Chapter 2 this phenomenon is governed partly by the conditions used 
during the spray drying process in particular the relationship between inlet temperature 
and the boiling point of the solvent, and is partly the result of the chemical nature of the 
solute. The doughnut shape, usually comes about through rapid drying in the initial 
stages, which would have come about as a result of the relatively high inlet temperature 
(250°C) which was substantially higher than the boiling point of droplet solution in this 
case water (100°C), and later due to the chemical nature of the human serum albumin 
(Sacchetti and Van Oorte, 1996, Maa et al, 1997).
For use of microparticles as vaccine adjuvants/carriers of DNA vaccines, the 
particle size needs to remain in the size range of <10 pm as it has been reported that 
smaller microparticles were significantly more immunogenic than larger particles 
(O’Hagan, 1993). Table 4.1 shows the volume median diameter of the microparticles 
produced by both batches. Generally, the particle size distribution at 50% cumulative 
under size fell in the range of 3.53-3.66 for both batches. This is well within the range 
required for these microparticles to be suitable as carriers for vaccines.
In order to monitor loading of plasmid DNA onto the surface of the DHSA 
microparticles, a method had to be developed. As DNA and albumin essentially both 
absorb at 280 nm it was difficult to monitor the loading of DNA onto albumin directly 
by spectrophotometry (Plummer, 1987). One way around this problem was to
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artificially create a chromophore for the plasmid by intercalation of a higher-affinity 
fluorophore. In 1990, Glazer and Rye reported that complexes of ethidium homodimer 
(EthD) with double-stranded (dsDNA), allowed fluorescence and quantitation of DNA 
fragments on agarose gels (Glazer and Rye, 1992). These observations and other 
reports of stability of complexes between DNA and other appropriately linked dimers or 
oligomers of intercalating-compounds, suggested that this phenomenon could be 
exploited to generate a family of highly fluorescent stable dsDNA-dye complexes with 
distinctive properties, which could have many analytical applications. This led to 
attention to asymmetric cyanine dyes, thiazole orange (TO) and oxazole yellow (YO) an 
analogue of thiazole orange. When free these dyes are weakly fluorescent but upon 
binding to DNA can give rise to a 3,000 fold enhancement of fluorescence, and binding 
is readily reversible (Rye et al, 1992). Further investigation led to suggestions that 
unsymmetrical cyanine dyes such as thiazole orange or its analogues could be bridged 
through bis-cationic linker similar to that linking the chromophores in ethidium 
homodimer to produce dimeric dyes, which led to the development of a thiazole orange 
dimer (TOTO) and an oxazole yellow dimer (YOYO). YOYO-1, commercially 
available from Molecular Probes, was chosen as a suitable intercalating dye as it is 
essentially non-fluorescent in the absence of DNA, gives rise to a 1000 fold increase in 
fluorescence upon binding to DNA and is very stable (Molecular Probes). 
Complexation appeared to occur almost immediately and remained stable for at least 3 
hours and 40 minutes, the length of time monitored.
In order to load any DNA onto the surface of the DHSA microparticles, it would 
be necessary to coat the surface with a positive charge, because as expected removal of 
the fatty acids left the microparticles with negative surface charge, evidence of this is 
provided by the zeta potential data in table 4.2. Initial DNA loading experiments were
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carried out by loading the acyl chain binding sites within the DHSA microparticles with 
a cationic lipid i.e. DOTAP which is known to interact with plasmid DNA (Feigner et 
al, 1994). Preliminary studies carried out for Quadrant indicated that this was a feasible 
approach to DNA binding. The results obtained here showed very little DNA bound to 
DOTAP-loaded microparticles, the highest DNA adsorption, lay in the region of 1.5 pg 
DNA/15 mg microparticles. The latter was probably due to the limited number of fatty 
acid binding sites being present for DOTAP to bind to. An alternative cationic lipid 
with non-specific binding was investigated, the alkyl trimethyl ammonium bromides 
(TABs) which will also bind such that the longer the alkyl chain the higher the binding 
affinity, which gives more flexibility on the quantity of plasmid to be loaded. C12TAB, 
C14TAB, and C16TAB were investigated. The C16TAB which had the longest alkyl 
chain of the three TABs investigated had the highest binding affinity, loading DNA in 
the range of 15pg/15 mg of microparticles. Still, relatively speaking the quantity of the 
DNA being loaded onto the surface of these microparticles was relatively low, and in 
order to provide therapeutic levels of DNA, it was thought that the microparticles must 
be able to load more than 15 fig/15 mg. Further experiments were carried out to 
determine whether increasing the quantity of cationic lipid loaded onto the surface of 
the microparticles results in an increase in the quantity of DNA loading onto the surface 
of the microparticles. It was accepted that in such circumstances not all of the CTAB 
would have been specifically bound. Results (see Fig 4.5) showed that increasing the 
exposure to C16TAB from 0.2-2.0 mg/15 mg of microparticles lead to an increase in 
loading of the DNA. However, at concentrations of 5 and 25 mg/15 mg of 
microparticles no further loading of the DNA took place. This probably indicates that a 
saturation of the surface of the microparticles with the lipid may have occurred at 
exposure of 2.0 mg of C16TAB to 15 mg of microparticles. It can be assumed that the
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charge on the surface of these is more than likely to be similar, regardless of the 
quantity of cationic lipid loaded, another reason for there not being an increase in the 
loading of DNA.
As it appeared that cationic lipids may not be the choice of adjuvant to promote 
loading of DNA onto the surface of the DHSA microparticles alternatives were 
investigated. One approach was to spray dry a positively charged polypeptide along 
with DHSA. Protamine a polypeptide used in the formulation of potential non-viral 
gene delivery (Li et al, 1998) was spray dried with the DHSA to enable modification of 
the surface charge of the microparticles during microparticle formation. A batch of 
2%w/w protamine/DHSA microparticles was produced, however it was found that the 
2%w/w content of protamine was not a sufficient concentration to change the surface 
charge from negative to positive (see Table 4.3). It was clear that further batches of 
protamine/DHSA microparticles had to be produced with higher protamine content to 
investigate surface modification during microparticle formation, but this was not 
possible during the under taking of this research due to lack of access to equipment, 
time and money. Another alternative investigated was the grafting of cationic polymers 
onto the surface of the microparticles. Poly-L-lysine a polypeptide widely used in 
research towards developing a successful non-viral gene delivery vector (Wagner et al, 
1990, 1991a) and protamine, were investigated for loading plasmid DNA onto the 
surface of the DHSA microparticles. The polymers were grafted onto the surface of the 
microparticles using a carbodimide strategy at ratios of 50 mg of microparticles to 5 mg 
polycation to 0.1, 1.0, and 10.0 mg of ED AC. ED AC is a cross-linking agent whose 
mechanism of action is based on the activation of the carboxyl groups, which then 
permits their cross-linking to amino groups (Jorge-Herrero et al, 1999). ED AC was 
used to facilitate the grafting of the polymers onto the albumin microparticles. The zeta
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potentials of the polymer coated microparticles were measured. As expected, before 
coating with the polymer the DHSA microparticles had a negative surface charge. The 
polycation-coated microparticles all displayed positive surface charges, and raising the 
quantity of polymer available for the grafting reaction did not effect the final surface 
charges significantly. Poly-L-lysine coated microparticles had higher positive surface 
charges than those coated with protamine, which is possibly related to the chain length 
of the poly-L-lysine used compared to protamine.
The quantity of plasmid that could be loaded onto the surface of these polymer 
coated microparticles was investigated. Samples of polymer coated microparticles (1.5 
mg) were incubated with 12, 24, 48 and 96 pg of pCMV/z/c/1.5 ml (1.5 ml was the 
minimum volume required to obtain a reasonable reading in the spectrofluorimeter). 
The poly-L-lysine coated microparticles bound more DNA onto the surface of the 
microparticles than those coated with protamine. In agreement with the zeta potential 
results increasing the ratio of polymer to microparticles did not appear to make a 
significant difference.
7 or 21 pg pCMVluc was incubated with poly-L-lysine coated microparticles 
produced using a reaction ratio (MpLLE) of 50:5:1 (w/w). These microparticles were 
then used for in vitro transfection of RIF-1 cells. Negative controls were 7 and 21 pg of 
naked pCMV/wc, which is known to give little or no transfection. The positive controls 
were lipoplexes of pCMV/wc /DOTAP using 7 or 21 pg of pCMV/wc condensed with 
DOTAP at a charge ratio of 2.5. DOTAP is known to aid transfection, through 
condensation of plasmid DNA modifying its size, charge and surface characteristics, 
therefore enhancing the interaction of pCMVluc with the surface of the target cells; 
inducing endocytosis thus eventually leading to transfection. No transfection was 
obtained from naked DNA as expected, the pCMV/wc/DOTAP lipoplexes gave rise to
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gene expression between 4000-7000 pg/mg of protein. However, only 10-35 fig/mg 
protein of gene expression was obtained from the pCMV/wc loaded microparticles. This 
was possibly due to poor uptake of large particles. Unless the polyplexes of poly-L- 
lysine/pCMV/wc were shed by the microparticles, which may be the reason why some 
gene expression was obtained, there is very little chance of any transfection occurring. 
As the microparticles alone were probably too big to enter the RIF-1 cells which were 
cultured as a monolayer. Poly-L-lysine has been reported to give rise to transfection in 
a similar manner to cationic lipids (Wagner et al, 1991a) in various cell lines. However, 
it is also known to be toxic and to have very limited solubility 20 pg/ml (Wagner et al, 
1998), which may also affect transfection efficiency. Protein levels were monitored 
through the transfection experiment (see Figure 4.10) and there appears to be relatively 
no change, ruling out possible effects through toxicity.
It is clear that DNA can be loaded onto these microparticles, but a lot more 
experiments need to be carried out to find the most suitable means of modifying the 
surface of the DHSA microparticles to obtain an optimal quantity of DNA that these 
microparticles can carry. The latter includes finding a suitable polypeptide, and either 
directly loading onto the DHSA microparticles or spray drying this polypeptide with the 
DHSA to produce microparticles.
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CHAPTER 5
INVESTIGATION OF THE FATE OF ALBUMIN MICROPARTICLES AFTER 
INTRAMUSCULAR OR INTRATUMORAL INJECTION
5.1. INTRODUCTION
Particulate carrier systems such as albumin microparticles have the potential to 
deliver DNA vaccines (or indeed peptide antigens) to antigen presenting cells (APCs) or 
macrophages. This study is concerned exclusively with DNA delivery. Several gene 
expression studies have been carried out in vitro and in vivo to assess the ability of 
professional phagocytosing cells to phagocytose microparticles. Condon et al used the 
gene gun technology to deliver DNA-coated gold particles to the cutaneous dendritic 
cells (Langerhans cells) of mice. Some gold particles were subsequently formed located 
in the draining lymph nodes, where they were thought to be inside migrant cutaneous 
dendritic cells (Condon et al., 1996). This suggests that a genuine immune response 
could be stimulated by such an approach. Other studies involved monitoring the 
behaviour of phagocytic particles such as neutrophil, monocytes and macrophages when 
incubated in vitro with microparticles (Wang et al., 1999). Microparticle delivery 
studies have also involved the transfection of solid tumour models with microparticles 
loaded with reporter genes (Dass et al., 2000).
This chapter explores the possibility of albumin microparticles inducing an immune 
response in vivo and the likelihood that these microparticles are taken up by APCs 
particularly macrophages. FITC labelled DHSA microparticles were assessed in vivo 
to investigate the relationship between the presence of the microparticles and the 
number of macrophages present in the tumour and muscle tissue. However, before in
133
vivo experiments were conducted it was considered sensible to carry out, in vitro 
experiments to determine whether macrophages were able to phagocytose the 
microparticles, and if so to determine how long macrophages take to phagocytose 
microparticles.
This chapter also describes investigations of the distribution of the microparticles in 




5.2.1. FITC Labelling of DHSA Microparticles
In order to locate the microparticles in vitro and in vivo the microparticles were 
labelled with fluorescein isothiocyanate commonly known as FITC, which is a widely 
used reagent to attach a fluorescent label to proteins via the amine group.
100 mg of DHSA microparticles were suspended in 2 ml 1% Tween 80 solution, 
vortexed and left for 30 minutes to allow the microparticles to settle. Microparticles 
were collected via centrifugation for 2 minutes at 3500 rpm, then washed 3 times with 5 
ml water and once with 5 ml 0.1M Tris buffer, to remove the detergent and excipients, 
collecting the microparticles after each was by centrifugation as before. To a 
suspension of DHSA microparticles in 1 ml 0.1M Tris buffer (pH 8) was added a 
solution of 35 mg fluorescein isothiocyanate (Sigma, UK) in 2 ml 0.1M sodium 
hydroxide solution (making sure the FITC had dissolved before it was added to the 
microparticles). The reaction mixture was stirred overnight at room temperature and the 
next day the microparticles were collected by centrifugation as before. The supernatant 
was removed and discarded, the microparticles were washed with 5 ml 0.1M Tris buffer 
until the supernatant was clear. Microparticles were collected each time by 
centrifugation as before. The microparticles were labelled with FITC and therefore 
appeared orange in colour.
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5.2.I.1. Scanning Electron Microscopy (SEM)
SEM images were taken to observe particle shape and surface characteristics. 
Samples were prepared, and images were recorded under the same conditions as 
described in Chapter 4.
5.2.2. Isolation of Mouse Peritoneal Macrophages
The C3H mouse peritoneal cavity was injected with 2 ml of sterilised Hanks 
Balanced Salt Solution (37°C)(Mann, 1973). The abdomen was massaged for a few 
minutes. The peritoneal cavity was revealed and a small incision was made to withdraw 
the fluid in the cavity using a syringe without a needle. It was difficult to establish how 
many macrophages were present in the peritoneal cavity therefore in order to get a 
reasonable yield of macrophages several mice were needed, depending on the size of the 
experiment. Once all the samples were collected and collated the suspension was 
centrifuged at 1000 rpm for 5 minutes which was sufficient to sediment the cells 
without distorting them. The supernatant was poured away and the cells were 
resuspended in RPMI. A cell count was performed before plating out the cells in six 
well plates. Cells at 2xl05 were plated out and left to adhere overnight. Macrophages 
are reported to adhere to the surface of the plates therefore before experiments 
commenced the medium was replaced removing any cells that had not adhered to the 
surface. 1.5 mg FITC labelled DHSA microparticles, were introduced either in 
aggregated form or after sonication for 1 minute. Microparticles were incubated with 
the peritoneal macrophages for 2, 24, 48, and 72 hour incubation periods. Cells were 
then washed with PBS three times, fixed with fixative solution (l%(v/v) glutaraldehyde,
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ImM magnesium chloride, 0.1 M sodium phosphate pH 7.3), using 1 ml fixative per 
well for 5minutes at 4°C. The fixative solution was then aspirated. The macrophages 
were monitored with an inverted microscope. Images were taken using an inverted or 
fluorescent microscope, where appropriate.
5.2.3. Animal Studies
Female C3H mice were obtained from Charles River at 6-7 weeks of age and 
then allowed to acclimatise for a further week prior to experiments. Before implanting 
murine fibrosarcoma RIF-1 cells (Twentyman et al., 1980) the fur from the lower half 
of the mouse back was removed using clippers. The RIF-1 cells were previously 
cultured in RPMI 1640 medium supplemented with 15% foetal calf serum, penicillin 
and streptomycin, and were not passaged more than 7 times prior to trypsinisation for 
implantation. On the day of implantation the mice were slightly anaesthetised using 
intraperitoneal Hypnorm (mix of fentanylcitrate 0.315 mg/ml and fluanisone 10 mg/ml, 
0.05 ml per mouse). An injection of 0.05 ml PBS containing 2xl05 RIF-1 cells was 
made intradermally mid way along the back of the mouse (approximately 2 cm from the 
base of the tail). To obtain an acceptable tumour implant care was taken to ensure that 
the cell suspension left a spherical bump at the implant site, devoid of any tracks caused 
by the leakage of cell suspension on needle removal. Tumours were visible after 
approximately seven days and were ready for delivery experiments 12-14 days post­
implantation. On the day of treatment the mice were weighed and the dimensions of the 
tumour recorded. The average tumour was approximately 6-7 mm in diameter. The 
mice were then randomly assigned to the different treatment cages.
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Injections were made into the right hind leg muscle of each mouse and the 
implanted tumours. Tissues were harvested following the killing (cervical dislocation) 
of the mice on days 2 and 7. To facilitate intramuscular injection the mice were 
anaesthetised using a combination of Hypnovel (midazolam 5mg/ml) and Hypnorm 
(1ml of Hypnovel + 1 ml of Hypnorm + 2 ml sterile water, injection 0.1 ml 
intraperitoneal) and the right hind thigh shaved with an electric shaver. Muscle 
injections were made using a sterile Hamilton syringe fitted with a 31G1/2 needle and 
calibrated dosing clamp. This clamp insured that each mouse was injected with 20 pi of 
formulation. The needle was left in place for a short period to prevent formulation 
being expelled by the tissue. The same procedure was carried out for the dosing of 
implanted tumour. Each 20 pi injection contained 0.8 mg of DHSA microparticles 
either with FITC coupled to their surface or without. A second large experiment was 
carried using the same parameters, however on this occasion 20 pi injections contained 
either a) saline alone as the control or b) 0.8 mg of FITC labelled DHSA microparticles. 
The mice were killed and tissue was excised after 2 and 24 hours after the injection.
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5.2.3.1. Tissue Collection and Preparation
Specimens were frozen to cork blocks in Tissue-Tekk (Raymond A Lamb, UK) 
mounting medium by immersion in liquid nitrogen-cooled isopentane (BDH, UK). 
Subsequently 5 pm sections were cut using a Bright OTF/AS-OOl motorized cryostat 
(Bright, Huntingdon, UK) maintained at -25 °C during sectioning.
5.2.4. Tissue Analysis
The tissues were analysed for the whereabouts of the FITC labelled 
microparticles in the tumour and muscle tissue. In addition, investigations were made 
on the influence of the particle injection on the immune response in tumour and muscle 
tissue. This involved using immunocytochemistry and enzyme histochemistry to assess 
the macrophage content of the relative tissues. Various staining procedures were used to 
observe the nuclear structure of the tissues. All reagents were purchased from BDH, 
UK except where stated.
5.2.4.1. Harris’s Haematoxylin
This is a useful general-purpose alum haematoxylin and results in particularly 
clear nuclear staining. It stains nuceli a red colour, which is converted to the familiar 
blue-black when the section is washed in weak alkali (water). For this purpose cut 
sections were air dried for 1 hour and then fixed in cold acetone (-20°C). The sections 
were then rehydrated in running water for 3 minutes. Once rehydrated the tissues were 
incubated in Harris’s Haematoxylin (mercury free, 1 part in 3 parts water) for 5minutes, 
then placed back in the water for a further 5 minutes. Sections were then incubated in
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ACID ALCOHOL (1% of concentrated HCL in 100% IMS) for 1 minute and then 
returned to water for 5 minutes. The next incubation was in Eosin for 30 seconds and 
then water for 5 minutes. Finally, the tissue sections were incubated in IMS for 30 
seconds twice, immersed into xylene for 30 seconds, and then into a final xylene 
incubation ready for mounting. DPX was used to mount the cover-slips.
5.2.4.2. Immunocytochemical staining (Avidin-Biotin Technique)
This method relies on the marked affinity of the glycoprotein avidin for biotin, a 
low molecular weight vitamin. Vectastain have developed a procedure called the 
‘ABC’ or preformed complex method, which employs biotinylated antibody and a 
preformed ‘Avidin:Biotinylated enzyme Complex’, based on the affinity of avidin for 
biotin which can be used to amply the sensitivity of immunohistochemical staining.
Cut sections were left to air dry for at least 1 hour and 30 minutes, they are then 
fixed in cold acetone (-20°C) for 30 seconds. Sections then underwent two 5 minute 
washes in PBS. After washing sections were bathed for 20 minutes in incubation buffer 
(10 ml PBS containing 5 mg BSA and 2 drops of goat serum provided as Vectastain 
ABC-AP™ kit). After incubation sections underwent 2x (5 minute) washes in PBS, 
with slight agitation. Next the primary antibody was added, made up in incubation 
buffer to the required concentration, 100 pi to each section, and sections were incubated 
overnight at 4°C. The 1° antibody was washed off with 2x 5 minute washes in PBS. 
Sections were incubated with 100 pi secondary antibody, made up in PBS to the 
required concentration for 30 minutes. The ABC reagent (2 drops of part A in 10 ml of 
PBS mix then 2 drops of part B mix of ABC-AP™ kit) was prepared at this time. 2x 5 
minute washes were followed by incubating sections in ABC reagent (100 pi per
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section) for 30 minutes. This was followed by 2x 5 minute washes in PBS and 
incubation in Fast Red (Sigma Diagnostics, UK) for 8-10 minutes. Sections were then 
washed in running water, and counter stained with Mayers Haemotoxylin (Sigma 
Diagnostics, UK) for 1 minute, washed in cold running water, and mounted with 
Aquamount.
5.2.4.2.I. Antibodies
The 1° antibodies used were CDllb (Mac-1) (rat antimouse) a macrophage 
marker, and CDllc (hamster antimouse) a dendritic cell marker. 2° antibodies used 
were IgG:biotin goat anti rat (for CD1 lb) and IgG:biotin goat antihamster (for CDllc). 
All antibodies were purchased from Serotec, UK.
5.2.4.3. Enzyme Histochemistry (Non-Specifc Esterase: a  Naphthyl Acetate Method)
Solutions
0.2M Sodium Phosphate In 200ml of milli-Q water (stored at room 
temperature).
4% Pararosaniline HCL 0.5 g pararosaniline was dissolved in 10 ml milli- 
Q water, heated gently on hot plate (without 
boiling). 2.5 ml concentrated 12M HCL was 
added, cooled to room temperature, filtered and 
stored at 4°C.
4% Sodium Nitrite 
“Azotized Paraosaniline”
In 12.5 ml of milli-Q water was stored at 4°C.
This was prepared freshly for each stain. 4% 
Parasaniline-HCL (0.4 ml) was added to 4% 




a  Naphthyl acetate 3-5 mg 
Acetone 0.75 ml 
0.2M Sodium phosphate 12.5 ml 
Azotized Pararosaniline
Prepared freshly for each stain, a  naphthyl 
acetate was dissolved in acetone, mixed well, then 
sodium phosphate buffer was added (solution may 
become cloudy-OK). The solution was mixed 
well, and freshly prepared azotized pararosaniline 
was added with mixing prior to use.
Esterases are enzymes, which are capable of hydrolysing carboxylic acid. The 
majority of esterase enzymes are able to hydrolyse a  naphthyl acetate as a substrate; 
these enzymes are called ‘non-specific’ esterases. The a  naphthyl acetate method 
employed a  naphthyl acetate as the substrate; the enzyme released a  naphthol during 
hydrolysis of the substrate. The a  naphthol was then coupled with a suitable diazonium 
salt to produce an insoluble azo dye at the site of enzyme activity, the diazonium salt 
used in this case was hexazotized pararosaniline, which gave good localisation of the 
enzyme.
Cut sections were air dried for at least 1 hour 30 minutes. Sections were fixed in 
Formol-Saline and rehydrated in running water. Sections were placed in freshly 
prepared staining solution (when staining solution is gold to orange in colour) for 5 
minutes. To stop reaction sections were placed in running water for several minutes. 
Sections were dehydrated in 2x 100% IMS, transferred immediately to xylene 2x to 
clear, then mounted in DPX.
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5.2.4.4. Imaging
All images in this chapter were obtained from inverted or normal Zeiss 
Microscopes, Zeiss, West Germany, or the Nikon Fluorescent Microscope, Nikon, 
Japan, using an Olympus OM4-Ti, 35 mm camera or Zeiss KS 300 version 3.0 where 
appropriate.
5.2.4.5. Data Analysis
The optimum number of sections per animal and number of fields per section 
were determined using 10 fields from each of 10 consecutive sections of RIF-1 tumour 
model. The cumulative number of fields that gave the lowest coefficient of variation 
was chosen as the number of fields per section to be quantified. The number of sections 
per tumour model was selected to give a SE ±25% of the mean (appendix E). One and 




The surface morphology of the FITC labelled DHSA microparticles was 
examined using scanning electron microscopy. Typical images of FITC labelled DHSA 
microparticles are shown in Figure 5.1. The microparticles appeared to have smooth 
surfaces with some particles containing internal voidages. The particles appear to be 
quite aggregated. The crystal fragments present in the images are the mannitol 
fragments in which the microparticles were blended to increase bulk density.
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Figure 5.1. A and B are typical scanning electron microscopy images of spray dried 
defatted human serum albumin microparticles labelled with FITC.
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5.3.2. Incubation of DHSA Microparticles with Macrophages In Vitro
FITC labelled DHSA microparticles were incubated in vitro with mouse 
peritoneal macrophages. 1.5 mg samples of aggregated or sonicated FITC labelled 
DHSA microparticles were incubated with mouse peritoneal macrophages in six well 
plates with RPMI medium at 37 °C. Samples were incubated at time intervals of 2, 24, 
48, and 72 hours. Macrophage activity was monitored using an inverted light 
microscope. Cells were fixed to allow images to be taken where appropriate at xlOO, 
x200, and x600 magnification, using both normal/fluorescent and inverted light 
microscopes. Figure 5.2 shows typical images taken using inverted light microscopes 
of mouse peritoneal macrophages, after 2 hours of incubation at x200 magnification. It 
appeared that the phagocytic cells were beginning to exhibit dendritic morphology, 
which is very evident in Figure 5.3, which shows macrophages after 24 hours of 
incubation.
Images of sonicated particles incubated with mouse peritoneal macrophages are 
shown in Figures 5.4 and 5.5. The particles were of comparable size to peritoneal 
macrophages in vitro. It appears that microparticles incubated with macrophages at 2 
hours (Figure 5.4 A) were under going the initial contact phase of phagocytosis, which 
was beginning to lead to the ingestion phase. At 24 hours of incubation (Figure 5.4 B) 
of microparticles with macrophages it appears that the majority of the cells were in the 
ingestion phase of phagocytosis. These cells were also becoming more dendritic. After 
48 hours (Figure 5.5 A) incubation, the cells appeared to be in the digestion phase of 
phagocytosis i.e. the ingested particles were under going digestion, and after 72 hours it 
appeared that the majority of cells were in the digestion phase and were beginning to
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look unhealthy. Some of the phagocytic cells may have completed digestion, as the 
cells appear to have a glowing halo, which could be attributed to the FITC.
Figures 5.6 and 5.7 show images of aggregated microparticles were introduced 
to peritoneal macrophages. It appeared that at 2 hours of incubation (Figure 5.6) only a 
small number of cells that had microparticles bound to their surface. In fact the 
aggregate of microparticles had a combined size which was greater than the phagocytic 
cells. By 72 hours the cells had ingested some free microparticles or small aggregates 
and were under going the digestion phase. The larger aggregated microparticles were 
still not ingested after 72 hours.
The phagocytosis of the microparticles was also monitored using fluorescence 
microscopy. Figure 5.8 shows untreated mouse peritoneal macrophages at x200 
magnification observed by inverted light microscopy (Figure 5.8 A) and normal light 
settings at xlOO magnification (Figure 5.8 B) on a fluorescence microscope. The 
morphology of the cells is clearer in the Figure 5.8 A but by using normal light the cells 
could also be clearly visualised using the fluorescence microscope. As expected at this 
sensitivity no fluorescence was observed from the cells. Figures 5.9-5.12 show further 
evidence of the three phases of phagocytosis. At 2 hour incubation (Figure 5.9) most 
cells had associated fluorescence which may have been are undergoing the initial 
attachment phase. At 24 hours (Figure 5.10) the majority of the phagocytic cells were 
probably undergoing the ingestion phase and beginning the digestion phase. The 
spherical particles could be seen inside the cells by normal light microscopy (Figure 
5.10 A). By 48 hours it appeared that many of the cells had under gone the digestion 
phase as the FITC was distributed throughout the main body of the cell and was starting 
to be seen in the dendritic parts of the cells. By 72 hours it clear that the macrophages 
had digested more of the particles, releasing FITC to the dendritic process of the cells.
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Images taken at x600 magnification are shown in Figures 5.13-5.18. These images 
suggest that at 48 hours the FITC had not spread throughout the cell but by 72 hours 
FITC could be seen throughout the cytoplasm.
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Figure 5.2. Typical images from inverted light microscopy of mouse peritoneal 
macrophages. A-C show typical images of untreated macrophages incubated with 
RPMI in vitro, after a 2 hour incubation period. Images were taken at x200 
magnification.
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Figure 5.3. Mouse peritoneal macrophages. A-C show typical images of untreated 
macrophages incubated with RPMI for 24 hours. Images were taken at x200 
magnification.
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Figure 5.4. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg samples of FITC labelled 
DHSA microparticles and incubated for 2 (A) and 24 (B) hour periods. Images were 
taken at x200 magnification. Scale bar = 100pm.
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Figure 5.5. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 48 hour (A) and 72 hour (B) periods. Images were taken at x200 
magnification.
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Figure 5.6. Mouse peritoneal macrophages treated with aggregated FITC labelled
DHSA microparticles. Macrophages were treated with 1.5 mg of aggregated FITC
labelled DHSA microparticles for 2 hours. Images were taken at x200 magnification.
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Figure 5.7. Mouse peritoneal macrophages treated with aggregated FITC labelled
DHSA microparticles. Macrophages were treated with 1.5 mg of aggregated FITC
labelled DHSA microparticles for 72 hours. Images were taken at x200 magnification.
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Figure 5.8. Typical images of mouse peritoneal macrophages obtained from inverted 
(A) and fluorescent (B) microscopes. Untreated macrophages at x200 magnification 
(A) and, xlOO magnification (B). Scale bar = 100 pm.
Figure 5.9. Normal light (A) and fluorescent (B) images of mouse peritoneal 
macrophages treated with FITC labelled DHSA microparticles. Macrophages were 
treated with sonicated FITC labelled DHSA microparticles for 2 hours.
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Figure 5.10. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with sonicated FITC labelled DHSA 
microparticles for 24 hours.
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Figure 5.11. Mouse peritoneal macrophages treated with FITC labelled DHSA
microparticles. Macrophages were treated with 1.5 mg of sonicated samples of FITC
labelled DHSA microparticles for 48 hours. Images were taken at xlOO magnification.
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Figure 5.12. Mouse peritoneal macrophages treated with FITC labelled DHSA
microparticles. Macrophages were treated with 1.5mg sonicated samples of FITC
labelled DHSA microparticles for 72 hours.
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Figure 5.13. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 24 hours. Images were taken at x600 magnification. Scale bar = 
100pm.
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Figure 5.14. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 24 hours. Images were taken at x600 magnification.
Figure 5.15. Mouse peritoneal macrophages treated with FITC labelled DHSA
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 48 hours. Images were taken at x600 magnification.
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/Figure 5.16. Mouse peritoneal macrophages treated with FITC labelled DHSA
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA
microparticles for 48 hours. Images were taken at x600 magnification.
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Figure 5.17. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 72 hours. Images were taken at x600 magnification.
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Figure 5.18. Mouse peritoneal macrophages treated with FITC labelled DHSA 
microparticles. Macrophages were treated with 1.5 mg of FITC labelled DHSA 
microparticles for 72 hours. Images were taken at x600 magnification.
165
5.3.3. In Vivo Evaluation of DHSA Microparticles
DHSA microparticles were administered directly to mouse muscle and tumour 
by injection. The fate of microparticles was investigated in vivo after 2 or 7 day 
periods; both FITC and non-FITC labelled microparticles were analysed. Tissues were 
analysed using enzyme histochemistry for evidence of macrophage infiltration, and by 
fluorescence microscopy to investigate microparticle distribution and stability.
Further in vivo experiments were carried out, directly administering FITC 
labelled DHSA microparticles to tumour tissue, and investigated their fate 2 and 24 
hours after injection.
To assess tissue distribution of the FITC labelled microparticles, excised 
tumours were sectioned all the way through (from top to the bottom of the tumour) at 5 
pm per section, and tissues were viewed using fluorescence microscopy. Figure 5.19 
shows typical images obtained at 2 days after injection. The majority of microparticles 
were quite localised in their distribution in the tumour tissue (Figure 5.19 A). It also 
appeared that at day 2 the majority of the microparticles were still intact. As expected 
the microparticle distribution was localised within the middle region of the tumours 
near the site of injection. Tumours were also sectioned all the way through 7 days after 
injection (Figure 5.20). After this period microparticles were less easily detectable 
using fluorescence microscopy, and the more diffuse distribution of FITC suggested 
that they were partially degraded.
Macrophages in the excised tissue were identified through 
enzymehistochemistry using the non-specific esterase (a  naphthyl acetate method) 
(Figures 5.23 and 5.24). Figure 5.21 D shows the nuclear structure of the tumour tissue, 
and Figure 5.21 F shows positive non-specific esterase staining of the tumour tissue
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revealing macrophages in the tumour tissue. Non-specific esterase staining was also 
carried out on the excised mouse thigh muscle tissue (Figure 5.22) and as expected no 
macrophages were revealed in the tissue. However the test revealed the two different 
types of muscle fibre within the thigh muscle. Once the macrophages had been 
identified in tumour tissue, macrophage counts were carried out. The optimum number 
of sections per animal and the number of fields of view per section, were determined 
using 10 fields from each of the 10 consecutive sections of the RIF-1 tumour. The 
cumulative number of fields that gave the lowest coefficient variation, was chosen as 
the number of fields per section to be quantified, in this case it was 10, and the number 
of sections per tumour model was selected to be 5 which gave an S.E. ±25% of the 
mean (appendix E).
Figure 5.25 describes results from the first in vivo experiment, in which 1.5 mg 
of unlabelled and FITC labelled microparticles were injected directly. Tumours excised 
2 days after treatment with FITC labelled microparticles appeared to have fewer 
macrophages than the control tumours, which were untreated. However, for tumours 
treated with unlabelled microparticles, after 7 days, there was no significant change in 
the number of macrophages present, in comparison to the untreated tumours. Tumours 
treated with FITC-labelled microparticles, which were excised 7 days after injection, 
appeared to have fewer macrophages than the untreated tumours, and slightly less than 
those tumours, which were excised after 2 days.
In a second larger in vivo experiment, tumours were either untreated, treated 
with saline or treated with FITC labelled microparticles (Figure 5.28), and excised 
either 2 or 24 hours after injection. Again fluorescence microscopy was used to observe 
the distribution of the microparticles with in the tumour. The microparticles appeared 
to be distributed around the periphery of the tumour (Figure 5.26). Injecting the
167
tumours with saline alone caused an increase in the number of macrophages present, 2 
and 24 hours after injection. However, after 2 hours there appears to be a further 
increase in the number of macrophages present in tumours treated with FITC labelled 
microparticles, where as after 24 hours the number of macrophages present had 
decreased.
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Figure 5.19. Typical fluorescent images of FITC labelled microparticles directly 
injected into solid tumours. Samples of 1.5 mg of FITC labelled microparticles were 
directly injected into solid tumours. The tumours were excised 2 days post injection. 
Image A was taken at xlOO magnification and image B was taken at x600 
magnification.
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Figure 5.20. Typical fluorescent images of FITC labelled microparticles directly 
injected into solid tumours. Samples of 1.5 mg of FITC labelled microparticles were 
directly injected into solid tumours. The tumours were excised 7 days post injection. 
Images A and B were taken at x600 magnification.
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Figure 5.21. Enzyme histochemical staining of spleen (A-C) and tumour (D-F) tissue. 
Spleen (C) and tumour (F) tissue was treated with non-specific esterase (NSE). A & D 
are H&E stains of spleen (A) and tumour (D) to reveal nuclear structure of tissue. B&E 
are spleen (B) and tumour (E) negative controls for NSE staining. * denotes 
macrophages. Scale bar = 100 pm.
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Figure 5.22. Enzyme histochemical staining of mouse muscle. A is an H&E stain of 





Figure 5.23. Images A&B show the distribution of macrophages in RIF-1 tumour 
tissue through non-specific esterase staining. Images were taken at x 160 magnification.
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Figure 5.24. Images A&B show the distribution of macrophages in RIF-1 tumour 
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Figure 5.25. Effect of DHSA microparticles on the macrophage content of tumour tissue. 1.5 
mg samples of both FITC and non-FITC labelled particles were directly injected into tumours. 
Control animals were not injected with microparticles. Field of view per treatment group n=250 
or n=200. Data represents the mean of 250 or 200 (where applicable) samples ±SEM. For both 
1 and 2 tailed t-test at P=0.05 it was found that the results of control group compared to the 2 
day FITC-paiticles group (with 8 degrees of freedom), and control group compared with 7 day 
particles only (with 7 degrees of freedom), and control group compared with 7 day FITC- 
particles (with 7 degrees of freedom), and finally 7 day particles only compared with 7 day 
FITC-particles were all significantly different, see Appendix E.
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Figure 5.26. Typical fluorescent images of FITC labelled microparticles directly 
injected into solid tumours. Samples of 1.5 mg of FITC labelled microparticles were 
directly injected into solid tumours. The tumours were excised 2 hours post injection. 
Images A and B were taken at xlOO magnification.
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Figure 5.27. Typical fluorescent images of FITC labelled microparticles directly 
injected into solid tumours. Samples of 1.5 mg of FITC labelled microparticles were 
directly injected into solid tumours. The tumours were excised 24 hours post injection. 
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Figure 5.28. Effect of DHSA microparticles on the macrophage content of tumour tissue after 
2 and 24 hour incubation post injection. Samples of 1.5 mg of FITC labelled microparticles 
were directly injected into tumour. Control animals were not injected with microparticles. 
Additional control animals were injected with saline. Field of view per treatment group n=250. 
Data represents the mean of 250 samples ±SEM. For both 1 and 2 tailed t-test at P=0.05 (given 
that there were 8 degrees o f freedom), it was found that the results of 2h control compared to 2h 
saline; 2h saline compared to 2h FITC-particles; and finally 2h control compared to 2h FITC- 
particles were all significantly different. The results of 24h control compared to 24h saline; 24h 
saline compared to 24h FITC-particles; and finally 24h control compared to 24h FITC-particles 
were all significantly different, see Appendix E.
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5.4. DISCUSSION
Among a variety of cancer gene therapy treatments currently in use, immunotherapy 
is the most promising. Generally the present strategies in immunotherapy involve the 
manipulation of the antigen processing and presentation pathway.
Antigen processing involves the degradation of externally or internally derived 
antigen into short peptide sequences and the association of the peptide with MHC 
molecules, either MHC class I or class II on antigen presenting cells and presentation of 
these peptide molecules on the surface of these antigen presenting cells. The location of 
the antigen, extracellular or intracellular, determines which MHC molecule will bind the 
peptide. Peptides derived from antigenic proteins that reside within the cell (or self 
produced) such as viral proteins, bind to MHC class I molecules. While peptides 
derived from antigenic proteins that reside outside of the cell (or non-self produced), 
such as either bacterial proteins or large proteins bind to MHC class II molecules. 
MHC class I molecules are found on the surface of all nucleated cells, however MHC 
class II are far more restricted in their distribution. B cells, macrophages, dendritic cells 
and in the human, activated T cells are among the most strongly positive for class II. An 
improved understanding of the molecular mechanism of antigen processing and 
presentation, and the identification of tumour-associated antigens (TAA) in melanoma 
and other cancers, have allowed the development of specific vaccines.
Peptide vaccines, consist of peptide sequences recognised by cytotoxic T 
lymphocytes (CTL), can induce CTL responses (Schulz et al., 1991). These peptide 
vaccines can be formulated with immunostimulating complex, entrapped in liposomes, 
or coated on their surface. Peptide vaccines are advantageous as they can be designed 
to induce well-defined immune responses and can be synthesised with very high purity
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and reproducibility in large quantities. They can also identify the specific epitopes of 
the tumour antigens to which an individual is able to mount an immune response, 
(reviewed by Minev et al., 1999).
Another vaccine approach is the use of dendritic cells (DC) for inducing antitumour 
immune responses. DCs are the most potent APCs for the initiation of antigen-specific 
immune responses. In addition to their ability to efficiently acquire and process 
antigens, DCs express high levels of MHC Class I and Class II molecules, as well as co- 
stimulatory molecules essential in antigen presentation. Therefore many investigators 
have attempted to immunise with peptide-pulsed DCs. The results showed 
immunisation with peptide-pulsed DCs is superior to injection of peptide in adjuvant in 
inducing potent cytotoxic T-cell responses (reviewed by Minev et a l, 1999).
The use of heat shock protein (HSP)-peptide complexes for vaccination is also being 
investigated. Vaccination of mice and rats with HSP-peptide complexes has resulted in 
powerful immune responses against the peptide bound to HSP, but not the HSP itself 
(Udono et a l, 1994). A disadvantage of this approach is the requirement for generation 
of customised patient-specific vaccines for cancer.
DNA vaccines involve direct inoculation of expression plasmids, which result in the 
induction of long lasting immune responses against the expressed antigens. Several 
elegantly designed studies addressed the important question of the mechanism of DNA 
immunisation (Corr et al., 1996; Ulmer et al., 1996; Condon et a l, 1996). Results 
demonstrate that the APCs can be transfected directly or they can acquire antigens 
expressed by other transfected cells. However, only professional APCs are able to 
initiate primary immune responses as result of DNA immunisation. A promising DNA 
vaccine has been developed against a B-cell lymphoma (Syrengelas et a l, 1996). DNA 
vaccines have several potential advantages over peptide vaccines. DNA vaccines are
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simpler and cheaper to produce, are not rapidly cleared from the host, and produce very 
long-lasting immune responses. In all DNA-based vaccines seem to be promising 
approach for the treatment of cancer.
The disadvantage of peptide-based vaccines is their low immunogenicity, therefore 
careful selection of the adjuvants used with these vaccines is important. The function of 
each adjuvant depends on its ability to affect the pathway of the antigen presentation to 
prolong the antigen exposure to the APCs, as well as to influence the number and the 
type of APCs, and the release of cytokines in the local environment. One promising 
new adjuvant that is currently being investigated is unmethylated CpG dinucleotides, 
found in bacterial DNA. CpGs cause direct immunostimulatory effects in the immune 
cells in vitro. They trigger cells of the innate immune system, including macrophages 
and DCs, to upregulate MHC class II and costimulatory molecules. They also bring 
about the conversion of immature DCs into mature APCs, however CpGs have mainly 
been evaluated in rodent models and with murine cells, thus their potency and safety in 
humans remains to be established (reviewed by Singh and O’Hagan, 1999).
The use of particulate adjuvants, an alternative to immunostimulatory adjuvants has 
been evaluated by several groups. Particulate adjuvants e.g. microparticles have 
comparable dimensions to the pathogens that the immune system evolved to combat, 
therefore particulate adjuvants are naturally targeted for uptake by APCs to facilitate the 
induction of potent immune responses. Immunostimulatory adjuvants may also be 
included to enhance the level of immune activation, or to focus the response through a 
desired pathway (e.g. Thl or Th2) (reviewed by Singh and O’Hagan, 1999). The use of 
microparticles to target antigens to APCs is one approach. Primary candidates have 
been biodegradable and biocompatible polyesters or poly(lactide-co-glycolides) (PLGs) 
for the development of microparticles as adjuvants, as they have been used in humans
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for many years as suture material and as controlled-release delivery systems (Okada and 
Toguichi, 1995). Microparticles appear to mediate their effects largely as a 
consequence of their uptake into DCs, macrophages and local lymph nodes. A 
particularly attractive feature of microparticles is their ability to control the rate of 
release of entrapped antigens (O’Hagan, 1998) as controlled release of antigens may 
allow the development of single dose vaccines.
This chapter has investigated whether the DHSA microparticles induced a humoral 
immune response in vivo, without the presence of therapeutic DNA. FITC labelled 
DHSA microparticles were assessed in vivo to investigate the relationship between the 
presence of the microparticles and the number of macrophages present in the tumour or 
muscle tissue. However, before the latter could be carried out, in vitro experiments 
were carried out to determine whether macrophages were able to phagocytose the 
microparticles and if so the time frame it would take for the macrophages to 
phagocytose the microparticles. The distribution of the microparticles in the tissue after 
injection and the length of time the particles resided in the tissue before degradation was 
also investigated.
Mouse peritoneal macrophages were collected by injecting warmed Hank’s 
balanced salt solution (37°C), as described in section 5.2.2. (Mann, 1973). The salt 
solution was warmed to avoid activating the macrophages before collection, this is to 
ensure that if the macrophages become phagocytic it is due to the properties of the 
microparticles (Femandez-Repollet and Swartz, 1988). Three general types of 
phagocytosis have been described: spontaneous, normal and immune. Spontaneous 
phagocytosis is serum-independent ingestion, relatively few phagocytes participate in 
spontaneous phagocytosis and few particles are ingested. However, the rate of 
phagocytosis can be enhanced, by increasing (1) the number of collisions between
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phagocytes or particles, (2) the size and density of phagocytes and (3) the absolute 
number of particles or phagocytes. Normal phagocytosis is mediated by the normal 
serum opsonins or natural antibody, so called as the addition of normal serum enhances 
phagocytosis. Such non-specific opsonizing activity appears to reside in the alpha-2 
globulin fraction. Phagocytic activity of phagocytes is dramatically enhanced by 
specific-immune antibody and further accelerated by complement. Specific 
opsonization, implies binding of the particle surface to specific antibody, induced by 
previous exposure to the antigen and directed against antigenic determinants on the 
particle surface (reviewed by Fernandez-Repollet & Swartz, 1988).
FITC-labelled microparticles were incubated with the mouse peritoneal 
macrophages for 2, 24, 48, and 72 hour periods and observed using microscopy. It 
appears that the microparticles did undergo the three phases of phagocytosis, the initial 
attachment, the ingestion and the digestion. The initial attachment and ingestion 
occurred as early as 2 hours and continued between 2-24 hours. The digestion process 
took place 24-72 hours in vitro conditions. This indicated that there were an adequate 
number of collisions between the phagocytes and the microparticles. The microparticles 
were generally within a similar size range as the macrophages. Less aggregated 
microparticles were phagocytosed more efficiently as expected due to their more 
manageable size. It can be assumed that the mechanism of uptake was spontaneous 
phagocytosis. However, as the microparticles were essentially spray dried human 
serum albumin and there was serum in the incubation medium (RPMI), the 
phagocytosis could also be regarded as normal phagocytosis.
Once the time-frame for phagocytosis had been established (note that macrophages 
were possibly activated by the presence of the FITC labelled microparticles), the next 
stage was to monitor the behaviour of the microparticles in vivo. Upon directly
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injecting the FITC-labelled and unlabelled microparticles into tumour and muscle 
tissue, the distribution and stability of the microparticles in tumour tissue was observed 
using fluorescent microscopy. It was found generally, the majority of the microparticles 
were located in the periphery of the tumour tissue removed from the mid-region of the 
RIF-1 tumour near the site of injection (i.e the tumour can be divided into three areas 
top, middle and bottom). The particles appeared to be quite aggregated, possibly due to 
the mass of tumour tissue being quite tightly packed not to mention the intratumoral 
pressure. After 2 days in vivo the microparticles are still intact, however after 7 days the 
microparticles appear to have degraded (Figure 5.20). The degradation was most likely 
due to naturally occurring proteases gradually breaking down the albumin microparticle 
matrix. This localisation of microparticles and their long residence offers promise of 
controlled gene delivery of cancer vaccines.
Attempts were made to assess the adjuvant effects of these microparticles i.e. to 
determine if upon injection into tumour tissue they caused an immune response. To 
assess the immune response qualitatively and quantitatively macrophages were located 
within the tissue and cell counts were carried out. Initial attempts to locate 
macrophages and distinguish between residing and infiltrating macrophages, involved 
the use of immunocytochemical staining in particular the ‘Avidin-Biotin’ technique, 
which relies on the marked affinity of the glycoprotein for biotin. Essentially, a 
mono/polyclonal primary antibody was directed towards a specific determinant on the 
cells i.e. in this case rat-antimouse Mac-1 (CDlib) for the general detection of 
macrophages. After the 1° antibody was applied biotinylated anti-rat IgG is added, 
followed by preformed complex between avidin and biotinylated enzyme (with enzyme 
substrate-alkaline phosphatase). This preformed complex consisted of many 
biotinylated enzyme molecules cross-linked by avidin into a three-dimensional array.
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The complex apparently has few exposed biotin residues but has at least one remaining 
biotin site to bind to the biotin on the 2° antibody (Vector Laboratories, UK). The latter 
method did not work for the RIF-1 tumour as the 1° antibody did not appear to pick out 
individual macrophages but coated the whole of the tissue sections, indicating that a 
protein on the surface of the tumour cells was reacting with the Mac-1. Leek et al, have 
found in invasive breast carcinomas, that the neoplastic cell population is often out 
numbered by such stromal cells as tumour-associated macrophages, which can comprise 
more than 50% of the total tumour mass. (Leek et al., 1996, 1998). The latter 
observation could also offer a possible explanation on why the Mac-1 general 
macrophage marker coated the majority of the RIF-1 tumour tissue sections, as the use 
of the RIF-1 tumour model up until now has only been associated with in vivo 
evaluation of chemotherapy and radiotherapy (Twentyman et al., 1980). As it was 
clearly difficult to detect macrophages using Mac-1, attempts to detect dendritic cells 
using CD llc were also futile, as a relationship between the quantity of macrophages 
and dendritic cells could not be observed using immunocytochemical staining.
An alternative method for the detection of macrophages was sought out, enzyme 
histochemistry is one alternative method. Enzymes are vital components of biological 
systems, they may be free and soluble in the cytoplasm or body fluids (lysoenzymes) or 
bound to specific cell components (desmoenzymes). In the case for detecting 
macrophages esterase enzymes were of interest as these hydrolytic enzymes are found 
in the macrophages (Femandez-Repollet & Swartz, 1988). The majority of esterase 
enzymes are able to hydrolyse a  naphthyl acetate as a substrate, these enzymes are 
called ‘non-specific’ esterases. The enzymes release a  naphthol during the hydrolysis 
of the substrate. The a  naphthol is then coupled with a suitable diazonium salt, to 
produce an insoluble azo dye at the site of enzyme activity. The diazonium salt,
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hexazotized pararosaniline was used as it gives good localisation of the enzyme 
(Bancroft & Stevens, 1996).
Once the macrophages had been identified, macrophage counts were carried out. 
The results from the first in vivo experiment, where RIF-1 tumours were treated with 
FITC-labelled microparticles and excised after 2 and 7 day periods, (Figure 5.25) appear 
to show a decrease in the number of macrophages in the tumours treated with FITC 
labelled microparticles. However, there seems to be no decrease in the number of 
macrophages present in tumours treated with unlabelled microparticles. The latter 
phenomenon could be attributed to the presence of FITC.
A second in vivo experiment was performed, this time tumours were excised 2 and 
24 hours post injection (Figure 5.28). Injecting tumours with saline caused an increase 
in the number of macrophages found in tumour tissue. There was a further increase in 
the number of macrophages in tumour tissue, upon injection of FITC-labelled 
microparticles. However in tumours excised 24 hours post injection there seems to be a 
decrease in the number of macrophages present in tumours injected with FITC-labelled 
microparticles. The latter phenomenon could be explained by infiltrating macrophages 
migrating away from the tumour.
It is clear that the microparticles are taken up by peritoneal macrophages in vitro. 
An immune response is also mediated by the presence of the microparticles in vivo. 
However, more clinical work needs to be carried to establish whether the microparticles 
are taken up by the immune system and taken to the local lymph nodes, before DNA 




Gene therapy has enormous promise as a strategy for providing safe and effective 
therapies for some disorders. To fulfil this promise, approaches to gene therapy must be 
developed that are consistently effective and are also as safe and cost effective as 
conventional pharmaceutical and biotechnology products. These are familiar clinical 
challenges in drug development challenges against which methods for gene therapy and 
progress towards developing gene therapy products must be measured.
Biodegradable microparticles are already a well-established form of drug 
delivery, currently used for sustained delivery of hormones and vaccines to mention a 
few (Cleland, 1997). Currently their potential for use in the field of gene delivery is 
being explored (Schaefer & Singh, 1997, O’Hagan, 1997).
The objective of the research described in this thesis was to investigate the 
potential of spray-dried microparticles produced by an established spray-drying method 
at Quadrant Healthcare, for use in the field of gene delivery to the lung and solid 
tumours.
Spray drying is an extremely useful technique for producing powders to 
predetermined specifications, which was shown in Chapter 2 when spray drying 
mannitol microparticles. Spherical microparticles of a narrow size distribution between 
3-6 pm were produced. The DNA retained its biological activity, which was 
determined via in vitro transfection of mammalian cells, with the re-dispersed 
lipoplexes. Further investigation is required however, as the spray drying of lipoplexes 
still needs a lot of work. The product recovery was low, which is expected with 
laboratory scale spray dryers (Broadhead, 1994) but as DNA is very costly regarding
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time and money to obtain, further work needs to be done to optimise the conditions 
further to avoid loss of the DNA, but keeping in mind the heat sensitivity of DNA. 
Other areas that need further investigation are the moisture content of the mannitol 
particles as it has been reported not to be the most stabilising excipient to use when 
spray drying a biologically active compound (Broadhead et al, 1994), therefore 
alternatives need to be investigated. The in vitro transfection experiment was adequate 
to determine if the DNA had retained its biological activity after undergoing spray 
drying but the next step would be to take this in vivo as with all drug deliveries their 
behaviour in vitro does not reflect their behaviour in vivo. Therefore a suitable in vivo 
lung model would have to be sought to evaluate clinical response, mode of deposition, 
the effect of mucociliary clearance and most importantly the safety of potential carriers. 
The other key area of investigation would be an alternative gene delivery vector to 
DOTAP, which has been recently reported to be inefficient when transfecting in vivo.
The potential for using microparticles for DNA vaccination strategy by 
introducing plasmid DNA encoding antigenic proteins via intratumoral delivery into 
host cells was investigated in Chapter 4. As with the mannitol formulation the 
specifications adopted for spray drying the DHSA suspension also gave poor product 
recovery reiterating the need for process optimisation. DNA was adsorbed onto the 
surface of DHSA microparticles with the aid of polycations. However, further 
experiments need to be carried out to determine a more efficient way of adsorbing DNA 
onto the surface of these microparticles in order that these microparticles can provide a 
sufficient depot of therapeutic DNA. Another alternative may be to spray dry several 
different types of polycations with defatted human serum albumin at different 
percentages of the overall spray drying suspension to see if DNA can be adsorbed more 
efficiently when directly loaded onto the surface of these microparticles. Using YOYO-
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1 to monitor the adsorption of DNA onto microparticles was adequate, however its 
sensitivity did make it difficult to monitor adsorption at saturation levels where the 
DNA adsorbed was close to the DNA remaining in solution. Therefore for future work 
it would be useful to explore the possibility of finding an alternative, such as a reporter 
gene that is pre-labelled with a chromophore which gives absorption at a pre-determined 
wavelength.
Once it was determined that it was possible to adsorb DNA onto the surface of 
these microparticles these DNA loaded microparticles were used to transfect in vitro. 
Very little gene expression was obtain, this is probably because B16 mouse melanoma 
is a monolayer and the microparticles were too big to be taken up for transfection. The 
little transfection obtained was probably due polyplexes that had been shed from the 
microparticles. Further transfection experiments need to be carried out with active cells 
such as peritoneal macrophages or a macrophage cell line as the macrophages are able 
to engulf these microparticles and digest them, which was shown in chapter 5. 
Peritoneal macrophages were shown to engulf microparticles in vitro, which was 
demonstrated with fluorescent images. The following in vivo experiments showed that 
the presence of these microparticles stimulated an immune response, but further 
experiments need to be carried to verify whether these microparticles are taken up by 
macrophages in vivo, this could be achieved by locating and analysing local lymph 
nodes. Work also need to go into establishing the stability of these microparticles in 
vivo. The RIF-1 tumour model was difficult to analyse in terms of identifying specific 
immune cells, as it is normally used for radiation studies, therefore for future work it 
would be wise to investigate a model which was established as a means of monitoring 
immunity in tumours in vivo. Overall, a lot of clinical work needs to be carried out to 
verify the potential of these microparticles for intratumoural vaccines.
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The future work mentioned was not carried out due to time and money 
constraints as well as limited access to equipment. The results obtained showed great 
promise for using microparticles in the field of gene delivery. Although we still have a 
long way to go, as with conventional products a lot of expensive research over along 
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B. 1.Molecular Weight Marker
For agarose gel electrophoresis, the marker used was EcoR I/Hind DI cut X DNA (NBL 
Gene Sciences Ltd, UK).
1 21226 6 2027 11 831
2 5148 7 1904 12 564
3 4973 8 1584 13 125
4 4268 9 1375
5 3530 10 947
B.2. Antibiotics
1. Ampicillin sodium (Sigma, UK) was prepared as a 100 mg/ml solution in water 
and filter sterilised using a 0.2 pm pore membrane (Millipore, UK) and stored at 
-20 °C for upto 3 months.
2. Tetracycline (Sigma, UK) was prepared as 25 mg/ml solution in methanol and 
stored at -20 °C for upto 3 months.
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B. 3. Solutions
TAE buffer 0.04 mM Tris-Acetate 
0.001 mMEDTA
TE buffer 10 mM Tris. Cl (pH 8)
1 mMEDTA (pH 8)
Electrophoresis Loading Buffer (5x)
0.25% Bromophenol blue 
0.25% Xylene cyanol FF 
15% Ficoll (type 400, Pharmacia)







Bacto-yeast extract 5 g
Sodium Chloride 10 g
Agar Technical 12 g
DDDW to 1000 ml
Reagents for preparing LB were obtained from Difco, UK. Solutions were sterilised by
autoclaving at 121 °C and 15 psi for 15 minutes on a liquid cycle in a Swingate Type






B.4. Preparation of Competent E. coli DH5a cells
Tfbl Buffer 
30 mM KCL 
lOOmMRbCl 
10 mM CaC12 
50 mM MnC12 
15% (v/v) Glycerol 
Water
3 ml of a 1 M solution 
1.209 g
12.5 ml of 80 mM solution 
5 ml (1 M solution)
15 ml 
to 100 ml
Adjust to pH 5.8 with 0.2 M acetic acid and filter sterilise.
Tfbll Buffer
10 mM MOPS 0.209 g
75mMCaC12 1.1 g
lOmMRbCl 0.1209 g
15% (v/v) Glycerol 15 ml
Water to 100 ml
Adjust to pH 6.6 with 1 M KOH and filter sterilise.
A single colony of E. coli DH5a was picked from a fresh agar plate and 
inoculated into 5 ml of LB medium and incubated at 37°C overnight in a shaking 
incubator. The following morning, 1 ml of the culture was diluted to 100 ml with LB 
and grown under standard conditions until the optical density (OD550nm) of the 
solution reached 0.48 (2.5-3 hours). The cell suspension was then chilled on ice for 5 
minutes and centrifuged in sterile falcon tubes for 5 minutes, 6000 rpm (Beckman J2- 
MC) at 4°C. The supematent was discarded and the cells re-suspended in 40 ml of Tfbl 
buffer (2/5* volume of culture) and chilled on ice for 5 minutes. Cells were centrifuged 
at 6000 rpm for 5 minutes at 4°C and the supernatant discarded. Cells were 
subsequently re-suspended in 4 ml (1/25* volume of culture) of Tfbll buffer and chilled 
on ice for 15 minutes. Cells were stored in 200 pi aliquots, snap frozen in a dry- 
ice/methanol bath and stored at -70°C until required.
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B.5. Transformation of Competent E. coli DH5a Cells
Two hundred microlitres of competent cell suspension was thawed at room 
temperature and then placed on ice for 10 minutes. Plasmid DNA (<100 ng) was then 
added and gently mixed using a Gilson tip followed by incubation on ice for 30 -  45 
minutes. The cells were shocked by incubating at 37°C for 2 minutes and then returned 
to ice for 2 minutes. The cell suspension was then diluted to 800 pi with LB followed 
by incubation at 37°C for 1 hour. After this time, 100 pi of this suspension was plated 
out on a LB-agar plate containing ampicillin at a concentration of 100 pg/ml, or other 
antibiotic depending on the plasmid. Plates were incubated overnight at 37°C.
B. 6. Colony Picking and Plasmid Purification
After checking the controls, sterile toothpicks (autoclaved) were used to transfer 
single colony forming units from the LB plates into 10 ml of LB broth containing 
ampicillin at a concentration of 100 pg/ml. The plasmid was then propagated, isolated, 
purified and quantified as described in chapter 2. The DNA sample was then screened 
using a restriction digest followed by gel electrophoresis and the undigested plasmid 
was loaded onto a gel and sized using a supercoiled ladder.
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Lanes 1 2  3 4
Lane 4 DNA EcoR I/Hind III Digest
Lane 3 pCMVlacZ (unrestricted)
Lane 2 pCMVlacZ (Not 1, Pst 1 restriction, Not 1-3530 base pairs, Pst 1-2675 base 
pairs, Pst 1-Not 1 855 base pairs, Not 1-Pst 1 196 base pairs rarely seen.)
Lane 1 pCMVlacZ (pCMVlacZ (Not 1, Pst 1, EcoR I restriction, Not l-3530bp, Pst 




Calibration Curves for Quantitative Assays 
Cl. ONPG
Calibration curve for B-galactosidase using ONPG as a standard. From a 0.2 
mU/ml stock solution of enzyme (ONPG)(Sigma) 300 pi samples were prepared in 0.1 
M Sodium phosphate buffer (pH 7.4) containing 0, 0.001, 0.002, 0.004, 0.006, 0.008, 
0.010, 0.012 pU of B-galactosidase. The following linear regression analysis was 
obtained:









A series of solutions was prepared by dilution of purified luciferase (Promega) 
stock with lx lysis buffer (Promega). Samples were produced which contained 0, 1, 50, 
100, 500, 600, 700, 800, 900, 1000 ng of luciferase in 20 pi. Analysis was performed as 
described in 3.2.5.2. A Beer-Lambert plot for light units was determined with the 
following regression analysis:











C3. Assay fo r soluble protein content o f cell extracts
Calibration curve for protein using bovine serum albumin (BSA) as a standard 
and the Bio-Rad Dc protein assay kit. From a 2 mg/ml stock solution of BSA (Sigma) 
100 pi samples were prepared in 0.1 M sodium phosphate buffer (pH 7.4) containing 0, 
20, 40, 60, 80, 100, 120, 140, 160, 180 and 200 pg of protein. The following linear 
regression analysis was obtained:







Bovine Serum Albumin (ug)
212
C4. Biuret Assay
Calibration curve for protein using albumin as a standard and the Biuret reagent 
(3 g of copper sulphate and 9 g of sodium potassium tartrate dissolved in 500 ml of 0.2 
mol/L sodium hydroxide; added 5 g potassium iodide and made upto 1 litre with 0.2 
mol/L sodium hydroxide). Samples were prepared containing 0, 2, 4, 6, 8, 10, 12 
mg/ml of albumin. The following linear regression analysis was obtained:

















Taking into account that the molar ratio of 50 base pairs: 1 dye was used in the 
calculation of the absorption and fluorescence maxima, 50 base pair: 1 ratio was taken 
as the starting point to obtain a calibration curve (RMM base pair = 660, YOYO-1 = 
1271). Serial dilutions of stock solution of 50:1 base pair/dye ratio were made.
Aqueous solutions of dimeric cyanine dyes without added DMSO are unstable 
due to surface adsorption. To circumvent this problem aqueous solutions were prepared 
by diluting from the DMSO stock solution immediately before they were required for 
use, in plastic rather than glass containers and left to stabilise for 10 minutes before 
readings were taken at excitation 491 nm and emission 509 nm. Minimal transfer steps 
were adopted to further circumvent surface adsorption. The following linear regression 
analysis was obtained:












All tumours collected were sectioned all the way through at 5 pm per section, and every 
5 th section was qualitatively assessed via fluorescence microscopy. For macrophage 
counts, consecutive sections from the mid-region of the tumours were collected for 
enzyme histochemical staining and counts were made manually at x250 magnification, 
see tables a & b. The optimum number of sections per animal and number of fields per 
section were determined using 10 fields from each of 10 consecutive sections of RIF-1 
tumour model. The cumulative number of fields that gave the lowest coefficient of 
variation was chosen as the number of fields per section to be quantified. The number 









Field of view 
per section
Control (untreated) 5 5 10
2 days FITC microparticles 5 5 10
7 days non-FITC microparticles 4 5 10









Field of view 
per section
2 hour control (untreated) 5 5 10
2 hour saline 5 5 10
2 hour FITC microparticles 5 5 10
24 hour control (untreated) 5 5 10
24 hour saline 5 5 10
24 hour FITC microparticles 5 5 10
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Statistical Analysis












compared to 7 
day FITC 
particles
7 day particles 
only compared 
to 7 day FITC- 
particles
Variable Mean 76.768 76.768 76.768 76.69
1 Variance 52.462 52.462 52.462 31.183
Variable Mean 60.687 76.69 56.02 56.02
2 Variance 54.734 31.183 4.583 4.583
Observati Variable 1 5 5 5 4
ons Variable 2 5 4 4 4
Degrees of 
freedom
8 7 7 6
P(T<=t) 1-tail 0.004203 0.493201 0.000467 0.000227
Critical 11-tail 1.859548 1.894578 1.894578 1.943181
P(T<=t) 2-tail 0.008406 0.986402 0.000933 0.000453
































































5 5 5 5 5 5
Degrees of 
freedom
















2.306006 2.306006 2.306006 2.306006 2.306006
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